Erlotinib Plus Gemcitabine Compared With Gemcitabin Pancreatic Cancer: A Phase III Trial of the National Can Trials Group

Journal of Clinical Oncology

25, 1960-1966

DOI: 10.1200/jco.2006.07.9525

Citation Report

#	Article	IF	Citations
1	Risk factors for coronary calcification in older subjects The Rotterdam Coronary Calcification Study. European Heart Journal, 2004, 25, 48-55.	1.0	75
2	Pancreatic cancer. Lancet, The, 2004, 363, 1049-1057.	6.3	1,761
3	Evolving Molecular-Based Targeted Therapy for Cancer: An Exciting Field. Comprehensive Therapy, 2005, 31, 299-305.	0.2	0
4	Randomized phase II â€“ study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer â€“ PARC: study protocol [ISRCTN56652283]. BMC Cancer, 2005, 5, 131.	1.1	61
5	Current Treatment Strategies for Pancreatic Cancer in the Elderly. Drugs and Aging, 2006, 23, 403-410.	1.3	11
6	Treatment update for metastatic pancreatic cancer. Community Oncology, 2006, 3, 428-430.	0.2	0
7	ThÃ©rapies ciblÃ©es etÂimmunomodulation dansÂlesÂtumeurs solides. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2006, 15, 297-302.	0.1	0
8	Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. Clinical Cancer Research, 2006, 12, 4283-4287.	3.2	154
9	Targeted tumor therapy with the TGF-Î²2 antisense compound AP 12009. Cytokine and Growth Factor Reviews, 2006, 17, 129-139.	3.2	180
10	Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Medical Hypotheses, 2006, 66, 715-731.	0.8	11
11	Cancer remains the dominant disease target for biotech through to 2010. Journal of Commercial Biotechnology, 2006, 12, 294-298.	0.2	3
12	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 2006, 94, 1107-1115.	2.9	71
13	A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer, 2006, 95, 587-592.	2.9	188
14	The case for adjuvant chemotherapy in pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 383-401.	1.0	15
15	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with nonâ€“small cell lung cancer. Clinical Pharmacology and Therapeutics, 2006, 80, 136-145.	2.3	195
16	Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. Hpb, 2006, 8, 22-28.	0.1	16
17	Maintenance Chemotherapy after Chemoradiation Improves Survival of Patients with Locally Advanced Pancreatic Carcinoma. Strahlentherapie Und Onkologie, 2006, 182, 210-215.	1.0	14
19	Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Current Treatment Options in Oncology, 2006, 7, 381-388.	1.3	7

#	Article	IF	Citations
20	Advances in molecular diagnostics and therapeutics in head and neck cancer. Current Treatment Options in Oncology, 2006, 7, 3-11.	1.3	28
21	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Current Gastroenterology Reports, 2006, 8, 111-120.	1.1	4
22	New Therapies in the Treatment of Breast Cancer. Seminars in Oncology, 2006, 33, 3-8.	0.8	16
23	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33, 369-385.	0.8	645
24	Targeting Loss-of-Function Mutations in Tumor-Suppressor Genes as a Strategy for Development of Cancer Therapeutic Agents. Seminars in Oncology, 2006, 33, 513-520.	0.8	27
25	Epidermal Growth Factor Receptor (EGFR) Inhibitors in Gastrointestinal Cancer. Oncology Research and Treatment, 2006, 29, 99-105.	0.8	4
26	Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases. Seminars in Interventional Radiology, 2006, 23, 099-108.	0.3	16
27	Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology, 2006, 70, 255-264.	0.9	154
28	Erlotinib: Optimizing Therapy with Predictors of Response?. Clinical Cancer Research, 2006, 12, 2961-2963.	3.2	20
29	Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. British Journal of Cancer, 2006, 94, 481-485.	2.9	123
31	Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?. Journal of Clinical Oncology, 2007, 25, 4320-4321.	0.8	3
32	Role of platinum agents in the management of advanced pancreatic cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2719-2727.	0.9	17
33	Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275.	0.2	0
34	Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?. Journal of Clinical Oncology, 2007, 25, 4506-4507.	0.8	75
35	Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer. Oncology, 2007, 73, 221-227.	0.9	46
36	The Area Between the Curves Gets No Respect: Is It Because of the Median Madness?. Journal of Clinical Oncology, 2007, 25, 5531-5531.	0.8	12
38	Prognostic Factors and Prognostic Index for ChemonaÃ¯ve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology, 2007, 73, 41-51.	0.9	58
39	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 1287-1298.	1.5	24

#	Article	IF	Citations
40	Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. Current Cancer Drug Targets, 2007, 7, 666-673.	0.8	19
41	Targeted Therapies: Cui Prodest?. Journal of Clinical Oncology, 2007, 25, 4691-4692.	0.8	2
42	Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Annals of Oncology, 2007, 18, 1582-1583.	0.6	26
43	Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 515-520.	0.6	11
44	Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 4587-4592.	0.8	51
45	Mechanisms of Disease: chronic inflammation and cancer in the pancreasâ€"a potential role for pancreatic stellate cells?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 454-462.	1.7	94
46	Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?. Journal of Clinical Oncology, 2007, 25, 5836-5837.	0.8	6
47	Methodological Issues of Clinical Research with EGFR Inhibitors. Current Cancer Therapy Reviews, 2007, 3, 292-302.	0.2	3
48	Lessons Learned in the Management of Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 1949-1952.	0.8	33
49	Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 4787-4792.	0.8	161
50	Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies. Clinical Cancer Research, 2007, 13, 3913-3921.	3.2	370
51	Erlotinib: Recent Clinical Results and Ongoing Studies in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4589s-4592s.	3.2	11
53	Targets, Trials, and Travails in Pancreas Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 1042-1053.	2.3	10
54	An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer. Oncology Research and Treatment, 2007, 30, 355-360.	0.8	25
55	EGFR Targeting of Solid Tumors. Cancer Control, 2007, 14, 295-304.	0.7	245
56	Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 257-262.	1.0	21
57	Update in colorectal, hepatobiliary and pancreatic cancers. Update on Cancer Therapeutics, 2007, 2, 141-156.	0.9	0
58	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Letters, 2007, 254, 165-177.	3.2	143

#	Article	IF	Citations
59	EGFR Genomic Gain and Aberrant Pathway Signaling in Pancreatic Cancer Patients. Journal of Surgical Research, 2007, 143, 20-26.	0.8	32
60	Oncogenic K-Ras Signals through Epidermal Growth Factor Receptor and Wild-Type H-Ras to Promote Radiation Survival in Pancreatic and Colorectal Carcinoma Cells. Neoplasia, 2007, 9, 341-348.	2.3	82
61	Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature. Oncologist, 2007, 12, 1332-1335.	1.9	62
62	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.4	280
63	EGFR, HER2 and VEGF Pathways. Drugs, 2007, 67, 2045-2075.	4.9	125
65	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evidence, 2007, .	4.7	0
66	Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry, 2007, 102, 580-592.	1.2	127
67	Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?. Cancer, 2007, 110, 525-533.	2.0	87
68	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
69	A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer, 2007, 7, 142.	1.1	70
70	Future Strategies for Targeted Therapies and Tailored Patient Management in Pancreatic Cancer. Seminars in Oncology, 2007, 34, 354-364.	0.8	9
71	Adjuvant Therapy for Pancreas Cancer: Advances and Controversies. Seminars in Oncology, 2007, 34, 321-326.	0.8	9
73	A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Investigational New Drugs, 2007, 25, 553-558.	1.2	75
74	Progress in the Development of Prognostic and Predictive Markers for Gastrointestinal Malignancies. Current Treatment Options in Oncology, 2007, 8, 339-351.	1.3	16
75	Pancreatic cancer: An update. Current Oncology Reports, 2007, 9, 170-176.	1.8	29
77	Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews, 2008, 27, 273-288.	2.7	23
78	Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer and Metastasis Reviews, 2008, 27, 495-522.	2.7	75
79	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews, 2008, 27, 387-402.	2.7	26

#	Article	IF	Citations
80	Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews, 2008, 27, 415-434.	2.7	42
81	HER2 Gene Amplification and Chromosome 17 Copy Number Do Not Predict Survival of Patients with Resected Pancreatic Adenocarcinoma. Digestive Diseases and Sciences, 2008, 53, 3026-3032.	1.1	16
82	A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs, 2008, 26, 241-247.	1.2	33
83	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs, 2008, 26, 369-379.	1.2	74
84	The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYPâ„¢) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology, 2008, 64, 31-41.	0.8	109
85	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemotherapy and Pharmacology, 2008, 62, 605-620.	1.1	30
86	A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 763-768.	1.1	13
89	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	1.7	1
90	Innovative TherapieansÃtze fÃ¼r das Pankreasadenokarzinom. Onkopipeline, 2008, 1, 8-10.	0.0	0
93	Rash from EGFR inhibitors: Opportunities and challenges for palliation. Current Oncology Reports, 2008, 10, 304-308.	1.8	17
94	Future perspectives in the treatment of pancreatic cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 27-30.	0.3	0
95	Molecular biology of pancreatic cancer. Clinical and Translational Oncology, 2008, 10, 530-537.	1.2	12
97	Unilateral face swelling as first manifestation of metastatic pancreatic cancer: Case report and review of the literature. Wiener Klinische Wochenschrift, 2008, 120, 693-696.	1.0	3
98	Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. Journal of Gastroenterology, 2008, 43, 905-911.	2.3	42
99	Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbeck's Archives of Surgery, 2008, 393, 901-910.	0.8	31
100	Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer, 2008, 113, 808-814.	2.0	109
101	Systemic cancer therapy: Evolution over the last 60 years. Cancer, 2008, 113, 1857-1887.	2.0	43
102	Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as secondâ€line therapy for patients with advanced pancreatic cancer. Cancer, 2008, 113, 2046-2052.	2.0	130

#	Article	IF	Citations
103	End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy. Cancer, 2008, 113, 3540-3547.	2.0	25
104	EGFR inhibition in the treatment of nonâ€small cell lung cancer. Drug Development Research, 2008, 69, 359-372.	1.4	51
105	Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry, 2008, 104, 1124-1149.	1.2	186
106	Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology, 2008, 67, 27-38.	2.0	32
107	Pancreatic cancer: From molecular signature to target therapy. Critical Reviews in Oncology/Hematology, 2008, 68, 197-211.	2.0	40
108	Locally Advanced Non-Metastatic Pancreatic Cancer â€" Can We Do More?. Clinical Oncology, 2008, 20, 532-534.	0.6	2
109	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 2008, 19, 717-723.	0.6	243
110	Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplantation, 2008, 42, 99-103.	1.3	7
111	Survival from cancer of the pancreas in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S24-S25.	2.9	7
112	Palliative treatment of pancreatic cancer. Journal of Digestive Diseases, 2008, 9, 1-7.	0.7	21
113	Enhanced distribution of NK012, a polymeric micelleâ€encapsulated SNâ€38, and sustained release of SNâ€38 within tumors can beat a hypovascular tumor. Cancer Science, 2008, 99, 1258-1264.	1.7	42
114	Tumeurs digestives et bÃ©vacizumab. Journal De Chirurgie, 2008, 145, 16-20.	0.1	0
115	Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous	1.1	70
116	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, 82.	1.1	377
117	Molecular Mechanisms for Individualized Cancer Care. Journal of the American College of Surgeons, 2008, 207, 250-258.	0.2	23
118	Targeted agents in cancer therapy. Medicine, 2008, 36, 33-37.	0.2	6
119	Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2057-2062.	1.8	141
120	Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs, 2008, 17, 511-522.	1.9	18

#	Article	IF	Citations
121	Epidermal Growth Factor Receptor Inhibitorâ€“Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker. Clinical Colorectal Cancer, 2008, 7, 33-43.	1.0	53
122	Biological Approaches to Therapy of Pancreatic Cancer. Pancreatology, 2008, 8, 431-461.	0.5	24
123	Clinical Approaches to Minimize Rash Associated With EGFR Inhibitors. Oncology Nursing Forum, 2008, 35, 103-111.	0.5	20
124	Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 1595-1607.	0.9	9
125	Current challenges and future perspectives in the medical treatment of solid tumours. European Journal of Cancer, Supplement, 2008, 6, 91-93.	2.2	0
126	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
127	Radiotherapy Combined with Gemcitabine and Oxaliplatin in Pancreatic Cancer Cells. Translational Oncology, 2008, 1, 36-43.	1.7	22
128	Drug Insight: antiangiogenic therapies for gastrointestinal cancersâ€”focus on monoclonal antibodies. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 250-267.	1.7	32
130	Molecular targeted therapies for pancreatic cancer. American Journal of Surgery, 2008, 196, 430-441.	0.9	45
131	EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174.	13.9	1,869
132	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resistance Updates, 2008, 11, 99-109.	6.5	29
133	Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. European Journal of Cancer, 2008, 44, 419-426.	1.3	44
134	Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clinical Therapeutics, 2008, 30, 775-784.	1.1	22
135	Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 4491-4499.	3.2	1,158
137	Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet, The, 2008, 371, 2101-2108.	6.3	241
138	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology, The, 2008, 9, 39-44.	5.1	130
139	Improving treatment of pancreatic cancer. Lancet Oncology, The, 2008, 9, 7-8.	5.1	18
140	Trials in palliative treatmentâ€”have the goal posts been moved?. Lancet Oncology, The, 2008, 9, 186-187.	5.1	33

#	Article	IF	Citations
141	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncology, The, 2008, 9, 962-972.	5.1	709
142	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	0.6	12
143	Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer. Surgical Oncology Clinics of North America, 2008, 17, 357-376.	0.6	1
144	Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1626-1634.	0.8	3,032
145	Implications of EGFR PharmDxâ„¢ Kit for cetuximab eligibility. Expert Review of Molecular Diagnostics, 2008, 8, 141-148.	1.5	15
146	Activated Epidermal Growth Factor Receptor as a Novel Target in Pancreatic Cancer Therapy. Journal of Proteome Research, 2008, 7, 4651-4658.	1.8	42
147	Biology and management of pancreatic cancer. Postgraduate Medical Journal, 2008, 84, 478-497.	0.9	254
148	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of Oncology, 2008, 19, 1624-1628.	0.6	55
149	Targeted therapies for pancreatic cancer. British Medical Bulletin, 2008, 87, 97-130.	2.7	26
150	Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review. Clinical Cancer Research, 2008, 14, 6744-6750.	3.2	56
151	S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2008, 39, 49-53.	0.6	20
152	Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. Annals of Oncology, 2008, 19, vii281-vii288.	0.6	4
153	Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer. Archives of Surgery, 2008, 143, 75.	2.3	275
154	New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. Oncologist, 2008, 13, 289-298.	1.9	81
155	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	0.8	169
156	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. Cancer Research, 2008, 68, 2841-2849.	0.4	89
157	A Population-Based, Descriptive Analysis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2737-2741.	1.1	24
158	HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2008, 14, 1470-1477.	3.2	79

#	Article	IF	Citations
159	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 6277-6283.	3.2	69
160	Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells. Cancer Research, 2008, 68, 3803-3809.	0.4	170
161	How I Treat Pancreatic Ductal Adenocarcinoma. Journal of Oncology Practice, 2008, 4, 46-47.	2.5	0
162	Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets, 2008, 12, 1389-1401.	1.5	16
164	Venous Thromboembolism and Pancreatic Cancer: Incidence, Pathogenesis and Clinical Implications. Onkologie, 2008, 31, 129-135.	1.1	3
165	Biologic therapies for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2008, 8, 1331-1338.	1.1	6
166	RCAS-Mediated Retroviral Gene Delivery: A Versatile Tool for the Study of Gene Function in a Mouse Model of Pancreatic Cancer. Human Gene Therapy, 2008, 19, 896-906.	1.4	8
167	Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy, 2008, 8, 1965-1976.	1.1	5
168	Novel advances in pancreatic cancer treatment. Expert Review of Anticancer Therapy, 2008, 8, 993-1002.	1.1	47
169	Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Review of Anticancer Therapy, 2008, 8, 1611-1621.	1.1	1
170	A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer, 2008, 98, 1774-1780.	2.9	47
171	Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Review of Anticancer Therapy, 2008, 8, 511-523.	1.1	37
172	Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together?. Journal of Clinical Oncology, 2008, 26, 3478-3480.	0.8	12
173	Allogeneic Granulocyte Macrophage Colony-Stimulating Factorâ€“Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research, 2008, 14, 1455-1463.	3.2	309
174	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 4943-4950.	3.2	63
175	Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study. Journal of Clinical Oncology, 2008, 26, 4921-4927.	0.8	113
176	Nuclear Factor-ÎºB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clinical Cancer Research, 2008, 14, 8143-8151.	3.2	126
177	Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trialâ€”SAKK 44/00â€“CECOG/PAN.1.3.001. Journal of Clinical Oncology, 2008, 26, 3695-3701.	0.8	93

#	Article	IF	Citations
178	Pilot Study of Combination Chemotherapy Using Irinotecan plus S-1 for Metastatic Pancreatic Cancer. Oncology, 2008, 75, 67-70.	0.9	5
179	Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Annals of Oncology, 2008, 19, 1742-1748.	0.6	6
180	Pancreatic Cancer: A Review and Update. Clinical Journal of Oncology Nursing, 2008, 12, 735-741.	0.3	24
181	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of Oncology, 2008, 19, 86-91.	0.6	72
182	New treatment options for advanced pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2008, 2, 673-696.	1.4	27
183	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. Current Molecular Medicine, 2008, 8, 12-37.	0.6	24
184	Determinants of RASistance to Antiâ€“Epidermal Growth Factor Receptor Agents. Journal of Clinical Oncology, 2008, 26, 1582-1584.	0.8	71
185	Neuropilin-2â€“Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2008, 14, 8052-8060.	3.2	84
186	Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Molecular Cancer Therapeutics, 2008, 7, 3624-3631.	1.9	30
187	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Annals of Oncology, 2008, 19, 340-347.	0.6	70
188	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. Molecular Therapy, 2008, 16, 979-984.	3.7	46
189	The treatment of advanced pancreatic cancer: current evidence and future challenges. Annals of Oncology, 2008, 19, vii304-vii308.	0.6	3
190	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. Annals of Oncology, 2008, 19, vii146-vii152.	0.6	10
191	Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?. Oncologist, 2008, 13, 562-576.	1.9	103
192	Pancreatic Stellate Cells and Pancreatic Cancer Cells: An Unholy Alliance. Cancer Research, 2008, 68, 7707-7710.	0.4	204
193	Coagulation, anticoagulation and pancreatic carcinoma. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 445-455.	1.7	25
194	Apoptosis-inducing effect of erlotinib is potentiated by 3,3â€²-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Molecular Cancer Therapeutics, 2008, 7, 1708-1719.	1.9	82
195	Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials. Journal of Clinical Oncology, 2008, 26, 1371-1378.	0.8	60

#	Article	IF	Citations
196	Small Molecules: Big Changes in the Cancer Treatment Paradigm. Journal of Pharmacy Practice, 2008, 21, 17-35.	0.5	2
197	Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry. Toxicologic Pathology, 2008, 36, 133-139.	0.9	17
198	Second-Line Therapy in Gemcitabine-Pretreated Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2008, 26, 1178-1179.	0.8	23
199	The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 5142-5149.	3.2	113
200	Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2008, 14, 215-223.	3.2	26
201	A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of Oncology, 2008, 19, 332-339.	0.6	28
202	Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. Nature Clinical Practice Oncology, 2008, 5, 312-313.	4.3	3
203	Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy, 2008, 8, 975-991.	1.1	6
204	Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma. Current Medicinal Chemistry, 2008, 15, 1674-1683.	1.2	15
205	Pancreatic cancerâ€"is the wall crumbling?. Annals of Oncology, 2008, 19, 1224-1230.	0.6	31
206	The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncology, 2008, 4, 41-50.	1.1	18
207	Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?. Future Oncology, 2008, 4, 241-255.	1.1	0
208	Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia, 2008, 24, 97-110.	1.1	3
209	Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. Cancer Investigation, 2008, 26, 784-793.	0.6	66
210	Society of Internal Medicine, 2008, 97, 2098-2104.	0.0	0
211	Cytostatic and cytotoxic drugs. Side Effects of Drugs Annual, 2008, , 520-532.	0.6	2
212	Cancer of the Pancreas: Are we Making Progress? A Review of Studies in the US Oncology Research Network. Cancer Control, 2008, 15, 308-313.	0.7	56
214	Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 221-224.	0.6	2

#	Article	IF	Citations
215	Borderline Resectable Pancreatic Cancer: On the Edge of Survival. Cancer Control, 2008, 15, 295-307.	0.7	44
216	Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1003-1011.	0.5	64
217	New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs, 2008, 19, 435-446.	0.7	36
218	PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 145-150.	0.6	21
219	Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 140-144.	0.6	41
221	A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies. Clinical Cancer Research, 2008, 14, 1131-1137.	3.2	20
222	Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma. Pancreas, 2008, 37, 154-158.	0.5	184
223	From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs, 2008, 19, 941-956.	0.7	0
224	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. Current Opinion in Oncology, 2008, 20, 454-458.	1.1	15
225	Protein Kinase C. Pancreas, 2008, 36, 346-352.	0.5	27
226	Tolerance and Efficacy of Gemcitabine and Gemcitabine-Based Regimens in Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2008, 36, e16-e21.	0.5	58
227	Cell Signaling Modifiers in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 40-45.	1.0	7
228	Treatment of locally advanced and metastatic pancreatic cancer. , 0, , 166-174.		0
229	Are selfâ€regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry?. Medical Journal of Australia, 2008, 189, 263-266.	0.8	18
230	Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 83.	3.0	52
231	Evolving therapies in the treatment of hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, Volume 2, 453-462.	3.0	17
232	Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707.	3.0	17
233	Therapy of Adenocarcinoma of Unknown Primary: Are We Making Progress?. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 1061-1067.	2.3	13

#	Article	IF	Citations
234	The Role of PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>and Its Interaction with COX-2 in Pancreatic Cancer. PPAR Research, 2008, 2008, 1-6.	1.1	32
235	Endoscopic Ultrasound-Guided Intratumoural Therapy for Pancreatic Cancer. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 405-410.	1.8	31
236	Effects of a Sequential Combination of Hyperthermia and Gemcitabine in the Treatment of Advanced Unresectable Pancreatic Cancer: A Retrospective Study. Thermal Medicine, 2008, 24, 131-139.	0.0	9
237	What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. Medical Journal of Australia, 2009, 190, 74-77.	0.8	11
238	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets and Therapy, 2009, , 419.	3.0	19
239	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, , 429.	3.0	2
240	First-line simplified GEMOX (S-GemOx) versus classical GEMOX inÂmetastatic pancreatic cancer (MPA): results ofÂaÂGERCOR randomized phase II study. Bulletin Du Cancer, 2009, 96, e18-e22.	0.6	11
241	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009, 2009, 1-14.	0.6	99
242	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	0.6	2
243	Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy. PLoS ONE, 2009, 4, e6539.	1.1	110
244	EGFR genomic alterations in cancer: prognostic and predictive values. Frontiers in Bioscience - Elite, 2009, E3, 879.	0.9	4
245	Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2009, 14, 311-328.	1.0	13
246	Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology, 2009, 76, 270-274.	0.9	35
247	Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs, 2009, 18, 1829-1842.	1.9	25
248	Management of advanced pancreatic cancer. Expert Review of Clinical Pharmacology, 2009, 2, 527-541.	1.3	4
249	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 2231-2237.	0.8	611
250	Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies. Oncologist, 2009, 14, 119-124.	1.9	19
251	Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy, 2009, 1, 223-239.	1.0	35

#	Article	IF	Citations
252	Pancreatic cancer: advances in medical therapy. Expert Review of Clinical Pharmacology, 2009, 2, 173-180.	1.3	0
253	Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate) Tj ETQq1 1 0.784314 rgBT /Overloc E6201: A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2009, 27, 3778-3785.	0.8	382
254	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	0.8	708
255	Molecular changes in pancreatic cancer. Expert Review of Anticancer Therapy, 2009, 9, 1487-1497.	1.1	21
256	Erlotinib: applications in therapy and current status of research. Expert Review of Clinical Pharmacology, 2009, 2, 15-36.	1.3	1
257	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	3.2	113
258	DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 1806-1813.	0.8	976
259	A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. British Journal of Cancer, 2009, 101, 1658-1663.	2.9	149
260	A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer, 2009, 100, 37-43.	2.9	5
261	Cancer: The Road to Amiens. Journal of Clinical Oncology, 2009, 27, 328-333.	0.8	97
262	Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan. International Journal of Risk and Safety in Medicine, 2009, 21, 161-167.	0.3	0
263	Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development. Journal of Clinical Oncology, 2009, 27, 5487-5491.	0.8	26
264	Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets, 2009, 13, 339-362.	1.5	77
265	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 193-198.	0.8	275
266	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Molecular Cancer Therapeutics, 2009, 8, 1484-1493.	1.9	39
267	Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site. Oncologist, 2009, 14, 1189-1197.	1.9	60
268	Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary Cilia. Cancer Research, 2009, 69, 422-430.	0.4	256
269	An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. Journal of Clinical Pathology, 2009, 62, 314-324.	1.0	36

#	Article	IF	Citations
270	Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 629-633.	0.8	33
271	Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904. Journal of Clinical Oncology, 2009, 27, 5506-5512.	0.8	84
272	Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology, 2009, 77, 40-48.	0.9	20
273	Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?. Oncology, 2009, 77, 217-223.	0.9	28
274	Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study. Oncology, 2009, 76, 333-337.	0.9	17
275	Epigenetic modulation and attacking the hedgehog pathway; potentially synergistic therapeutic targets for pancreatic cancer. Cancer Biology and Therapy, 2009, 8, 1340-1342.	1.5	4
276	Gemcitabine Combined With Uracil-Tegafur in Patients With Advanced Pancreatic Cancer. Journal of the National Medical Association, 2009, 101, 761-764.	0.6	0
277	The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells. Current Cancer Drug Targets, 2009, 9, 72-80.	0.8	42
278	Changing the clinical picture of challenging tumors: tales becoming reality?. Future Oncology, 2009, 5, 785-802.	1.1	1
279	Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor. Molecular Cancer Research, 2009, 7, 1572-1581.	1.5	96
280	Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study. Oncology Research and Treatment, 2009, 32, 99-102.	0.8	21
282	Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development. Current Medicinal Chemistry, 2009, 16, 4066-4218.	1.2	107
283	Prognostic signature for pancreatic cancer: are we close?. Future Oncology, 2009, 5, 313-321.	1.1	12
285	Tyrosine Kinase Inhibitors â€“ A Review on Pharmacology, Metabolism and Side Effects. Current Drug Metabolism, 2009, 10, 470-481.	0.7	510
286	Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel. Current Pharmaceutical Design, 2009, 15, 207-242.	0.9	10
287	Risk in Clinical Research: Size Matters!. Molecular Therapy, 2009, 17, 1833-1834.	3.7	2
288	Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 797-806.	0.6	55
289	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. Clinical Cancer Research, 2009, 15, 5895-5901.	3.2	101

#	Article	IF	Citations
290	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv37-iv40.	0.6	27
291	Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5499-5505.	0.8	23
292	Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase Iâ€“II study. Annals of Oncology, 2009, 20, 1369-1374.	0.6	13
293	Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Molecular Cancer Therapeutics, 2009, 8, 141-151.	1.9	94
294	Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. Journal of Clinical Oncology, 2009, 27, 5868-5873.	0.8	88
295	Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity. Clinical Cancer Research, 2009, 15, 6367-6377.	3.2	39
296	Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opinion on Investigational Drugs, 2009, 18, 469-479.	1.9	28
297	3,3â€²-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer. Cancer Research, 2009, 69, 5592-5600.	0.4	93
298	Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. Expert Reviews in Molecular Medicine, 2009, 11, e34.	1.6	6
299	Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer. Annals of Pharmacotherapy, 2009, 43, 542-545.	0.9	22
300	How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Journal of the National Cancer Institute, 2009, 101, 1044-1048.	3.0	325
301	A Case of Bullous Dermatitis Induced by Erlotinib. Oncologist, 2009, 14, 1201-1204.	1.9	6
302	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncology, 2009, 45, 1015-1020.	0.8	379
303	Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer. Journal of Pain and Symptom Management, 2009, 37, 135-143.	0.6	22
304	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery, 2009, 146, 241-249.	1.0	15
305	Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer, 2009, 9, 66.	1.1	36
306	Management of Venous Thromboembolism and the Potential to Impact Overall Survival in Patients with Cancer. Pharmacotherapy, 2009, 29, 1344-1356.	1.2	5
307	Novel Agents on the Horizon for Cancer Therapy. Ca-A Cancer Journal for Clinicians, 2009, 59, 111-137.	157.7	275

#	Article	IF	Citations
308	Models for prevention and treatment of cancer: Problems vs promises. Biochemical Pharmacology, 2009, 78, 1083-1094.	2.0	140
310	Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling, 2009, 21, 1255-1268.	1.7	72
311	Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors. Seminars in Oncology, 2009, 36, 65-74.	0.8	87
312	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Human Mutation, 2009, 30, E451-E459.	1.1	41
313	Carbohydrate antigen 19â€9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer, 2009, 115, 2630-2639.	2.0	104
314	Pancreatic adenocarcinoma in a young patient populationâ€”12â€year experience at Memorial Sloan Kettering Cancer Center. Journal of Surgical Oncology, 2009, 100, 8-12.	0.8	31
315	Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1377-1386.	1.2	23
316	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1137-1148.	1.2	39
317	Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 115-121.	1.1	116
318	Inhibition of protein synthesis by imexon reduces HIF-1Î± expression in normoxic and hypoxic pancreatic cancer cells. Investigational New Drugs, 2009, 27, 89-98.	1.2	11
319	Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Investigational New Drugs, 2009, 27, 374-378.	1.2	42
320	Interplay of Tumor Microenvironment Cell Types with Parenchymal Cells in Pancreatic Cancer Development and Therapeutic Implications. Journal of Gastrointestinal Cancer, 2009, 40, 1-9.	0.6	17
321	Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology, 2009, 11, 290-301.	1.2	4
322	Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology, 2009, 4, 107-119.	1.7	240
323	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology, 2009, 4, 267-273.	1.7	20
324	Axitinibâ€”a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted Oncology, 2009, 4, 297-305.	1.7	80
325	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. Targeted Oncology, 2009, 4, 311-322.	1.7	3
326	CC Chemokine Receptor 9 Enhances Proliferation in Pancreatic Intraepithelial Neoplasia and Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery, 2009, 13, 1955-1962.	0.9	30

#	Article	IF	Citations
327	Pancreatic cancer â€“ ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 211-213.	0.3	0
330	Basic Principles and Technologies for Deciphering the Genetic Map of Cancer. World Journal of Surgery, 2009, 33, 615-629.	0.8	13
331	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 313-319.	1.1	89
332	Adaptive group sequential design for phase II clinical trials: A Bayesian decision theoretic approach. Statistics in Medicine, 2009, 28, 3347-3362.	0.8	12
333	Tumor biology and cancer therapy â€“ an evolving relationship. Cell Communication and Signaling, 2009, 7, 19.	2.7	11
334	Substrateâ€dependent bidirectional modulation of Pâ€glycoproteinâ€mediated drug resistance by erlotinib. Cancer Science, 2009, 100, 1701-1707.	1.7	65
335	Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 22, 651-659.	2.9	83
336	Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene, 2009, 28, 2903-2909.	2.6	113
337	Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. British Journal of Cancer, 2009, 100, 1267-1276.	2.9	115
338	Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. British Journal of Cancer, 2009, 100, 1837-1841.	2.9	17
339	Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer â€“ a multi-centre randomised phase II study. British Journal of Cancer, 2009, 101, 1853-1859.	2.9	58
340	Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer, 2009, 33, 245-294.	1.0	9
341	Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1450-1455.	0.4	12
342	Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surgery Today, 2009, 39, 466-475.	0.7	43
343	Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference. Annals of Surgical Oncology, 2009, 16, 1757-1759.	0.7	5
344	Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial. Journal of Clinical Oncology, 2009, 27, 6243-6250.	0.8	79
345	Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation, 2009, 28, 186-194.	0.6	72
346	Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutaneous and Ocular Toxicology, 2009, 28, 181-184.	0.5	4

#	Article	IF	Citations
347	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treatment Reviews, 2009, 35, 167-174.	3.4	50
348	Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews, 2009, 35, 221-227.	3.4	80
349	Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treatment Reviews, 2009, 35, 335-339.	3.4	94
350	Pancreatic cancer: Current and future treatment strategies. Cancer Treatment Reviews, 2009, 35, 431-436.	3.4	86
351	Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treatment Reviews, 2009, 35, 676-684.	3.4	30
352	Cachexia in pancreatic cancer â€“ Mechanisms and potential intervention. European E-journal of Clinical Nutrition and Metabolism, 2009, 4, e337-e343.	0.4	1
353	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. European Journal of Cancer, 2009, 45, 1589-1596.	1.3	66
354	Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. European Journal of Cancer, 2009, 45, 2316-2323.	1.3	76
355	Staging for locally advanced pancreatic cancer. European Journal of Surgical Oncology, 2009, 35, 963-968.	0.5	32
356	HER-family gene amplification and expression in resected pancreatic cancer. European Journal of Surgical Oncology, 2009, 35, 1098-1104.	0.5	22
357	Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Letters, 2009, 273, 250-256.	3.2	22
358	Cancers of the Pancreas and Hepatobiliary System. Seminars in Oncology Nursing, 2009, 25, 76-92.	0.7	12
359	Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naÃ¯ve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial. Urology, 2009, 74, 665-671.	0.5	43
361	Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Review of Anticancer Therapy, 2009, 9, 1473-1485.	1.1	25
362	Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology, 2009, 53, 2231-2247.	1.2	1,083
363	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
364	Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Molecular Cancer, 2009, 8, 125.	7.9	120
366	The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America, 2009, 89, 1-15.	0.5	13

#	Article	IF	Citations
367	Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 412-422.	8.2	194
368	Surgical Treatment of Pancreatic Diseases. , 2009, , .		5
369	Targeting targeted agents: open issues for clinical trial design. Journal of Experimental and Clinical Cancer Research, 2009, 28, 66.	3.5	18
370	In vitromodels of pancreatic cancer for translational oncology research. Expert Opinion on Drug Discovery, 2009, 4, 429-443.	2.5	24
371	Current status and future prospects for anti-angiogenic therapies in cancer. Expert Opinion on Drug Discovery, 2009, 4, 961-979.	2.5	24
372	Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 170-183.	8.2	18
373	Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells. Cancer Research, 2009, 69, 5876-5884.	0.4	226
374	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptorâ€"Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	3.0	486
375	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. International Journal of Radiation Biology, 2009, 85, 943-954.	1.0	38
376	Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology, 2009, 27, 5660-5669.	0.8	211
377	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	0.5	37
379	EGFR Signaling and Drug Discovery. Oncology, 2009, 77, 400-410.	0.9	387
380	Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117Âpatients. Gastroenterologie Clinique Et Biologique, 2009, 33, 1036-1044.	0.9	16
381	Medical Management of Pancreatic Adenocarcinoma. Pancreatology, 2009, 9, 223-232.	0.5	13
382	Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-Cancer Drugs, 2009, 20, 634-638.	0.7	41
383	Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 44-48.	0.6	33
384	Economic Analysis of Radiation Therapy Oncology Group 97-14. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 423-428.	0.6	90
385	Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Current Opinion in Oncology, 2009, 21, 445-454.	1.1	48

#	Article	IF	Citations
386	Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 115-121.	0.6	23
387	Chemoradioimmunotherapy in Locally Advanced Pancreatic and Biliary Tree Adenocarcinoma. Pancreas, 2009, 38, e163-e168.	0.5	14
388	Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science, 2009, 117, 209-228.	1.8	28
389	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-5-S-21.	2.3	102
390	Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology, 2009, 4, 862-868.	0.5	47
391	Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncology Reports, 2009, 22, 105-13.	1.2	21
392	Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics, 2010, 17, 79-85.	0.5	1
393	Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis. Current Pharmaceutical Design, 2010, 16, 1396-1409.	0.9	11
394	Molecular Targeted Therapy of Biliary Tract Cancer â€“ Results of the First Clinical Studies. Current Drug Targets, 2010, 11, 834-850.	1.0	36
395	Gemox: A Widely Useful Therapy Against Solid Tumors-Review and Personal Experience. Journal of Chemotherapy, 2010, 22, 298-303.	0.7	7
396	Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines. Journal of Chemotherapy, 2010, 22, 129-133.	0.7	9
397	Update on Pancreatic Cancer Treatment. Nurse Practitioner, 2010, 35, 16-22.	0.2	3
398	Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma. Journal of Immunotherapy, 2010, 33, 828-833.	1.2	950
399	Preclinical Studies of Apogossypolone, a Novel Pan Inhibitor of Bcl-2 and Mcl-1, Synergistically Potentiates Cytotoxic Effect of Gemcitabine in Pancreatic Cancer Cells. Pancreas, 2010, 39, 323-331.	0.5	22
400	Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients. Otology and Neurotology, 2010, 31, 1135-1143.	0.7	91
401	Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer. Journal of Clinical Gastroenterology, 2010, 44, 286-288.	1.1	59
402	Meta-Analysis of Randomized Trials. Pancreas, 2010, 39, 253-255.	0.5	2
403	Erlotinib 150â€‰mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™. Anti-Cancer Drugs, 2010, 21, 94-100.	0.7	28

#	Article	IF	Citations
404	Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer. Pancreas, 2010, 39, 1284-1292.	0.5	26
405	Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 461-464.	0.6	40
406	The Road Not Taken and Choices in Radiation Oncology. Oncologist, 2010, 15, 332-337.	1.9	3
407	Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer. Pancreas, 2010, 39, 989-993.	0.5	27
409	Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 972-1017.	2.3	152
410	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncology Reports, 2010, 23, 1183-92.	1.2	116
411	Inhibition of MLK3 Decreases Proliferation and Increases Antiproliferative Activity of Epidermal Growth Factor Receptor (EGFR) Inhibitor in pancreatic cancer cell Lines. Cancer Growth and Metastasis, 2010, 3, CGM.S2824.	3.5	4
413	Nutrition and diet in the aetiology and management of pancreatic cancer. Gastrointestinal Nursing, 2010, 8, 24-29.	0.0	1
414	Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery. AAPS Journal, 2010, 12, 223-232.	2.2	95
415	EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 1442-1452.	0.7	24
416	Society of Surgical Oncology Presidential Address: The War on Cancerâ€"Shifting from Disappointment to New Hope. Annals of Surgical Oncology, 2010, 17, 1971-1978.	0.7	4
417	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews, 2010, 62, 346-361.	6.6	376
418	Advanced or Metastatic Pancreatic Cancer: Molecular Targeted Therapies. Mount Sinai Journal of Medicine, 2010, 77, 606-619.	1.9	31
419	Cardioâ€Oncology/Oncoâ€Cardiology. Clinical Cardiology, 2010, 33, 733-737.	0.7	74
420	Personalized Medicine in Nonâ€"Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptorâ€"Targeted Therapy?. Journal of Clinical Oncology, 2010, 28, 4769-4777.	0.8	243
421	A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 527-536.	1.1	33
422	A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 287-294.	1.1	19
423	A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 1051-1057.	1.1	64

#	Article	IF	Citations
424	Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 395-403.	1.1	53
427	Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. Langenbeck's Archives of Surgery, 2010, 395, 697-706.	0.8	28
429	Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. Journal of Gastroenterology, 2010, 45, 1146-1154.	2.3	33
430	Changing paradigms in clinical trials. Memo - Magazine of European Medical Oncology, 2010, 3, 1-2.	0.3	1
432	Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology, 2010, 3, 307-317.	0.4	4
433	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biology, 2010, 31, 351-357.	0.8	46
435	ABC Transporters as Molecular Effectors of Pancreatic Oncogenic Pathways: The Hedgehog-GLI Model. Journal of Gastrointestinal Cancer, 2010, 41, 153-158.	0.6	19
436	TRAIL and Triptolide: An Effective Combination that Induces Apoptosis in Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery, 2010, 14, 252-260.	0.9	39
437	Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients. Journal of Gastrointestinal Surgery, 2010, 14, 1547-1559.	0.9	103
439	EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Research and Treatment, 2010, 122, 685-697.	1.1	64
440	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology, 2010, 96, 219-230.	1.4	208
441	Venous thromboembolism and cancer: a systematic review. Journal of Thrombosis and Thrombolysis, 2010, 30, 67-78.	1.0	40
442	Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational New Drugs, 2010, 28, 343-349.	1.2	15
443	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. , 2010, 128, 82-90.		10
444	Angiogenesis Inhibitors: Current Strategies and Future Prospects. Ca-A Cancer Journal for Clinicians, 2010, 60, 222-243.	157.7	413
445	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer, 2010, 10, 368.	1.1	152
446	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer, 2010, 10, 570.	1.1	12
447	Targeted drug delivery in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 97-104.	3.3	46

#	Article	IF	Citations
448	Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3â€²-deoxy-3â€²-fluorothymidine. Biochemical Pharmacology, 2010, 79, 587-595.	2.0	37
449	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	1.7	88
450	Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy. FEBS Letters, 2010, 584, 2699-2706.	1.3	141
451	Targeting histone deacetylases in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2010, 14, 1255-1263.	1.6	27
452	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	2.0	143
453	Sorafenib: Where do we go from here?. Hepatology, 2010, 52, 360-369.	3.6	92
454	Concurrent inhibition of NFâ€ºB, cyclooxygenaseâ€2, and epidermal growth factor receptor leads to greater antiâ€tumor activity in pancreatic cancer. Journal of Cellular Biochemistry, 2010, 110, 171-181.	1.2	24
455	Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5â€fluorouracil, and cisplatin followed by radiotherapy and 5â€fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. Journal of Surgical Oncology, 2010, 101, 587-592.	0.8	141
456	Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: an Effective and Well-tolerated Treatment. Clinical Oncology, 2010, 22, 27-35.	0.6	11
457	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Critical Reviews in Oncology/Hematology, 2010, 74, 193-202.	2.0	24
458	18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1420-1425.	0.4	119
459	Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. Radiation Oncology, 2010, 5, 60.	1.2	4
460	TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. Journal of Molecular Signaling, 2010, 5, 18.	0.5	18
461	Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. British Journal of Pharmacology, 2010, 160, 998-1007.	2.7	68
462	In vitro and in vivo evidence that a combination of lapatinib plus Sâ€1 is a promising treatment for pancreatic cancer. Cancer Science, 2010, 101, 468-473.	1.7	20
463	Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Science, 2010, 101, 433-439.	1.7	101
464	Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Science, 2010, 101, 2351-2360.	1.7	46
465	Expression of L1CAM, COXâ€2, EGFR, câ€KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?. Histopathology, 2010, 56, 440-448.	1.6	28

#	Article	IF	Citations
466	Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene, 2010, 29, 1941-1951.	2.6	40
467	Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells. Oncogene, 2010, 29, 3146-3152.	2.6	15
468	Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. British Journal of Cancer, 2010, 103, 223-231.	2.9	20
469	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British Journal of Cancer, 2010, 103, 649-655.	2.9	65
470	Inhibition of reninâ€“angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer, 2010, 103, 1644-1648.	2.9	150
471	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotechnology, 2010, 28, 585-593.	9.4	210
472	Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer, 2010, 10, 130-137.	12.8	618
473	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer, 2010, 10, 241-253.	12.8	506
474	Metastatic Pancreatic Cancer: Systemic Therapy. Medical Radiology, 2010, , 137-146.	0.0	0
476	Current and emerging therapies for the treatment of pancreatic cancer. OncoTargets and Therapy, 2010, 3, 111.	1.0	32
477	Therapeutic Antibodies for the Treatment of Pancreatic Cancer. Scientific World Journal, The, 2010, 10, 1107-1120.	0.8	15
478	Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model. PLoS ONE, 2010, 5, e9430.	1.1	62
479	The Locally Advanced Nonmetastatic Cancer. Medical Radiology, 2010, , 123-136.	0.0	0
480	Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncology Letters, 2010, 1, 231-235.	0.8	10
481	Fixed-Dose-Rate Gemcitabine Infusion in Patients with Advanced Pancreatic or Biliary Tree Adenocarcinoma. Tumori, 2010, 96, 405-410.	0.6	5
482	Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World Journal of Gastroenterology, 2010, 16, 673.	1.4	49
483	Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study. Oncology Letters, 2010, 1, 335-338.	0.8	3
484	Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2010, 56, 22-26.	0.3	3

#	Article	IF	Citations
486	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. Journal of Clinical Oncology, 2010, 28, 1645-1651.	0.8	279
487	Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile. Drug Metabolism and Disposition, 2010, 38, 1238-1245.	1.7	71
488	Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2423-2429.	1.9	14
489	Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2010, 16, 986-994.	3.2	41
490	Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study. Japanese Journal of Clinical Oncology, 2010, 40, 1135-1138.	0.6	22
491	Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment. Molecular and Cellular Proteomics, 2010, 9, 695-704.	2.5	33
492	Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Annals of Oncology, 2010, 21, 1391-1393.	0.6	2
493	Pain and Emotional Well-Being Outcomes in Southwest Oncology Groupâ€“Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer. Journal of Clinical Oncology, 2010, 28, 3611-3616.	0.8	21
494	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Annals of Oncology, 2010, 21, 2233-2239.	0.6	35
495	Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies. Molecular Cancer Therapeutics, 2010, 9, 1419-1431.	1.9	120
496	Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?. Clinical Cancer Research, 2010, 16, 5972-5980.	3.2	105
497	Translating Clinical Trials into Meaningful Outcomes. Clinical Cancer Research, 2010, 16, 5951-5955.	3.2	19
498	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). Oncologist, 2010, 15, 1310-1319.	1.9	58
499	Regimen-related gastrointestinal toxicities in cancer patients. Current Opinion in Supportive and Palliative Care, 2010, 4, 26-30.	0.5	43
500	Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past. Clinical Cancer Research, 2010, 16, 5963-5971.	3.2	23
501	The way forward in treating pancreatic cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 157-160.	1.4	0
502	Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan. Japanese Journal of Clinical Oncology, 2010, 40, 183-187.	0.6	2
503	Role of Vitamin D in the Prevention of Pancreatic Cancer. Journal of Nutrition and Metabolism, 2010, 2010, 1-9.	0.7	16

#	Article	IF	Citations
504	Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Annals of Oncology, 2010, 21, 98-103.	0.6	67
505	S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure. Japanese Journal of Clinical Oncology, 2010, 40, 567-572.	0.6	24
507	Radiosensitization of Epidermal Growth Factor Receptor/HER2â€“Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status. Clinical Cancer Research, 2010, 16, 912-923.	3.2	53
508	Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Annals of Oncology, 2010, 21, 7-12.	0.6	147
509	Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort. Molecular Cancer Therapeutics, 2010, 9, 751-760.	1.9	20
510	Palliative Management of Pancreatic Cancer. , 2010, , 813-838.		0
511	Understanding resistance to EGFR inhibitorsâ€”impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	12.5	593
512	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€“Directed Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610.	0.8	570
513	Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology, 2010, 28, 3617-3622.	0.8	758
514	Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 529-540.	1.1	37
515	Explaining Marginal Benefits to Patients, When â€œMarginalâ€•Means Additional but Not Necessarily Small. Clinical Cancer Research, 2010, 16, 5981-5986.	3.2	22
516	On Target? Off Target? Why We Really Do Not Know. Journal of Clinical Oncology, 2010, 28, 2937-2938.	0.8	0
517	Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer. Clinical Cancer Research, 2010, 16, 5320-5328.	3.2	48
518	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v55-v58.	0.6	134
519	New and potential clinical applications ofKRASas a cancer biomarker. Expert Opinion on Medical Diagnostics, 2010, 4, 383-395.	1.6	7
520	Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer. Journal of Clinical Oncology, 2010, 28, 2058-2063.	0.8	36
521	Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers, 2010, 2, 2044-2054.	1.7	28
522	Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Journal of the National Cancer Institute, 2010, 102, 1207-1210.	3.0	6

#	Article	IF	Citations
523	Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan. Japanese Journal of Clinical Oncology, 2010, 40, 774-780.	0.6	34
525	Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2010, 2, 85-106.	1.4	5
526	Current Status of Adjuvant Therapy for Pancreatic Cancer. Oncologist, 2010, 15, 1205-1213.	1.9	26
527	Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist, 2010, 15, 1320-1328.	1.9	109
528	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology, 2010, 12, 1061-1070.	0.6	112
529	ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biology and Therapy, 2010, 10, 555-563.	1.5	56
530	Acute Fatal Liver Toxicity under Erlotinib. Case Reports in Oncology, 2010, 3, 182-188.	0.3	21
531	Potentiation of gemcitabine by Turmeric Forceâ„¢ in pancreatic cancer cell lines. Oncology Reports, 2010, 23, 1529-35.	1.2	26
532	Recent Advances in Combined Modality Therapy. Oncologist, 2010, 15, 372-381.	1.9	37
533	Clinical Medicine and Clinical Trials. Oncologist, 2010, 15, 382-387.	1.9	0
534	Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins. Current Drug Metabolism, 2010, 11, 618-628.	0.7	40
535	Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies. Current Pharmaceutical Design, 2010, 16, 2184-2193.	0.9	10
536	Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut, 2010, 59, 1527-1534.	6.1	70
537	Optimal treatment of metastatic pancreatic cancer. Gut, 2010, 59, 1454-1455.	6.1	4
538	Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptorâ€“Expressing Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 3090-3099.	1.9	21
539	Chemoprevention of Pancreatic Cancer: Ready for the Clinic?. Cancer Prevention Research, 2010, 3, 1375-1378.	0.7	7
540	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	1.1	47
542	Novel therapies for pancreatic cancer: setbacks and progress. Future Oncology, 2010, 6, 1061-1064.	1.1	9

#	Article	IF	Citations
543	Comparative Effectiveness and Health Care Spending â€" Implications for Reform. New England Journal of Medicine, 2010, 362, 460-465.	13.9	232
545	Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biology and Therapy, 2010, 9, 754-763.	1.5	26
546	Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations. Current Medicinal Chemistry, 2010, 17, 1635-1678.	1.2	76
547	Gemcitabine remains the standard of care for pancreatic cancer. Nature Reviews Clinical Oncology, 2010, 7, 135-137.	12.5	33
548	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604.	2.9	46
549	In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells. Current Cancer Drug Targets, 2010, 10, 600-610.	0.8	13
550	Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opinion on Drug Safety, 2010, 9, 207-213.	1.0	12
551	The role of radiotherapy in locally advanced pancreatic carcinoma. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 437-447.	8.2	36
552	Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2068-2078.	1.9	46
553	Novel Targets for Pancreatic Cancer Therapy. Surgical Oncology Clinics of North America, 2010, 19, 419-429.	0.6	10
554	DNA Mutational Differences in Cytological Specimens from Pancreatic Cancer and Cholangiocarcinoma. Pancreatology, 2010, 10, 429-433.	0.5	9
555	Randomized Clinical Trials in Pancreatic Adenocarcinoma. Surgical Oncology Clinics of North America, 2010, 19, 115-150.	0.6	5
556	Aspects mÃ©dico-Ã©conomiques de la pneumologie. Revue Des Maladies Respiratoires Actualites, 2010, 2, 205-222.	0.0	0
557	Targeted Therapies for Solid Tumors. BioDrugs, 2010, 24, 303-316.	2.2	18
558	A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer. Translational Oncology, 2010, 3, 373-379.	1.7	18
559	A review of erlotinib â€" an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opinion on Pharmacotherapy, 2010, 11, 311-320.	0.9	35
560	Targeted therapies for non-small cell lung cancer. Lung Cancer, 2010, 67, 257-274.	0.9	140
561	Pancreatic cancer stem cells â€" update and future perspectives. Molecular Oncology, 2010, 4, 431-442.	2.1	74

#	Article	IF	Citations
562	Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 297-304.	1.0	18
563	HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Molecular Cancer, 2010, 9, 80.	7.9	70
564	Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Human Pathology, 2010, 41, 1205-1209.	1.1	60
565	Cardiac side-effects of cancer chemotherapy. International Journal of Cardiology, 2010, 144, 3-15.	0.8	371
566	Survival comparison between glioblastoma multiforme and other incurable cancers. Journal of Clinical Neuroscience, 2010, 17, 417-421.	0.8	145
569	Dihydroartemisinin inactivates NF-Î¹B and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Letters, 2010, 293, 99-108.	3.2	149
570	Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters, 2010, 299, 1-10.	3.2	52
571	Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews, 2010, 36, 235-248.	3.4	52
572	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer, 2010, 46, 526-533.	1.3	30
573	Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. European Journal of Cancer, 2010, 46, 650-658.	1.3	26
574	Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European Journal of Cancer, 2010, 46, 2010-2019.	1.3	71
575	Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer, 2010, 46, 2753-2762.	1.3	91
576	Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology, 2010, 7, 163-172.	12.5	704
577	Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1175-1193.	1.5	92
578	Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer. Nutrition and Cancer, 2010, 62, 1137-1141.	0.9	230
579	Pancreatic Cancer. New England Journal of Medicine, 2010, 362, 1605-1617.	13.9	2,474
580	Gene Therapy for Pancreatic Cancer. , 2010, , 1237-1268.		0
581	Palliative Chemotherapy for Pancreatic Malignancies. Surgical Clinics of North America, 2010, 90, 365-375.	0.5	4

#	Article	IF	Citations
582	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	0.8	78
583	Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis. Journal of Clinical Oncology, 2010, 28, 4425-4433.	0.8	97
584	Therapeutic drug monitoring in cancer chemotherapy. Bioanalysis, 2010, 2, 863-879.	0.6	23
585	Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer. Molecular Therapy, 2010, 18, 435-441.	3.7	64
587	GSK3Î² and Î²-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer. Neoplasia, 2010, 12, 357-365.	2.3	43
588	Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 15.	3.5	6
589	Supportive Cancer Care with Chinese Medicine. , 2010, , .		15
590	Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 3965-3972.	0.8	332
591	Rexin-G, a targeted genetic medicine for cancer. Expert Opinion on Biological Therapy, 2010, 10, 819-832.	1.4	57
592	Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Nonâ€“Small-Cell Lung Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 830-840.	1.3	69
593	Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta OncolÃ³gica, 2010, 49, 404-406.	0.8	1
594	Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent. Radiation Research, 2011, 175, 10-20.	0.7	14
595	New Approaches to the Treatment of Pancreatic Cancer. BioDrugs, 2011, 25, 207-216.	2.2	10
596	Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 6071-6082.	3.2	44
597	Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy. Molecular Cancer Therapeutics, 2011, 10, 1993-1999.	1.9	126
598	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	3.2	47
599	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death and Disease, 2011, 2, e221-e221.	2.7	87
600	Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opinion on Drug Safety, 2011, 10, 147-157.	1.0	22

#	Article	IF	Citations
601	The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer. Advances in Surgery, 2011, 45, 301-321.	0.6	22
602	Complications cardio-vasculaires des thÃ©rapies ciblÃ©es. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 12-17.	0.0	0
603	Lâ€™intÃ©rÃªt des thÃ©rapies ciblÃ©es chez le patient atteint de cancer au stade palliatif. Medecine Palliative, 2011, 10, 51-63.	0.0	0
604	Acycloguanosyl 5â€²-thymidyltriphosphate, a Thymidine Analogue Prodrug Activated by Telomerase, Reduces Pancreatic Tumor Growth in Mice. Gastroenterology, 2011, 140, 709-720.e9.	0.6	10
605	Yet Another Nucleoside Analog for Pancreatic Cancer. Gastroenterology, 2011, 140, 400-404.	0.6	2
606	Medical treatment of pancreatic cancer: New hopes after 10years of gemcitabine. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 364-374.	0.7	13
607	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. Digestive and Liver Disease, 2011, 43, 225-230.	0.4	8
608	Novel Cytochrome P450 Bioactivation of a Terminal Phenyl Acetylene Group: Formation of a One-Carbon Loss Benzaldehyde and Other Oxidative Products in the Presence ofN-Acetyl Cysteine or Glutathione. Chemical Research in Toxicology, 2011, 24, 677-686.	1.7	7
609	Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. Oncology Reports, 2011, 27, 891-7.	1.2	23
610	Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis. Pancreatology, 2011, 11, 595-600.	0.5	22
611	High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. International Journal of Oncology, 2011, 38, 629-41.	1.4	25
612	ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer, 2011, 73, 274-282.	0.9	9
614	Molecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives. Oncology, 2011, 81, 259-272.	0.9	55
615	A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. Drug Safety, 2011, 34, 175-186.	1.4	9
616	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2011, 50, 371-403.	1.6	95
617	Targeted Therapies for Gastric Cancer. Drugs, 2011, 71, 1367-1384.	4.9	37
618	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	0.6	408
619	Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Therapy, 2011, 18, 598-608.	2.2	51

#	Article	IF	Citations
620	Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2011, 13, 1026-IN24.	2.3	41
621	New standards and a predictive biomarker for adjuvant therapy. Nature Reviews Clinical Oncology, 2011, 8, 70-72.	12.5	17
622	Efficacy and Safety of Standardized Allergen-Removed <i>Rhus verniciflua</i> Stokes Extract in Patients with Advanced or Metastatic Pancreatic Cancer: A Korean Single-Center Experience. Oncology, 2011, 81, 312-318.	0.9	20
623	Induction Chemotherapy. , 2011, , .		5
624	Cancer Stem Cells in Solid Tumors. , 2011, , .		7
625	Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology, 2011, 29, 587-601.	0.8	19
626	Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treatment Reviews, 2011, 37, 599-610.	3.4	27
627	An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Letters, 2011, 313, 76-83.	3.2	38
629	A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. European Journal of Cancer, 2011, 47, 199-205.	1.3	24
630	Pancreatic Cancer Stem Cells as New Targets for Diagnostics and Therapy. Else-KrÃ¶ner-Fresenius-Symposia, 2011, , 116-134.	0.1	1
631	The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology, 2011, 8, 562-566.	12.5	17
632	Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sciences, 2011, 89, 304-312.	2.0	97
633	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer â€" A Veterans Affairs Cancer Registry analysis. Journal of Geriatric Oncology, 2011, 2, 209-214.	0.5	22
634	Erlotinib-induced Hepatotoxicityâ€"Clinical Presentation and Successful Management: A Case Report. Journal of Clinical and Experimental Hepatology, 2011, 1, 38-40.	0.4	10
635	FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncology, The, 2011, 12, 8-9.	5.1	42
636	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncology, The, 2011, 12, 256-262.	5.1	356
637	Delivering affordable cancer care in high-income countries. Lancet Oncology, The, 2011, 12, 933-980.	5.1	571
638	Striking a balance between idealism and fatalism. Lancet Oncology, The, 2011, 12, 923-924.	5.1	5

#	Article	IF	Citations
639	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	13.9	6,140
640	Stromal biology and therapy in pancreatic cancer. Gut, 2011, 60, 861-868.	6.1	652
641	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	6.3	2,155
642	Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2011, 18, 126-138.	0.9	116
644	Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	2
645	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	0.8	7
646	Signaling Pathways in Pancreatic Cancer. Critical Reviews in Eukaryotic Gene Expression, 2011, 21, 115-129.	0.4	34
647	Oral chemotherapeutic agents in current use. Journal of the Korean Medical Association, 2011, 54, 1191.	0.1	5
649	Gemcitabine in elderly patients with advanced pancreatic cancer. World Journal of Gastroenterology, 2011, 17, 3497.	1.4	49
650	EGFR genomic alterations in cancer prognostic and predictive values. Frontiers in Bioscience - Elite, 2011, E3, 879-887.	0.9	29
651	Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer. Critical Reviews in Therapeutic Drug Carrier Systems, 2011, 28, 293-356.	1.2	5
652	Randomized trials in exocrine pancreatic cancer. Przeglad Gastroenterologiczny, 2011, 2, 85-96.	0.3	1
653	Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer. Journal of Oncology, 2011, 2011, 1-11.	0.6	6
654	Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. Clinical Journal of Oncology Nursing, 2011, 15, 501-508.	0.3	11
655	Phase II Study of Radiation Therapy Combined With Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 115-119.	0.6	32
656	DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance. PLoS ONE, 2011, 6, e26815.	1.1	64
657	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Molecular Imaging, 2011, 10, 7290.2010.00040.	0.7	23
658	Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer. Oncology Reports, 2011, 27, 423-32.	1.2	2

#	Article	IF	Citations
659	Interstitial Lung Disease Under Erlotinib Plus Gemcitabine for Pancreatic Carcinoma A Therapeutic Dilemma. Pancreas, 2011, 40, 170-171.	0.5	4
660	Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer. Journal of Immunotherapy, 2011, 34, 92-99.	1.2	91
661	Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anti-Cancer Drugs, 2011, 22, 864-874.	0.7	17
662	Advances in pancreatic cancer. Current Opinion in Gastroenterology, 2011, 27, 460-466.	1.0	29
663	Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anti-Cancer Drugs, 2011, 22, 719-731.	0.7	8
664	Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 70-75.	0.6	33
665	Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2011, 40, 415-421.	0.5	35
666	Fluorescence In Situ Hybridization and K-ras Analyses Improve Diagnostic Yield of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Solid Pancreatic Masses. Pancreas, 2011, 40, 1057-1062.	0.5	38
667	Metastatic pancreatic cancer: old drugs, new paradigms. Current Opinion in Oncology, 2011, 23, 390-395.	1.1	32
668	Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials. Current Drug Targets, 2011, 12, 1983-1988.	1.0	5
669	Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W.) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	1
670	Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis. Current Genomics, 2011, 12, 15-24.	0.7	99
671	Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer. Current Cancer Drug Targets, 2011, 11, 734-751.	0.8	97
672	Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas, 2011, 40, 657-663.	0.5	20
673	Molecular Targeted Approaches for Treatment of Pancreatic Cancer. Current Pharmaceutical Design, 2011, 17, 2221-2238.	0.9	22
674	Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma. Pancreas, 2011, 40, 1276-1282.	0.5	76
676	Pancreatic cancer: a whistle-stop tour. Gastrointestinal Nursing, 2011, 9, 41-45.	0.0	0
677	Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Experimental and Therapeutic Medicine, 2011, 2, 103-108.	0.8	22

#	Article	IF	Citations
678	PPARÎ³ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. International Journal of Oncology, 2011, 40, 679-85.	1.4	18
679	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. Experimental and Therapeutic Medicine, 2011, 2, 969-975.	0.8	7
680	A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age â‰¥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1569-1577.	0.5	34
682	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Science, 2011, 102, 425-431.	1.7	51
683	Transforming growth factorâ€beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Science, 2011, 102, 1193-1200.	1.7	108
684	Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. Hpb, 2011, 13, 597-604.	0.1	19
685	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-202.	0.4	28
686	Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums fÃ¼r den primÃr behandelnden Arzt. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-203.	0.4	14
687	Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 2011, 17, 500-503.	15.2	1,460
688	Cancer drugs should add months, not weeks, say experts. Nature Medicine, 2011, 17, 7-7.	15.2	6
689	Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery, 2011, 10, 351-364.	21.5	236
690	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Experimental Cell Research, 2011, 317, 1476-1489.	1.2	47
691	Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial. Trials, 2011, 12, 129.	0.7	18
692	The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. Biochemical Pharmacology, 2011, 82, 1583-1592.	2.0	13
693	Targeting ErbB3-mediated stromalâ€“epithelial interactions in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2011, 105, 523-533.	2.9	37
694	An oncolytic adenovirus defective in pRb-binding (dl922â€“947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Therapy, 2011, 18, 734-743.	2.2	40
695	Overcoming drug resistance in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 817-828.	1.5	194
696	Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?. Memo - Magazine of European Medical Oncology, 2011, 4, 257-259.	0.3	0

#	Article	IF	Citations
697	Inflammation and Gastrointestinal Cancers. Recent Results in Cancer Research, 2011, , .	1.8	10
698	Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 1122-1129.	0.7	24
699	MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 2381-2387.	0.7	81
700	Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial. Annals of Surgical Oncology, 2011, 18, 1319-1326.	0.7	275
701	Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Advanced Drug Delivery Reviews, 2011, 63, 184-192.	6.6	205
702	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Investigational New Drugs, 2011, 29, 499-505.	1.2	18
703	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2011, 29, 694-699.	1.2	52
704	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational New Drugs, 2011, 29, 1057-1065.	1.2	11
705	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Molecular Biology Reports, 2011, 38, 1315-1320.	1.0	35
706	Pancreatic cancer stem cells: new insights and perspectives. Journal of Gastroenterology, 2011, 46, 966-973.	2.3	35
707	Somatic variation and cancer: therapies lost in the mix. Human Genetics, 2011, 130, 79-91.	1.8	40
710	A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. International Journal of Clinical Oncology, 2011, 16, 637-645.	1.0	7
711	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunology, Immunotherapy, 2011, 60, 99-109.	2.0	38
712	Gemcitabine enhances Wilmsâ€™ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunology, Immunotherapy, 2011, 60, 1289-1297.	2.0	46
713	The Promise of a Personalized Genomic Approach to Pancreatic Cancer and Why Targeted Therapies Have Missed the Mark. World Journal of Surgery, 2011, 35, 1766-1769.	0.8	8
714	Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 2011, 67, 183-192.	1.1	7
715	A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 891-897.	1.1	30
716	Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 215-221.	1.1	27

#	Article	IF	Citations
717	Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemotherapy and Pharmacology, 2011, 68, 571-582.	1.1	14
718	Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 677-683.	1.1	6
719	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemotherapy and Pharmacology, 2011, 68, 1017-1026.	1.1	6
720	Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 1431-1438.	1.1	20
721	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemotherapy and Pharmacology, 2011, 68, 1173-1178.	1.1	6
722	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. Clinical and Translational Oncology, 2011, 13, 61-66.	1.2	2
723	SEOM clinical guidelines for the treatment of pancreatic cancer. Clinical and Translational Oncology, 2011, 13, 528-535.	1.2	5
724	Pulmonary toxicities from targeted therapies: a review. Targeted Oncology, 2011, 6, 235-243.	1.7	94
725	Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. Journal of Gastrointestinal Surgery, 2011, 15, 1026-1034.	0.9	10
727	Combination of recombinant adenovirus-p53 with radiochemotherapy in unresectable pancreatic carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 194-200.	0.7	5
728	Defining New Paradigms for the Treatment of Pancreatic Cancer. Current Treatment Options in Oncology, 2011, 12, 111-125.	1.3	36
729	Current Treatment Options for Pancreatic Carcinoma. Current Oncology Reports, 2011, 13, 195-205.	1.8	33
730	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer, 2011, 11, 313.	1.1	9
731	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 2011, 10, 37.	7.9	200
732	A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2011, 4, 11.	6.9	61
733	Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells. Stem Cells, 2011, 29, 883-887.	1.4	80
734	Phase 1 clinical trials in 83 patients with pancreatic cancer. Cancer, 2011, 117, 77-85.	2.0	8
735	Targeting ILâ€13RÎ±2 in human pancreatic ductal adenocarcinoma with combination therapy of ILâ€13â€PE and gemcitabine. International Journal of Cancer, 2011, 128, 1221-1231.	2.3	25

#	Article	IF	Citations
736	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 181-188.	0.4	230
737	Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology, 2011, 78, 227-242.	2.0	33
738	MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts. Clinical Cancer Research, 2011, 17, 2799-2806.	3.2	237
739	Role of the RAS in Pancreatic Cancer. Current Cancer Drug Targets, 2011, 11, 412-420.	0.8	27
740	Metastatic pancreatic cancerâ€"is FOLFIRINOX the new standard?. Nature Reviews Clinical Oncology, 2011, 8, 452-453.	12.5	23
741	Endoscopic management of malignant biliary obstruction by means of covered metallic stents: primary stent placement vs. re-intervention. Endoscopy, 2011, 43, 1039-1044.	1.0	30
742	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Review of Anticancer Therapy, 2011, 11, 1555-1565.	1.1	13
744	Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. British Journal of Nutrition, 2011, 106, 795-800.	1.2	21
745	Novel Approaches to Target Pancreatic Cancer. Current Cancer Drug Targets, 2011, 11, 698-713.	0.8	9
746	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 365, 768-769.	13.9	140
747	Changing Pathology with Changing Drugs: Tumors of the Gastrointestinal Tract. Pathobiology, 2011, 78, 76-89.	1.9	19
748	The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. Expert Review of Anticancer Therapy, 2011, 11, 579-588.	1.1	8
749	Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. International Journal of Hyperthermia, 2011, 27, 101-107.	1.1	73
750	Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment. Molecular Cancer Therapeutics, 2011, 10, 2135-2145.	1.9	185
751	Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2011, 29, 4105-4112.	0.8	721
752	Some essential considerations in the design and conduct of non-inferiority trials. Clinical Trials, 2011, 8, 432-439.	0.7	63
753	Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. Clinical Cancer Research, 2011, 17, 4862-4871.	3.2	35
754	FOLFIRINOX: A Small Step or a Great Leap Forward?. Journal of Clinical Oncology, 2011, 29, 3727-3729.	0.8	27

#	Article	IF	Citations
755	Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials. Journal of Clinical Oncology, 2011, 29, 174-185.	0.8	99
756	Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 953-958.	0.6	44
757	Antiâ€“Epidermal Growth Factor Receptor Treatment Strategies in Advanced Pancreatic Cancer: Success or Failure?. Journal of Clinical Oncology, 2011, 29, e70-e71.	0.8	4
758	The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab. Clinical Cancer Research, 2011, 17, 6766-6777.	3.2	30
759	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 2011, 12, 1641-1652.	0.6	45
761	Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis, 2011, 32, 445-451.	1.3	111
762	Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma. Clinical Cancer Research, 2011, 17, 5901-5912.	3.2	38
763	Metabolic Disorder, Inflammation, and Deregulated Molecular Pathways Converging in Pancreatic Cancer Development: Implications for New Therapeutic Strategies. Cancers, 2011, 3, 446-460.	1.7	9
764	The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers, 2011, 3, 267-284.	1.7	4
765	Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition. Clinical Cancer Research, 2011, 17, 3706-3715.	3.2	77
766	Targeted Therapy in Hepatocellular Carcinoma. International Journal of Hepatology, 2011, 2011, 1-11.	0.4	23
767	Oncolytic virotherapy for pancreatic cancer. Expert Reviews in Molecular Medicine, 2011, 13, e18.	1.6	23
768	When Are "Positive" Clinical Trials in Oncology Truly Positive?. Journal of the National Cancer Institute, 2011, 103, 16-20.	3.0	101
769	Randomized Phase II Trials: A Long-term Investment With Promising Returns. Journal of the National Cancer Institute, 2011, 103, 1093-1100.	3.0	82
770	Minimal Modeling Approaches to Value of Information Analysis for Health Research. Medical Decision Making, 2011, 31, E1-E22.	1.2	53
771	Pancreatic cancer treatment and research: an international expert panel discussion. Annals of Oncology, 2011, 22, 1500-1506.	0.6	51
772	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6983.	0.6	2
773	Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	66

#	Article	IF	Citations
774	Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Therapeutic Advances in Medical Oncology, 2011, 3, 27-33.	1.4	19
775	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Annals of Oncology, 2011, 22, 482-484.	0.6	8
777	Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer. Oncology, 2011, 80, 97-101.	0.9	16
778	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology, 2011, 81, 143-150.	0.9	15
779	Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV). Case Reports in Oncology, 2011, 4, 413-419.	0.3	2
780	Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. International Journal of Oncology, 2011, 39, 473-82.	1.4	23
781	KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy. Oncology, 2011, 81, 3-8.	0.9	41
782	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes and Cancer, 2011, 2, 335-343.	0.6	28
783	A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer. Oncology, 2011, 80, 175-180.	0.9	30
784	Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma. Oncology, 2011, 81, 50-54.	0.9	41
786	Anti-cancer agent-induced dyspnea. Progress in Palliative Care, 2011, 19, 235-242.	0.7	2
787	A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFÎ² in pancreatic cancer cells. Cancer Biology and Therapy, 2011, 12, 198-207.	1.5	48
789	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. Clinical Cancer Research, 2011, 17, 4091-4100.	3.2	60
790	Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1275-E1284.	3.3	65
791	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. Journal of Clinical Oncology, 2011, 29, 2543-2549.	0.8	64
792	Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells. Clinical Cancer Research, 2011, 17, 2744-2756.	3.2	69
793	Erlotinib â€˜dosing-to-rashâ€™: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer, 2011, 105, 938-944.	2.9	37
794	The molecular biology and novel treatments of vestibular schwannomas. Journal of Neurosurgery, 2011, 115, 906-914.	0.9	58

#	Article	IF	Citations
795	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 2011, 105, 1554-1562.	2.9	62
796	Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 993-999.	1.1	5
797	Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 2011, 29, 4548-4554.	0.8	957
798	Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacologica Sinica, 2011, 32, 399-407.	2.8	40
799	Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents. Journal of Oncology Pharmacy Practice, 2011, 17, 448-452.	0.5	26
800	Metastatic Pancreatic Cancer: What Can Nurses Do?. Clinical Journal of Oncology Nursing, 2011, 15, 424-428.	0.3	2
801	Current Surgical Aspects of Palliative Treatment for Unresectable Pancreatic Cancer. Cancers, 2011, 3, 636-651.	1.7	15
802	Management strategies in pancreatic cancer. American Journal of Health-System Pharmacy, 2011, 68, 573-584.	0.5	23
803	Rationale for Possible Targeting of Histone Deacetylase Signaling in Cancer Diseases with a Special Reference to Pancreatic Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-8.	3.0	15
804	Treatment of Pancreatic Cancer: What Can We Really Predict Today?. Cancers, 2011, 3, 675-699.	1.7	8
805	Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 2011, 12, 5895-5907.	1.8	12
806	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumabâ€™s Clinical Effects. Cancers, 2011, 3, 2014-2031.	1.7	29
807	Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model. Sarcoma, 2011, 2011, 1-5.	0.7	9
808	Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer. ISRN Oncology, 2011, 2011, 1-5.	2.1	7
809	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology, 2011, 13, 109-118.	0.6	137
810	Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi Journal of Gastroenterology, 2012, 18, 118.	0.5	67
811	Editorial: The case for a comparative, value-based alternative to the patient-centered outcomes research model for comparative effectiveness research. Neurosurgical Focus, 2012, 33, E8.	1.0	2
812	Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. Acta OncolÃ³gica, 2012, 51, 234-242.	0.8	12

#	Article	IF	Citations
813	Signaling Pathways in Inflammatory Breast Cancer. , 2012, , 151-160.		0
814	Anti-Austerity Agents from Rhizoma et Radix Notopterygii (Qianghuo). Planta Medica, 2012, 78, 796-799.	0.7	13
815	Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	7
816	Molecular Imaging in Tracking Tumor Stem-Like Cells. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-13.	3.0	21
817	Hurdles in anticancer drug development from a regulatory perspective. Nature Reviews Clinical Oncology, 2012, 9, 236-243.	12.5	28
818	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology, 2012, 23, 2799-2805.	0.6	184
820	Enhanced Antitumor Effect of Combination Therapy With Gemcitabine and Guggulsterone in Pancreatic Cancer. Pancreas, 2012, 41, 1048-1057.	0.5	26
821	Pancreatic adenocarcinoma: ESMOâ€“ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii33-vii40.	0.6	307
822	Postresection Chemotherapy for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 614-623.	1.0	7
823	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 255-260.	0.6	45
824	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Annals of Oncology, 2012, 23, 570-576.	0.6	69
825	The Pancreas Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 4266-4276.	3.2	1,087
826	Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.6	41
827	Unresectable Pancreatic Cancer: Arterial Embolization to Achieve a Single Blood Supply for Intraarterial Infusion of 5-Fluorouracil and Full-Dose IV Gemcitabine. American Journal of Roentgenology, 2012, 198, 1445-1452.	1.0	16
828	The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance. Current Molecular Medicine, 2012, 12, 288-303.	0.6	71
829	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. Current Cancer Drug Targets, 2012, 12, 439-452.	0.8	29
830	Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations. Current Pharmaceutical Design, 2012, 18, 2811-2829.	0.9	47
831	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 341-346.	1.4	30

#	Article	IF	Citations
832	Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle, 2012, 11, 1656-1663.	1.3	55
833	Aberrations and Therapeutics Involving the Developmental Pathway Hedgehog in Pancreatic cancer. Vitamins and Hormones, 2012, 88, 355-378.	0.7	5
834	Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?. Expert Review of Gastroenterology and Hepatology, 2012, 6, 149-161.	1.4	1
835	The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Review of Anticancer Therapy, 2012, 12, 469-480.	1.1	10
836	Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?. Pharmacogenomics, 2012, 13, 977-979.	0.6	3
837	Gemcitabine: A Critical Nucleoside for Cancer Therapy. Current Medicinal Chemistry, 2012, 19, 1076-1087.	1.2	83
838	Targeted Therapy at the End of Life in Advanced Cancer Patients. Journal of Palliative Medicine, 2012, 15, 991-997.	0.6	20
839	Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial. Human Gene Therapy, 2012, 23, 1224-1236.	1.4	17
840	Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 1352-1363.	3.2	212
841	Cetuximab dosing by rashâ€"is the scaling of EVEREST meaningful?. Nature Reviews Clinical Oncology, 2012, 9, 554-556.	12.5	3
842	A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naÃ¯ve patients with unresectable exocrine adenocarcinoma of the pancreas â€" a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. British Journal of Cancer, 2012, 107, 280-286.	2.9	67
843	A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. British Journal of Cancer, 2012, 106, 1934-1939.	2.9	89
844	Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer, 2012, 106, 666-672.	2.9	33
845	Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer, 2012, 106, 1033-1038.	2.9	160
846	Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. British Journal of Cancer, 2012, 107, 411-416.	2.9	79
847	Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes. Cancer Research, 2012, 72, 2695-2700.	0.4	115
848	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	0.8	18
849	VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Annals of Oncology, 2012, 23, 2812-2820.	0.6	31

#	Article	IF	Citations
850	Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study. Chemotherapy, 2012, 58, 371-380.	0.8	2
851	Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemotherapy Research and Practice, 2012, 2012, 1-10.	1.6	39
852	Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice, 2012, 2012, 1-11.	1.6	14
853	Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Eruption with Topical Recombinant Human Epidermal Growth Factor. Dermatology, 2012, 225, 135-140.	0.9	18
854	Aberrant glycogen synthase kinase 3Î² in the development of pancreatic cancer. Journal of Carcinogenesis, 2012, 11, 15.	2.5	11
855	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers, 2012, 4, 989-1035.	1.7	29
856	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology, 2012, 23, 1214-1222.	0.6	91
857	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology, 2012, 23, 2834-2842.	0.6	167
858	Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 446-450.	0.6	16
859	New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. American Journal of Health-System Pharmacy, 2012, 69, 1031-1037.	0.5	23
860	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. Oncologist, 2012, 17, 555-568.	1.9	44
861	Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?. Oncologist, 2012, 17, 192-200.	1.9	83
862	Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics, 2012, 11, 405-415.	1.9	21
863	Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. Oncology Reports, 2012, 28, 519-526.	1.2	14
864	Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report. Case Reports in Oncology, 2012, 5, 253-259.	0.3	8
865	Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash. Onkologie, 2012, 35, 747-752.	1.1	8
866	BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer. Molecular Cancer Therapeutics, 2012, 11, 2644-2653.	1.9	63
867	Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology Reports, 2012, 27, 923-928.	1.2	11

#	Article	IF	Citations
868	Molecular and Genetic Bases of Pancreatic Cancer. Current Drug Targets, 2012, 13, 731-743.	1.0	24
869	Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment. Current Signal Transduction Therapy, 2012, 7, 3-13.	0.3	0
870	Editorial [Hot Topic: Pancreatic Cancer: Between Bench and Bedside (Guest Editors: Davide Melisi and) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	10
871	Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer. Current Drug Targets, 2012, 13, 789-794.	1.0	2
872	Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics. Current Drug Targets, 2012, 13, 811-828.	1.0	15
873	Expanding Surgical Treatment of Pancreatic Cancer. Pancreas, 2012, 41, 678-684.	0.5	15
874	Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 653-664.	1.0	19
875	A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology Reports, 2012, 28, 763-767.	1.2	3
876	Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Oncology Reports, 2012, 28, 2211-2216.	1.2	10
878	Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. International Journal of Oncology, 2012, 41, 2093-2102.	1.4	73
880	Chemotherapy and Other Supportive Modalities in the Palliative Setting for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 633-641.	1.0	5
881	Why is pancreatic cancer difficult to treat in the elderly?. Aging Health, 2012, 8, 301-307.	0.3	2
882	Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity. Journal of Medicinal Chemistry, 2012, 55, 9531-9540.	2.9	34
883	Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. British Journal of Cancer, 2012, 107, 1797-1800.	2.9	15
884	Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement. Annals of Surgical Oncology, 2012, 19, 3659-3667.	0.7	26
885	Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 5031-5042.	3.2	54
886	Treatment options for advanced pancreatic cancer: a review. Expert Review of Anticancer Therapy, 2012, 12, 1327-1336.	1.1	36
887	Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. Journal of Vascular and Interventional Radiology, 2012, 23, 1613-1621.	0.2	205

#	Article	IF	Citations
888	What We Have Learned About Pancreatic Cancer From Mouse Models. Gastroenterology, 2012, 142, 1079-1092.	0.6	151
889	Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?. Biomarkers in Medicine, 2012, 6, 349-362.	0.6	6
890	HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. Pharmacogenomics, 2012, 13, 1469-1476.	0.6	9
891	Array-based pharmacogenomics of molecular-targeted therapies in oncology. Pharmacogenomics Journal, 2012, 12, 185-196.	0.9	13
892	Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 1531-1539.	1.2	17
893	A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 2371-2376.	1.2	12
894	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502	1.2	92
895	Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2012, 13, 181-188.	5.1	407
896	A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer. Science Translational Medicine, 2012, 4, 156ra139.	5.8	207
897	The Antitumor Activity of Recombinant Antitumor Antiviral Protein and the Associated Molecular Mechanism in Pancreatic Tumor Cells. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 426-433.	0.7	0
898	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. British Journal of Surgery, 2012, 100, 5-14.	0.1	5
899	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy, 2012, 61, 1373-1385.	2.0	242
900	Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1625-1630.	1.2	7
901	EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer Cell, 2012, 22, 304-317.	7.7	445
902	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 22, 318-330.	7.7	339
903	Ready, Set, Go: The EGF Receptor at the Pancreatic Cancer Starting Line. Cancer Cell, 2012, 22, 281-282.	7.7	20
904	Phase I Study of Conformal Radiotherapy and Concurrent Full-Dose Gemcitabine With Erlotinib for Unresected Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e187-e192.	0.4	6
905	Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 508-518.	0.4	36

#	Article	IF	Citations
906	Doseâ€“Volume Analysis of Predictors for Gastrointestinal Toxicity After Concurrent Full-Dose Gemcitabine and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1120-1125.	0.4	49
907	Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Journal of Surgical Research, 2012, 178, 758-767.	0.8	66
908	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. Pancreatology, 2012, 12, 388-393.	0.5	9
909	Management of Cancer in the Older Adult. Clinics in Geriatric Medicine, 2012, 28, 33-49.	1.0	12
910	Invasive markers identified by gene expression profiling in pancreatic cancer. Pancreatology, 2012, 12, 130-140.	0.5	13
911	Radiofrequency Ablation of Liver Metastasis in Patients with Locally Controlled Pancreatic Ductal Adenocarcinoma. Journal of Vascular and Interventional Radiology, 2012, 23, 635-641.	0.2	41
912	Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition. Neoplasia, 2012, 14, 519-525.	2.3	76
913	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America, 2012, 41, 189-209.	1.0	31
914	Locally Advanced Pancreatic Cancer. Seminars in Oncology, 2012, 39, e9-e22.	0.8	5
915	Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology, 2012, 12, 219-226.	0.5	10
916	HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology, 2012, 12, 146-155.	0.5	20
917	Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. International Journal of Hyperthermia, 2012, 28, 597-604.	1.1	40
918	Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy. Annals of Surgical Oncology, 2012, 19, 395-403.	0.7	44
919	Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor. Cancer Research, 2012, 72, 282-293.	0.4	139
920	Low Expression of Junctional Adhesion Molecule A Is Associated with Metastasis and Poor Survival in Pancreatic Cancer. Annals of Surgical Oncology, 2012, 19, 4330-4336.	0.7	38
921	Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. Hpb, 2012, 14, 260-268.	0.1	19
922	Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 2048-2055.	3.2	50
923	Ocular Toxicity of Targeted Therapies. Journal of Clinical Oncology, 2012, 30, 3277-3286.	0.8	117

#	Article	IF	Citations
924	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 2012, 106, 508-516.	2.9	233
925	Why RECIST Works and Why It Should Stayâ€"Counterpoint. Cancer Research, 2012, 72, 5151-5157.	0.4	28
926	Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression. American Journal of Pathology, 2012, 180, 1386-1393.	1.9	64
927	Combinational therapy: New hope for pancreatic cancer?. Cancer Letters, 2012, 317, 127-135.	3.2	85
928	Comorbidity, age and overall survival in patients with advanced pancreatic cancer â€“ Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo. European Journal of Cancer, 2012, 48, 1434-1442.	1.3	63
929	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 77-87.	8.2	91
930	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers in Surgery and Medicine, 2012, 44, 755-761.	1.1	11
931	Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?. BMC Cancer, 2012, 12, 104.	1.1	28
932	Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer, 2012, 12, 390.	1.1	31
933	RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 2012, 12, 395.	1.1	17
934	New biomarkers and targets in pancreatic cancer and their application to treatment. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 435-444.	8.2	194
935	Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis, 2012, 4, 2499-2511.	0.6	8
936	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opinion on Drug Discovery, 2012, 7, 723-743.	2.5	26
937	Systemic treatment of advanced pancreatic cancer. Cancer Treatment Reviews, 2012, 38, 843-853.	3.4	108
938	Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treatment Reviews, 2012, 38, 566-579.	3.4	113
939	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications. Cytokine and Growth Factor Reviews, 2012, 23, 343-356.	3.2	37
940	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. Drug Discovery Today: Disease Models, 2012, 9, e69-e73.	1.2	1
941	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointestinal Endoscopy, 2012, 75, 332-338.	0.5	138

#	Article	IF	Citations
942	Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointestinal Endoscopy, 2012, 76, 962-971.	0.5	95
944	Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics Journal, 2012, 12, 1-9.	0.9	10
945	The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 454-467.	8.2	535
946	Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opinion on Investigational Drugs, 2012, 21, 143-152.	1.9	28
947	Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs, 2012, 17, 571-582.	1.0	10
948	Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance. , 2012, , 135-164.		0
949	Biological Drugs: Classic Adverse Effects and New Clinical Evidences. Cardiovascular Toxicology, 2012, 12, 285-297.	1.1	7
950	Pancreatic Adenocarcinoma in Young Adults in a Moroccan Population. Journal of Gastrointestinal Cancer, 2012, 43, 607-611.	0.6	12
951	Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Medical Oncology, 2012, 29, 2831-2837.	1.2	7
952	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Medical Oncology, 2012, 29, 3003-3008.	1.2	13
953	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Medical Oncology, 2012, 29, 3092-3100.	1.2	187
954	In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia, 2012, 14, 121-130.	2.3	66
955	Stromal Cell-Derived Factor 1Î± Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer. Neoplasia, 2012, 14, 690-IN6.	2.3	44
956	Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months. Pancreatology, 2012, 12, 35-38.	0.5	4
958	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 547-553.	1.1	10
959	Cystic Pancreatic Lesions. , 2012, , 173-191.		0
960	Pancreatic Ductal Adenocarcinoma. , 2012, , 153-171.		1
961	Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. BioDrugs, 2012, 26, 83-99.	2.2	33

#	Article	IF	Citations
962	Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer Cells. Nucleic Acid Therapeutics, 2012, 22, 295-305.	2.0	67
963	Inflammatory Breast Cancer: An Update. , 2012, , .		0
964	Molecular Characterization of Head and Neck Cancer. Molecular Diagnosis and Therapy, 2012, 16, 209-222.	1.6	22
966	Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. Journal of Experimental and Clinical Cancer Research, 2012, 31, 73.	3.5	40
967	Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells. PLoS ONE, 2012, 7, e31004.	1.1	57
968	Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach. PLoS ONE, 2012, 7, e39545.	1.1	46
969	Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS ONE, 2012, 7, e29794.	1.1	213
970	Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?. Thrombosis, 2012, 2012, 1-9.	1.4	12
971	Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer. Current Pharmaceutical Design, 2012, 18, 2464-2471.	0.9	130
972	Current Knowledge on Pancreatic Cancer. Frontiers in Oncology, 2012, 2, 6.	1.3	62
973	Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence. Frontiers in Oncology, 2012, 2, 31.	1.3	26
974	Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience - Landmark, 2012, 17, 2698.	3.0	17
975	Role of Pharmacogenetics in Gastrointestinal Cancer. , 2012, , .		1
976	Targeted Nanoparticles for Cancer Therapy. , 0, , .		16
977	Medical Therapy of Pancreatic Cancer: Current Status and Future Targets. , 2012, , .		0
978	Novel therapeutic modalities and drug delivery in pancreatic cancer â€“ an ongoing search for improved efficacy. Drugs in Context, 2012, 2012, 1-4.	1.0	1
979	Gemcitabine and Erlotinib (GE) Regimen for Pancreatic Cancer. Hospital Pharmacy, 2012, 47, 19-23.	0.4	1
980	Targeted Therapy in Oncology: A Key Player in the Move towards Personalized Medicine. Journal of Developing Drugs, 2012, 01, .	0.9	0

#	Article	IF	Citations
981	Pancreatic Cancer: Current Concepts in Invasion and Metastasis. , 2012, , .		1
982	Hepatobiliary Pancreatic Cancer: Cutting-Edge Drug Therapy. Annals of Oncology, 2012, 23, xi67-xi68.	0.6	0
984	A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 232-237.	1.8	6
985	Novel and Targeted Therapies. , 2012, , 95-101.		0
986	Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; September 8â€“10, 2011. Current Oncology, 2012, 19, 468-477.	0.9	1
987	FDG PET/CT detected an insidious inguinal canal metastasis in a patient with pancreatic cancer. Journal of Biomedical Graphics and Computing, 2012, 2, .	0.2	0
988	Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway. International Journal of Biological Sciences, 2012, 8, 1-14.	2.6	62
989	Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine, 2012, 3, 931-936.	0.8	16
990	External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. Pancreas, 2012, 41, 738-744.	0.5	1
991	Recent Advances of Biliary Stent Management. Korean Journal of Radiology, 2012, 13, S62.	1.5	10
992	Targeted therapy for esophagogastric cancers: a review. OncoTargets and Therapy, 2012, 5, 91.	1.0	0
993	A twoâ€stage Bayesian design for coâ€development of new drugs and companion diagnostics. Statistics in Medicine, 2012, 31, 901-914.	0.8	37
994	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biology and Therapy, 2012, 13, 1072-1081.	1.5	205
995	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. Journal of Clinical Oncology, 2012, 30, 3012-3019.	0.8	152
996	Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. Science Translational Medicine, 2012, 4, 127ps8.	5.8	218
997	Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. British Journal of Surgery, 2012, 99, 1083-1088.	0.1	65
998	Longâ€term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer, 2012, 118, 3026-3035.	2.0	59
999	Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer, 2012, 118, 3484-3493.	2.0	99

#	Article	IF	Citations
1000	Phase 1 doseâ€escalation trial evaluating the combination of the selective MET (mesenchymalâ€epithelial) Tj ETQq0 0 0 rgBT /Overlock	2.0	74
1001	Fractionated radioimmunotherapy with ⁹⁰Yâ€clivatuzumab tetraxetan and lowâ€dose gemcitabine is active in advanced pancreatic cancer. Cancer, 2012, 118, 5497-5506.	2.0	79
1003	Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1138-1143.	1.2	60
1004	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational New Drugs, 2012, 30, 1164-1174.	1.2	19
1005	A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1175-1183.	1.2	38
1006	Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study) Tj ETQq1 1 0.784314 rgBT /Over	1.2	13
1007	A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 1203-1207.	1.2	22
1008	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology, 2012, 108, 499-506.	1.4	41
1009	18F-FDG PET/CT Imaging Detects Therapy Efficacy of Anti-EMMPRIN Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts. Molecular Imaging and Biology, 2012, 14, 237-244.	1.3	19
1010	High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas. Molecular Imaging and Biology, 2012, 14, 472-479.	1.3	31
1012	Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical Oncology, 2012, 29, 957-961.	1.2	9
1013	A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 1013-1020.	1.1	6
1014	Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	75
1015	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1641-1645.	1.1	78
1016	Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-ÎºB and nuclear factor-ÎºB-regulated gene products in pancreatic cancer both in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2012, 138, 785-797.	1.2	76
1017	Glycogen synthase kinase 3Î² inhibition sensitizes pancreatic cancer cells to gemcitabine. Journal of Gastroenterology, 2012, 47, 321-333.	2.3	48
1018	Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 21, 418-429.	7.7	1,664
1019	A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy. Clinical Oncology, 2012, 24, 105-111.	0.6	16

#	Article	IF	Citations
1020	Targeting heat shock response pathways to treat pancreatic cancer. Drug Discovery Today, 2012, 17, 35-43.	3.2	40
1021	Stroma and pancreatic ductal adenocarcinoma: An interaction loop. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 170-178.	3.3	25
1022	Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochemical Pharmacology, 2012, 83, 452-461.	2.0	23
1023	Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. Journal of Cellular and Molecular Medicine, 2012, 16, 988-994.	1.6	9
1024	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatology Research, 2012, 42, 879-886.	1.8	86
1025	Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB) Tj ETQq1 1 0.784314 rgBT/Overlock	1.3	57
1026	Stem cells as the root of pancreatic ductal adenocarcinoma. Experimental Cell Research, 2012, 318, 691-704.	1.2	42
1027	Molecularly targeted therapies in cervical cancer. A systematic review. Gynecologic Oncology, 2012, 126, 291-303.	0.6	68
1028	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: <scp>GECA</scp>1. Cancer Science, 2012, 103, 1489-1492.	1.7	36
1029	Bone marrowâ€derived proangiogenic cells in pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 23-26.	1.4	7
1030	Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving selfâ€expandable metallic stents for palliation. Digestive Endoscopy, 2012, 24, 226-230.	1.3	48
1031	Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Annals of Surgical Oncology, 2012, 19, 2256-2263.	0.7	30
1032	Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer, 2012, 118, 571-578.	2.0	18
1033	Aberrant signaling pathways in pancreatic cancer: A two compartment view. Molecular Carcinogenesis, 2012, 51, 25-39.	1.3	52
1034	Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. Medical Oncology, 2012, 29, 212-214.	1.2	7
1035	Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Medical Oncology, 2012, 29, 134-139.	1.2	18
1036	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.1	64
1037	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2012, 69, 415-424.	1.1	39

#	Article	IF	Citations
1038	The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2012, 69, 425-430.	1.1	10
1039	An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemotherapy and Pharmacology, 2012, 69, 605-612.	1.1	24
1040	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 2012, 30, 382-386.	1.2	91
1041	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 779-786.	1.2	49
1042	Prognostic value of cetuximabâ€related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group. International Journal of Cancer, 2013, 132, 236-245.	2.3	68
1043	Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study. BMC Research Notes, 2013, 6, 280.	0.6	10
1044	The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?. Cutaneous and Ocular Toxicology, 2013, 32, 248-251.	0.5	5
1045	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	5.7	408
1046	Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Quality of Life Research, 2013, 22, 1105-1112.	1.5	52
1048	Nuclear Medicine Therapy. , 2013, , .		5
1049	Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1065-1072.	1.1	33
1050	Neoadjuvant therapy in resectable pancreatic cancer: A critical review. Cancer Treatment Reviews, 2013, 39, 518-524.	3.4	39
1051	Triple approach strategy for patients with locally advanced pancreatic carcinoma. Hpb, 2013, 15, 623-627.	0.1	44
1052	Foolâ€™s gold, lost treasures, and the randomized clinical trial. BMC Cancer, 2013, 13, 193.	1.1	42
1053	Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer, 2013, 13, 41.	1.1	42
1054	Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 549-556.	1.4	31
1055	Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British Journal of Cancer, 2013, 108, 1-8.	2.9	265
1056	Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?. Archives of Dermatological Research, 2013, 305, 653-658.	1.1	3

#	Article	IF	Citations
1057	Benefit and Harms of New Anti-Cancer Drugs. Current Oncology Reports, 2013, 15, 270-275.	1.8	30
1058	Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. Journal of Gastrointestinal Cancer, 2013, 44, 182-189.	0.6	2
1059	TL-118â€"anti-angiogenic treatment in pancreatic cancer: a case report. Medical Oncology, 2013, 30, 585.	1.2	13
1060	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2013, 139, 681-689.	1.2	125
1061	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer, 2013, 21, 3243-3254.	1.0	46
1062	Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Supportive Care in Cancer, 2013, 21, 1167-1174.	1.0	73
1063	Met, IGF1R, and Other New Targets in Upper GI Malignancies. Current Treatment Options in Oncology, 2013, 14, 321-336.	1.3	2
1064	The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma. Memo - Magazine of European Medical Oncology, 2013, 6, 26-28.	0.3	0
1065	Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemotherapy and Pharmacology, 2013, 71, 1231-1240.	1.1	29
1066	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 85-92.	1.1	21
1067	Therapeutic Advances in Pancreatic Cancer. Gastroenterology, 2013, 144, 1316-1326.	0.6	257
1068	Reduction in circulating proâ€angiogenic and proâ€inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omegaâ€3 fish oil. Hpb, 2013, 15, 428-432.	0.1	31
1069	CÃ¡ncer de pÃ¡ncreas exocrino. Medicine, 2013, 11, 1526-1531.	0.0	0
1070	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Current Problems in Cancer, 2013, 37, 110-144.	1.0	50
1071	Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib. Neoplasia, 2013, 15, 143-IN10.	2.3	86
1072	Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247.	2.1	140
1073	Increased Survival After Resection of Pancreatic Cancer Liver Metastases. CirugÃa EspaÃ±ola (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
1074	Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-Î² signalling pathway. Pharmacological Reports, 2013, 65, 682-688.	1.5	5

#	Article	IF	Citations
1075	The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19, 1389-1400.	15.2	883
1076	Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. Pancreatology, 2013, 13, 140-146.	0.5	41
1077	Multidisciplinary Management ofÂPancreatic Cancer. Surgical Oncology Clinics of North America, 2013, 22, 265-287.	0.6	29
1078	Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer, 2013, 49, 2633-2642.	1.3	160
1079	Biliary tract carcinomas: From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology, 2013, 85, 136-148.	2.0	39
1080	The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. Annals of Oncology, 2013, 24, iv5-iv10.	0.6	8
1081	A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs, 2013, 31, 707-713.	1.2	86
1082	Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery, 2013, 154, 1078-1086.	1.0	79
1083	Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicology Letters, 2013, 222, 23-35.	0.4	38
1085	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 2013, 369, 1691-1703.	13.9	5,097
1086	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 985-990.	1.1	11
1087	Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma. World Journal of Surgical Oncology, 2013, 11, 266.	0.8	10
1088	Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer, 2013, 12, 104.	7.9	38
1089	A phase I study of sorafenib, oxaliplatin and 2Âdays of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational New Drugs, 2013, 31, 943-948.	1.2	9
1090	Targeting the Rasâ€“ERK pathway in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 147-162.	2.7	83
1091	EGFR and HER2 inhibition in pancreatic cancer. Investigational New Drugs, 2013, 31, 558-566.	1.2	28
1092	Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. Journal of Gastrointestinal Cancer, 2014, 45, 190-201.	0.6	24
1093	Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer Microenvironment, 2013, 6, 241-245.	3.1	27

#	Article	IF	Citations
1094	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 369-379.	0.7	3
1096	Regionale Therapie maligner Tumoren. , 2013, , .		1
1097	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Advanced Drug Delivery Reviews, 2013, 65, 1731-1747.	6.6	218
1098	Cardiovascular Toxicities of Cancer Chemotherapy. Seminars in Oncology, 2013, 40, 156-167.	0.8	37
1099	Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics, 2013, 35, 1282-1303.	1.1	81
1100	Regorafenib for Gastrointestinal Malignancies. BioDrugs, 2013, 27, 213-224.	2.2	37
1101	Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics Journal, 2013, 13, 181-188.	0.9	29
1102	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. Expert Opinion on Pharmacotherapy, 2013, 14, 2203-2220.	0.9	4
1103	Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Medicine, 2013, 5, 26.	3.6	18
1104	EGFR mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	1.5	14
1105	Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. Expert Review of Clinical Pharmacology, 2013, 6, 663-676.	1.3	11
1106	A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investigational New Drugs, 2013, 31, 85-91.	1.2	29
1107	Radioimmunotherapy of Pancreatic Adenocarcinoma. , 2013, , 239-255.		0
1108	Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2013, 132, 993-1003.	2.3	87
1109	Diagnostic Yield of Pancreatic Percutaneous Puncture Depending on the Size of the Lesion. CirugÃa EspaÃ±ola (English Edition), 2013, 91, 361-365.	0.1	0
1110	â€œChronicâ€•metastatic pancreatic acinar cell carcinoma. Pancreatology, 2013, 13, 549-552.	0.5	16
1111	Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer. Neoplasia, 2013, 15, 61-IN18.	2.3	13
1112	A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells. European Journal of Pharmaceutical Sciences, 2013, 48, 658-667.	1.9	12

#	Article	IF	Citations
1113	Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues. Surgical Oncology, 2013, 22, 69-76.	0.8	5
1114	Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 678-685.	0.4	35
1115	Nested Case Control Study of Proteomic Biomarkers for Interstitial Lung Disease in Japanese Patients With Nonâ€“Small-Cell Lung Cancer Treated With Erlotinib: A Multicenter Phase IV Study (JO21661). Clinical Lung Cancer, 2013, 14, 407-417.	1.1	10
1116	An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer, 2013, 82, 136-142.	0.9	53
1117	Synthetic Lethality Screen Identifies RPS6KA2 as Modifier of Epidermal Growth Factor Receptor Activity in Pancreatic Cancer. Neoplasia, 2013, 15, 1354-1362.	2.3	33
1118	Radiosensitizers in pancreatic cancerâ€”Preclinical and clinical exploits with molecularly targeted agents. Current Problems in Cancer, 2013, 37, 301-312.	1.0	1
1119	Current concepts and novel targets in advanced pancreatic cancer. Gut, 2013, 62, 317-326.	6.1	134
1122	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 2013, 49, 2077-2085.	1.3	72
1123	Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2517-2525.	1.1	23
1124	Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis. Pancreatology, 2013, 13, 415-422.	0.5	19
1125	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer, 2013, 49, 593-603.	1.3	106
1126	FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical Oncology, 2013, 30, 361.	1.2	121
1127	Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patientsâ€™ quality of life. World Journal of Surgical Oncology, 2013, 11, 3.	0.8	7
1128	SnapShot: Pancreatic Cancer. Cancer Cell, 2013, 23, 424-424.e1.	7.7	33
1129	Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2013, 31, 1405-1414.	0.8	188
1130	Multidisciplinary management of locally advancedâ€“borderline resectable adenocarcinoma of the head of the pancreas. Clinical and Translational Oncology, 2013, 15, 173-181.	1.2	9
1131	The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. Current Oncology Reports, 2013, 15, 182-189.	1.8	85
1132	The war on cancer: are we winning?. Tumor Biology, 2013, 34, 1275-1284.	0.8	42

#	Article	IF	Citations
1133	Nontoxic radioactive Listeria ^{at} is a highly effective therapy against metastatic pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8668-8673.	3.3	130
1134	Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opinion on Investigational Drugs, 2013, 22, 341-356.	1.9	25
1135	Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. AAPS Journal, 2013, 15, 78-84.	2.2	15
1136	Whole blood interferonâ€ˆ levels predict the therapeutic effects of adoptive Tâ€cell therapy in patients with advanced pancreatic cancer. International Journal of Cancer, 2013, 133, 1119-1125.	2.3	17
1137	Targeting apoptosis pathways in pancreatic cancer. Cancer Letters, 2013, 332, 346-358.	3.2	116
1138	Cetuximab: still an option in the treatment of pancreatic cancer?. Expert Opinion on Biological Therapy, 2013, 13, 791-801.	1.4	17
1139	Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 585-602.	2.7	104
1140	EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A caseâ€“control study of overall survival. Lung Cancer, 2013, 80, 306-312.	0.9	44
1141	Advanced-stage pancreatic cancer: therapy options. Nature Reviews Clinical Oncology, 2013, 10, 323-333.	12.5	183
1142	Toward the Goal of Personalized Therapy in Pancreatic Cancer by Targeting the Molecular Phenotype. Advances in Experimental Medicine and Biology, 2013, 779, 91-143.	0.8	11
1144	The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 500-508.	0.7	61
1145	Efficacy of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane Versus a Covered Metal Stent for Malignant Biliary Obstruction: A Prospective Comparative Study. Digestive Diseases and Sciences, 2013, 58, 865-871.	1.1	40
1146	The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 5572-5579.	3.2	56
1147	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™ (AIO-PK0104). Gut, 2013, 62, 751-759.	6.1	105
1148	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 845-852.	1.1	11
1149	Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbeck's Archives of Surgery, 2013, 398, 989-996.	0.8	13
1150	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investigational New Drugs, 2013, 31, 1375-1383.	1.2	6
1151	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investigational New Drugs, 2013, 31, 1294-1299.	1.2	45

#	Article	IF	Citations
1152	Adjuvant therapy for pancreas adenocarcinoma. Journal of Surgical Oncology, 2013, 107, 78-85.	0.8	13
1153	Indications et prise en charge des effets secondaires des biothÃ©rapies anti-EGFR. , 2013, , 143-158.		0
1154	Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. Journal of Medical Economics, 2013, 16, 1379-1386.	1.0	17
1155	Personalizing pancreatic cancer medicine: what are the challenges?. Personalized Medicine, 2013, 10, 45-59.	0.8	2
1156	Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor. Clinical Cancer Research, 2013, 19, 4282-4289.	3.2	55
1157	Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Review of Anticancer Therapy, 2013, 13, 721-728.	1.1	80
1158	Equipoise abandoned? Randomization and clinical trials. Annals of Oncology, 2013, 24, 2471-2474.	0.6	25
1160	Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointestinal Tumors, 2014, 1, 41-52.	0.3	16
1163	Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology, 2013, 24, 1972-1979.	0.6	120
1164	Systemic treatment of advanced pancreatic cancerâ€"step by step progress. Gut, 2013, 62, 660-661.	6.1	3
1165	What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International, 2013, 2013, 1-14.	0.9	19
1166	Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer. Current Oncology, 2013, 20, 90-106.	0.9	53
1167	Non-inferiority cancer clinical trials: scope and purposes underlying their design. Annals of Oncology, 2013, 24, 1942-1947.	0.6	27
1168	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology, 2013, 24, 1792-1801.	0.6	27
1169	Risk Factors and Therapeutic Targets in Pancreatic Cancer. Frontiers in Oncology, 2013, 3, 282.	1.3	38
1170	Pancreatic cancer: why is it so hard to treat?. Therapeutic Advances in Gastroenterology, 2013, 6, 321-337.	1.4	250
1171	Safety and Effectiveness of Gemcitabine in 855 Patients with Pancreatic Cancer under Japanese Clinical Practice Based on Post-marketing Surveillance in Japan. Japanese Journal of Clinical Oncology, 2013, 43, 139-145.	0.6	5
1172	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction. Japanese Journal of Clinical Oncology, 2013, 43, 2-7.	0.6	4

#	Article	IF	Citations
1173	Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 411-414.	0.6	24
1174	Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer. Pancreas, 2013, 42, 202-208.	0.5	54
1175	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Therapeutic Drug Monitoring, 2013, 35, 562-587.	1.0	77
1176	Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals. Cancer Research, 2013, 73, 2221-2234.	0.4	47
1177	Vitamin E Î´-Tocotrienol Prolongs Survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) Transgenic Mouse Model of Pancreatic Cancer. Cancer Prevention Research, 2013, 6, 1074-1083.	0.7	35
1178	Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 44-48.	0.6	30
1179	Molecularly Targeted Therapies in Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 760-773.	0.5	26
1180	Gemcitabine-Associated â€œPseudocellulitisâ€•and â€œPseudosepsisâ€• American Journal of Therapeutics, 2013, 20, 118-120.	0.5	14
1181	Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 1157-1163.	0.5	64
1182	A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 151-156.	0.6	94
1183	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. Anti-Cancer Drugs, 2013, 24, 980-985.	0.7	19
1184	Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 1143-1149.	0.5	72
1185	Disrupting Cytokine Signaling in Pancreatic Cancer. Pancreas, 2013, 42, 813-818.	0.5	59
1186	Cancer Drugs in the United States: Justum Pretiumâ€”The Just Price. Journal of Clinical Oncology, 2013, 31, 3600-3604.	0.8	276
1187	ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. Journal of International Medical Research, 2013, 41, 300-306.	0.4	52
1188	PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy. Clinical Cancer Research, 2013, 19, 4750-4759.	3.2	60
1189	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Clinical Cancer Research, 2013, 19, 4931-4940.	3.2	21
1190	Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics, 2013, 12, 2213-2225.	1.9	36

#	Article	IF	Citations
1191	Pancreatic Cancer Clinical Trials and Accrual in the United States. Journal of Clinical Oncology, 2013, 31, 3432-3438.	0.8	56
1192	Evolving Panorama of Treatment for Metastatic Pancreas Adenocarcinoma. Journal of Clinical Oncology, 2013, 31, 1621-1623.	0.8	4
1193	Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. Journal of Cell Science, 2013, 126, 3380-9.	1.2	27
1194	Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology, 2013, 24, 2576-2581.	0.6	28
1195	Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15389-15394.	3.3	40
1196	Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy. Frontiers in Oncology, 2013, 3, 155.	1.3	26
1197	Phase II Study of Dasatinib (BMSâ€354825) in Patients With Metastatic Adenocarcinoma of the Pancreas. Oncologist, 2013, 18, 1091-1092.	1.9	60
1198	Diagnosis and management of pancreatic cancer. Cmaj, 2013, 185, 1219-1226.	0.9	68
1199	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
1200	Recent progress in pancreatic cancer. Ca-A Cancer Journal for Clinicians, 2013, 63, 318-348.	157.7	743
1201	Adenovirusâ€mediated Interferonâ€Î³ Gene Therapy Induced Human Pancreatic Carcinoma Capanâ€2 Cell Apoptosis In Vitro and In Vivo. Anatomical Record, 2013, 296, 604-610.	0.8	8
1202	Phase 2, multicenter, openâ€label study of tigatuzumab (CSâ€1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapyâ€naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine, 2013, 2, 925-932.	1.3	80
1203	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology, 2013, 63, 157-166.	1.6	41
1204	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biology and Therapy, 2013, 14, 340-346.	1.5	13
1205	Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Physical Biology, 2013, 10, 026004.	0.8	3
1206	Mechanisms of resistance to EGFR targeted therapies. Cancer Biology and Therapy, 2013, 14, 304-314.	1.5	56
1207	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British Journal of Cancer, 2013, 108, 469-476.	2.9	84
1208	Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. British Journal of Cancer, 2013, 108, 1393-1401.	2.9	20

#	Article	IF	Citations
1209	Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death and Disease, 2013, 4, e791-e791.	2.7	48
1210	Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Oncogenesis, 2013, 2, e76-e76.	2.1	32
1211	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. Journal of Clinical Oncology, 2013, 31, 1640-1648.	0.8	548
1212	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. Journal of Clinical Oncology, 2013, 31, 1415-1421.	0.8	180
1213	Not all antibodies are equal. Cancer Biology and Therapy, 2013, 14, 1075-1076.	1.5	0
1214	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	3.0	51
1215	The Just Price of Cancer Drugs and the Growing Cost of Cancer Care: Oncologists Need to Be Part of the Solution. Journal of Clinical Oncology, 2013, 31, 3487-3489.	0.8	37
1216	A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncology Reports, 2013, 30, 1094-1100.	1.2	50
1217	Pancreatic cancer: is combination treatment better?. Clinical Practice (London, England), 2013, 10, 695-700.	0.1	1
1218	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. Oncology Letters, 2013, 5, 19-24.	0.8	8
1219	Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels. Case Reports in Oncology, 2013, 6, 602-608.	0.3	3
1220	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Advanced Pancreatic Ductal Adenocarcinoma: Impact of Baseline Fluctuation and Changes during Chemotherapy. Tumori, 2013, 99, 516-522.	0.6	20
1221	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
1222	The clinical significance of SWI/SNF complex in pancreatic cancer. International Journal of Oncology, 2013, 42, 403-410.	1.4	63
1223	Screening for Pancreatic Cancer. Annals of Surgery, 2013, 257, 17-26.	2.1	217
1224	Reply. American Journal of Roentgenology, 2013, 200, 468-468.	1.0	6
1225	Targeting HER Receptors in Cancer. Current Pharmaceutical Design, 2013, 19, 808-817.	0.9	39
1226	Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues. Pancreas, 2013, 42, 707-716.	0.5	94

#	Article	IF	Citations
1227	Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2013, 258, 1040-1050.	2.1	128
1228	Erlotinib-Induced Thrombocytosis in Patients With Recurrence of Pancreatic Cancer After Distal Pancreatectomy. Pancreas, 2013, 42, 1196-1197.	0.5	3
1229	A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 443-451.	0.5	55
1230	Small Molecule Inhibitors of CXCR4. Theranostics, 2013, 3, 47-75.	4.6	230
1233	Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. OncoTargets and Therapy, 2013, 7, 33.	1.0	66
1234	Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. OncoTargets and Therapy, 2013, 6, 491.	1.0	12
1235	Rationing Cancer Care: A Survey Among the Members of the German Society of Hematology and Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 658-665.	2.3	10
1237	Mechanistic Evaluation of a Novel Small Molecule Targeting Mitochondria in Pancreatic Cancer Cells. PLoS ONE, 2013, 8, e54346.	1.1	16
1238	Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e55128.	1.1	120
1239	Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics. PLoS ONE, 2013, 8, e57522.	1.1	27
1240	Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis. PLoS ONE, 2013, 8, e57528.	1.1	53
1241	Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway. PLoS ONE, 2013, 8, e61457.	1.1	39
1242	Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS ONE, 2013, 8, e77065.	1.1	62
1243	A view on EGFR-targeted therapies from the oncogene-addiction perspective. Frontiers in Pharmacology, 2013, 4, 53.	1.6	41
1244	The role of the renin angiotensin system in the treatment of advanced pancreatic cancer. Suizo, 2013, 28, 49-55.	0.1	0
1245	Radioactive bacteria attack cancer. Nature, 2013, , .	13.7	0
1246	Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e104346.	1.1	39
1247	Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells. PLoS ONE, 2014, 9, e106289.	1.1	45

#	Article	IF	Citations
1248	A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e108749.	1.1	37
1249	Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases. Case Reports in Oncology, 2014, 7, 97-101.	0.3	3
1250	Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets and Therapy, 2014, 7, 187.	1.0	25
1251	Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Frontiers in Physiology, 2014, 5, 87.	1.3	22
1252	Optimum chemotherapy in the management of metastatic pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 2352.	1.4	19
1253	Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World Journal of Gastroenterology, 2014, 20, 15564.	1.4	39
1256	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 23.	5.5	3
1257	Pancreatic Cancer Treatment. Journal of Drug Metabolism & Toxicology, 2014, 05, .	0.1	3
1258	Therapeutic options for the management of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11142.	1.4	114
1259	A Near-Complete Response to Treatment with Gemcitabine plus nabÂ®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. Case Reports in Oncology, 2014, 7, 711-717.	0.3	5
1260	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 2014, 5, 7138-7148.	0.8	43
1261	The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. Journal of Clinical Biochemistry and Nutrition, 2014, 55, 56-61.	0.6	16
1262	Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. Gastrointestinal Cancer: Targets and Therapy, 0, , 89.	5.5	0
1263	Druggable Targets in Pancreatic Adenocarcinoma. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 195-214.	0.1	0
1264	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or Without Erlotinib in Advanced Biliary Tract Cancer. Annals of Oncology, 2014, 25, iv244.	0.6	0
1265	Ten Weeks to Live: a Population-Based Study on Treatment and Survival of Patients with Metastatic Pancreatic Cancer in the South of the Netherlands. Annals of Oncology, 2014, 25, iv237.	0.6	0
1266	Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?. World Journal of Gastroenterology, 2014, 20, 2224.	1.4	51
1267	EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer. Journal of Carcinogenesis & Mutagenesis, 2014, 05, .	0.3	6

#	Article	IF	Citations
1268	N-methylhemeanthidine chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic cancer cell proliferation via down-regulating AKT activation. Toxicology and Applied Pharmacology, 2014, 280, 475-483.	1.3	27
1269	Current and future intratumoral targeted treatment for pancreatic cancer. Therapeutic Delivery, 2014, 5, 913-926.	1.2	6
1270	International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. BMC Health Services Research, 2014, 14, 595.	0.9	13
1272	Promising new therapies in advanced pancreatic adenocarcinomas. Future Oncology, 2014, 10, 2629-2641.	1.1	10
1273	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2014, 20, 5937-5945.	3.2	255
1274	Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2014, 8, 739-747.	1.4	32
1275	Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. British Journal of Cancer, 2014, 110, 1943-1949.	2.9	59
1276	Advanced stage pancreatic cancer: novel therapeutic options. Expert Review of Clinical Pharmacology, 2014, 7, 487-498.	1.3	14
1277	Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumor Biology, 2014, 35, 11551-11558.	0.8	4
1278	Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis, 2014, 3, e117-e117.	2.1	13
1279	Metabolism addiction in pancreatic cancer. Cell Death and Disease, 2014, 5, e1065-e1065.	2.7	124
1280	Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death and Disease, 2014, 5, e1162-e1162.	2.7	18
1281	A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle, 2014, 13, 3839-3856.	1.3	26
1282	Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. Oncologist, 2014, 19, 937-950.	1.9	9
1283	Desmoplasia and Chemoresistance in Pancreatic Cancer. Cancers, 2014, 6, 2137-2154.	1.7	121
1284	Altered Signaling Pathways and Potential Therapeutic Targets in Pancreatic Cancer. , 2014, , 2265-2273.		0
1285	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
1286	FOLFIRINOX â€“ a new paradigm in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2014, 14, 1115-1125.	1.1	14

#	Article	IF	Citations
1287	Integrating Traditional Medicine into Modern Inflammatory Diseases Care: Multitargeting byRhus vernicifluaStokes. Mediators of Inflammation, 2014, 2014, 1-17.	1.4	37
1288	Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy. Gut, 2014, 63, 1379-1380.	6.1	0
1289	Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Oncology Letters, 2014, 7, 1594-1598.	0.8	5
1290	Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. International Journal of Molecular Sciences, 2014, 15, 13768-13801.	1.8	174
1291	Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report. Oncology Letters, 2014, 7, 171-176.	0.8	3
1292	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncology, 2014, 10, 1255-1275.	1.1	5
1293	Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer. BioMed Research International, 2014, 2014, 1-17.	0.9	42
1294	Targeted therapy in gastrointestinal malignancies. Journal of Carcinogenesis, 2014, 13, 4.	2.5	7
1295	Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside. Cancer Treatment Reviews, 2014, 40, 1039-1047.	3.4	86
1296	Can we move towards personalised pancreatic cancer therapy?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 335-338.	1.4	5
1297	Phase <scp>II</scp> study of <scp>FOLFIRINOX</scp> for chemotherapyâ€naÃ¨ve Japanese patients with metastatic pancreatic cancer. Cancer Science, 2014, 105, 1321-1326.	1.7	156
1299	nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer. Zeitschrift Fur Gastroenterologie, 2014, 52, 360-366.	0.2	28
1300	Parpâ€1 genetic ablation in Elaâ€“myc mice unveils novel roles for Parpâ€1 in pancreatic cancer. Journal of Pathology, 2014, 234, 214-227.	2.1	14
1301	Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian Journal of Gastroenterology, 2014, 49, 1480-1485.	0.6	2
1302	Loss of membranous expression of the intracellular domain of Ep<scp>CAM</scp> is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology, 2014, 64, 683-692.	1.6	34
1303	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Annals of Oncology, 2014, 25, 1384-1390.	0.6	30
1304	Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Medicine, 2014, 3, 572-579.	1.3	27
1305	The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1277-1283.	1.5	5

#	Article	IF	Citations
1306	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2361-2372.	0.9	4
1307	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opinion on Pharmacotherapy, 2014, 15, 143-150.	0.9	7
1308	Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. Oncology, 2014, 86, 24-32.	0.9	45
1309	Smarter drugs emerging in pancreatic cancer therapy. Annals of Oncology, 2014, 25, 1260-1270.	0.6	72
1310	Comparison of the Efficacy of Covered versus Uncovered Metallic Stents in Treating Inoperable Malignant Common Bile Duct Obstruction: A Randomized Trial. Journal of Vascular and Interventional Radiology, 2014, 25, 1912-1920.	0.2	37
1311	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 35-40.	0.3	13
1312	Improved survival with combined gemcitabine and <scp>S</scp>â€1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 761-766.	1.4	25
1313	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British Journal of Cancer, 2014, 111, 2067-2075.	2.9	37
1314	A 60-Year-Old Male With Synchronous Acute Myeloid Leukemia and Metastatic Adenocarcinoma of the Pancreas. Seminars in Oncology, 2014, 41, e51-e59.	0.8	2
1315	Neutrophilâ€toâ€lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Medicine, 2014, 3, 406-415.	1.3	100
1316	Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Review of Anticancer Therapy, 2014, 14, 495-497.	1.1	8
1317	Response to <scp>GEMOX</scp> plus erlotinib in pancreatic cancer is associated with <scp>ERCC</scp>1 overexpression. European Journal of Clinical Investigation, 2014, 44, 958-964.	1.7	9
1318	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 1032-1043.	1.9	19
1319	Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. Oncologist, 2014, 19, 631-636.	1.9	159
1321	Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines. BMC Systems Biology, 2014, 8, 75.	3.0	36
1322	Chemotherapeutic Strategies in Advanced or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 194-200.	0.6	8
1323	Antiprotease Strategy in Pancreatic Cancer Treatment. Pancreas, 2014, 43, 53-63.	0.5	3
1324	Emerging combination therapies to overcome resistance in EGFR-driven tumors. Anti-Cancer Drugs, 2014, 25, 127-139.	0.7	15

#	Article	IF	Citations
1325	Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anti-Cancer Drugs, 2014, 25, 832-840.	0.7	10
1326	Maximum Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography and Glucose Transporter-1 Expression Correlates With Survival in Invasive Ductal Carcinoma of the Pancreas. Pancreas, 2014, 43, 1060-1065.	0.5	33
1327	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety, 2014, 13, 535-549.	1.0	30
1328	Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer. Pancreas, 2014, 43, 1022-1031.	0.5	10
1329	A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer. Journal of Immunotherapy, 2014, 37, 36-42.	1.2	62
1330	Taxanes. Anti-Cancer Drugs, 2014, 25, 584-592.	0.7	18
1331	Wilms Tumor Gene (WT1) Peptideâ€“based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer. Journal of Immunotherapy, 2014, 37, 105-114.	1.2	77
1332	The RON Receptor Tyrosine Kinase in Pancreatic Cancer Pathogenesis and Its Potential Implications for Future Targeted Therapies. Pancreas, 2014, 43, 183-189.	0.5	20
1333	Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer. Pancreas, 2014, 43, 1093-1100.	0.5	9
1334	Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3Kâ€“Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2014, 20, 4047-4058.	3.2	34
1335	Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Review of Anticancer Therapy, 2014, 14, 1243-1249.	1.1	13
1336	Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225.	1.2	263
1337	Erlotinib. Recent Results in Cancer Research, 2014, 201, 109-123.	1.8	13
1338	Autophagy and Cell Death to Target Cancer Cells: Exploiting Synthetic Lethality as Cancer Therapies. Advances in Experimental Medicine and Biology, 2014, 772, 167-188.	0.8	36
1339	Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virotherapy, 2014, 3, 35.	6.0	13
1340	Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy. Journal of the National Cancer Institute, 2014, 106, dju011-dju011.	3.0	141
1341	Comparative Outcomes Between Initially Unresectable and Recurrent Cases of Advanced Pancreatic Cancer Following Palliative Chemotherapy. Pancreas, 2014, 43, 411-416.	0.5	17
1342	KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Pancreas, 2014, 43, 578-583.	0.5	36

#	Article	IF	Citations
1343	Clinical Characteristics of Adenosquamous Carcinoma of the Pancreas. Pancreas, 2014, 43, 287-290.	0.5	49
1344	The Roles of Interferon Regulatory Factors 1 and 2 in the Progression of Human Pancreatic Cancer. Pancreas, 2014, 43, 909-916.	0.5	33
1345	Antitumor Effect of Angiotensin II Type 1 Receptor Blocker Losartan for Orthotopic Rat Pancreatic Adenocarcinoma. Pancreas, 2014, 43, 886-890.	0.5	25
1346	Epidermal Growth Factor Inhibition, a Novel Pathway to Prevent Chronic Allograft Injury. Transplantation, 2014, 98, 821-827.	0.5	12
1347	Pancreatic cancer, treatment options, and GI-4000. Human Vaccines and Immunotherapeutics, 2014, 10, 3347-3353.	1.4	16
1348	Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews, 2014, 40, 656-664.	3.4	36
1349	The enone motif of (+)-grandifloracin is not essential for â€˜anti-austerityâ€™ antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2815-2819.	1.0	13
1350	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer, 2014, 50, 1422-1429.	1.3	28
1351	Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis. Digestive and Liver Disease, 2014, 46, 452-459.	0.4	19
1352	Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2014, 40, 636-647.	3.4	33
1353	Rechallenge with imatinib in GIST: is more always RIGHT?. Lancet Oncology, The, 2014, 15, e2-e3.	5.1	5
1355	Neoadjuvant therapy in pancreatic cancer. Current Medicine Research and Practice, 2014, 4, 56-61.	0.1	3
1356	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.4	40
1357	A spectroscopic study on the interaction between the anticancer drug erlotinib and human serum albumin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 78, 405-413.	0.9	14
1358	Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Targeted Oncology, 2014, 9, 123-134.	1.7	36
1359	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer, 2014, 17, 621-629.	2.7	7
1360	Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 59-65.	2.0	61
1361	Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2014, 73, 125-130.	1.1	103

#	Article	IF	Citations
1362	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer and Metastasis Reviews, 2014, 33, 295-307.	2.7	5
1363	The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemotherapy and Pharmacology, 2014, 73, 613-621.	1.1	37
1364	Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 561-568.	1.1	13
1365	Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10. Annals of Surgical Oncology, 2014, 21, 691-698.	0.7	23
1366	Perifosine inhibits S6K1â€“Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Cancer Chemotherapy and Pharmacology, 2014, 73, 711-719.	1.1	27
1368	Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells. Tumor Biology, 2014, 35, 2271-2278.	0.8	14
1369	Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumor Biology, 2014, 35, 2313-2318.	0.8	27
1370	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Letters, 2014, 347, 183-190.	3.2	45
1371	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. International Journal of Cancer, 2014, 134, 731-739.	2.3	67
1372	Targeting cancer stem cells by curcumin and clinical applications. Cancer Letters, 2014, 346, 197-205.	3.2	160
1373	ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell, 2014, 25, 282-303.	7.7	817
1374	Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Advanced Drug Delivery Reviews, 2014, 69-70, 1-18.	6.6	156
1375	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews Clinical Oncology, 2014, 11, 282-298.	12.5	312
1376	Notch pathway activation is associated with pancreatic cancer treatment failure. Pancreatology, 2014, 14, 48-53.	0.5	30
1377	ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharmaceutical Research, 2014, 31, 2237-2255.	1.7	48
1378	Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. British Journal of Cancer, 2014, 110, 1698-1704.	2.9	316
1379	Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer. Integrative Cancer Therapies, 2014, 13, 217-225.	0.8	24
1380	Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions. Cancer Treatment Reviews, 2014, 40, 78-85.	3.4	31

#	Article	IF	Citations
1381	The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 2014, 79, 34-74.	3.1	1,028
1382	Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. International Journal of Clinical Oncology, 2014, 19, 634-642.	1.0	2
1383	Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 389-396.	1.1	41
1384	Tumor Microenvironment and Cellular Stress. Advances in Experimental Medicine and Biology, 2014, 772, v-viii.	0.8	29
1385	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
1386	Pancreaticoduodenetomy combined with hepatic artery resection following preoperative hepatic arterial embolization. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 850-855.	1.4	24
1387	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia Research, 2014, 38, 1430-1434.	0.4	16
1388	A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. Biochemical and Biophysical Research Communications, 2014, 454, 144-150.	1.0	10
1389	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer, 2014, 13, 232-238.	1.0	60
1390	Association Between Baseline Pulmonary Status and Interstitial Lung Disease in Patients With Nonâ€“Small-Cell Lung Cancer Treated With Erlotinibâ€”A Cohort Study. Clinical Lung Cancer, 2014, 15, 448-454.	1.1	23
1391	Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 1499-1515.	1.9	18
1392	Metabolomics in cell cultureâ€”A strategy to study crucial metabolic pathways in cancer development and the response to treatment. Archives of Biochemistry and Biophysics, 2014, 564, 100-109.	1.4	67
1393	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology, 2014, 41, 559-575.	0.8	3
1394	Dual blockade of epidermal growth factor receptor and insulinâ€like growth factor receptorâ€“1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer, 2014, 120, 2980-2985.	2.0	78
1395	Response to Nab-Paclitaxel plus Gemcitabine in a Patient with Primary Resistance to FOLFIRINOX. Journal of Gastrointestinal Cancer, 2014, 45, 278-281.	0.6	2
1396	Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. Journal of Clinical Oncology, 2014, 32, 1620-1629.	0.8	60
1397	1â€Acetylâ€3,5â€diarylâ€4,5â€dihydro(1H)pyrazoles: Exhibiting Anticancer Activity through Intracellular ROS Scavenging and the Mitochondriaâ€Dependent Death Pathway. Archiv Der Pharmazie, 2014, 347, 717-727.	2.1	19
1398	Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 3634-3642.	0.8	64

#	Article	IF	Citations
1399	Î±-Mangostin: A Dietary Antioxidant Derived from the Pericarp of Garcinia mangostana L. Inhibits Pancreatic Tumor Growth in Xenograft Mouse Model. Antioxidants and Redox Signaling, 2014, 21, 682-699.	2.5	68
1400	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1333-1348.	1.9	48
1401	Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4654-4658.	1.0	30
1402	Structure and Function of Human DnaJ Homologue Subfamily A Member 1 (DNAJA1) and Its Relationship to Pancreatic Cancer. Biochemistry, 2014, 53, 1360-1372.	1.2	52
1403	Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. Neoplasia, 2014, 16, 463-470.	2.3	15
1404	Screening for Pancreatic Cancer. Advances in Surgery, 2014, 48, 115-136.	0.6	20
1405	Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer. Neoplasia, 2014, 16, 562-571.	2.3	30
1406	Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies. Molecular Therapy, 2014, 22, 2056-2068.	3.7	16
1407	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Review of Anticancer Therapy, 2014, 14, 1219-1228.	1.1	1
1408	Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer, 2014, 111, 817-822.	2.9	423
1409	FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer, 2014, 14, 441.	1.1	30
1410	Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer, 2014, 14, 471.	1.1	105
1411	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer, 2014, 14, 624.	1.1	29
1412	Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Journal of Translational Medicine, 2014, 12, 175.	1.8	52
1413	Pancreatic Adenocarcinoma. New England Journal of Medicine, 2014, 371, 1039-1049.	13.9	1,821
1414	ALK expression is absent in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1625-1628.	1.2	5
1415	Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. Cancer Immunology, Immunotherapy, 2014, 63, 737-747.	2.0	9
1416	Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 2014, 63, 939-946.	2.0	67

#	Article	IF	Citations
1417	A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 131-139.	1.1	0
1418	Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 205-210.	1.1	12
1419	Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemotherapy and Pharmacology, 2014, 74, 379-387.	1.1	52
1420	Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology, 2014, 74, 333-340.	1.1	12
1421	Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile. Molecular Biology Reports, 2014, 41, 4361-4367.	1.0	6
1422	Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma. Integrative Cancer Therapies, 2014, 13, 332-340.	0.8	26
1423	Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer. Molecular Cancer Research, 2014, 12, 924-939.	1.5	89
1424	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	0.8	397
1425	Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer. Clinical Therapeutics, 2014, 36, 1054-1063.	1.1	10
1426	Management Options in Locally Advanced Pancreatic Cancer. Current Oncology Reports, 2014, 16, 388.	1.8	29
1427	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clinical and Translational Oncology, 2014, 16, 865-878.	1.2	5
1428	Case report of nab-paclitaxel in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 39-42.	0.3	1
1429	Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumor Biology, 2014, 35, 2461-2471.	0.8	46
1430	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer â€“ the CONKO 004 pilot trial. BMC Cancer, 2014, 14, 204.	1.1	14
1431	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 2014, 13, 126.	7.9	31
1432	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. Journal of Controlled Release, 2014, 192, 29-39.	4.8	48
1433	Pancreatic cancer genomics. Current Opinion in Genetics and Development, 2014, 24, 74-81.	1.5	50
1434	Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Survey of Ophthalmology, 2014, 59, 493-502.	1.7	29

#	Article	IF	Citations
1435	Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. International Immunopharmacology, 2014, 19, 10-16.	1.7	20
1436	Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain, Behavior, and Immunity, 2014, 40, 40-47.	2.0	192
1438	Ring-enhancement pattern on contrast-enhanced CT predicts adenosquamous carcinoma of the pancreas: A matched case-control study. Pancreatology, 2014, 14, 221-226.	0.5	28
1439	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (â‰¥70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg. Pancreatology, 2014, 14, 211-215.	0.5	25
1440	Tumourâ€“stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies. Cancer Treatment Reviews, 2014, 40, 118-128.	3.4	108
1441	Â¿Sigue representando la infiltraciÃ³n arterial un criterio de irresecabilidad en el carcinoma de pÃ¡ncreas?. CirugÃa EspaÃ±ola, 2014, 92, 305-315.	0.1	6
1442	Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. Protein Engineering, Design and Selection, 2014, 27, 235-243.	1.0	25
1443	Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental and Clinical Pharmacology, 2014, 28, 551-582.	1.0	16
1444	Intra-Articular Metastatic Pancreatic Carcinoma of the Right Knee Mimicking Septic Arthritis. Clinical Colorectal Cancer, 2014, 13, 131-133.	1.0	3
1445	Adrenocortical carcinoma: The management of metastatic disease. Critical Reviews in Oncology/Hematology, 2014, 92, 123-132.	2.0	43
1446	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081.	1.3	283
1447	Is Arterial Infiltration Still a Criterion for Unresectability in Pancreatic Adenocarcinoma?. CirugÃa EspaÃ±ola (English Edition), 2014, 92, 305-315.	0.1	2
1448	A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European Journal of Cancer, 2014, 50, 1909-1915.	1.3	31
1449	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene, 2014, 33, 514-524.	2.6	198
1450	Molecularâ€targeted agents combination therapy for cancer: Developments and potentials. International Journal of Cancer, 2014, 134, 1257-1269.	2.3	110
1451	Epidermal Growth Factor Receptor Inhibitors: Coming of Age. Cancer Control, 2014, 21, 74-79.	0.7	56
1452	Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action. Oncology Research and Treatment, 2014, 37, 128-134.	0.8	26
1453	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. International Journal of Oncology, 2014, 45, 311-321.	1.4	10

#	Article	IF	Citations
1454	Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review. International Journal of Oncology, 2014, 44, 319-326.	1.4	36
1456	Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. Molecular and Clinical Oncology, 2014, 2, 586-590.	0.4	3
1457	Personalization of Chemotherapy for Metastatic Pancreatic Cancer. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S14478.	0.3	1
1458	Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy. Case Reports in Oncology, 2014, 7, 583-590.	0.3	4
1459	Mass Spectrometry-Based Metabolic Profiling of Gemcitabine-Sensitive and Gemcitabine-Resistant Pancreatic Cancer Cells. Pancreas, 2014, 43, 311-318.	0.5	24
1460	Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine Chemotherapy: Clinical Characteristics of Long-Term Survivors. Annals of Oncology, 2014, 25, ii46.	0.6	0
1461	The Basic Helix-Loop-Helix Transcription Factor E47 Reprograms Human Pancreatic Cancer Cells to a Quiescent Acinar State With Reduced Tumorigenic Potential. Pancreas, 2015, 44, 718-727.	0.5	42
1463	Pancreatic cancer and FOLFIRINOX : a new era and new questions. Cancer Medicine, 2015, 4, 853-863.	1.3	35
1464	Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Medicine, 2015, 4, 1091-1100.	1.3	11
1465	Randomized phase <scp>II</scp>/<scp>III</scp> clinical trial of elpamotide for patients with advanced pancreatic cancer: <scp>PEGASUS</scp>â€<scp>PC</scp> Study. Cancer Science, 2015, 106, 883-890.	1.7	78
1467	Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression. Oncology Reports, 2015, 33, 383-390.	1.2	23
1468	New Advances in the Treatment of Metastatic Pancreatic Cancer. Digestion, 2015, 92, 175-184.	1.2	18
1469	Treatment of Advanced Pancreatic Cancer. , 2015, , 451-470.		0
1470	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. Internal Medicine, 2015, 54, 2969-2973.	0.3	12
1472	Pancreatic Cancer: Progress in Systemic Therapy. Gastrointestinal Tumors, 2014, 1, 167-179.	0.3	11
1473	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomarker Insights, 2015, 10s3, BMI.S22436.	1.0	7
1474	Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. Oncology Letters, 2015, 10, 3535-3541.	0.8	6
1476	Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. Journal of Visualized Experiments, 2015, , e52801.	0.2	17

#	Article	IF	Citations
1477	Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1309-1314.	1.1	44
1478	Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1217-1224.	1.1	15
1483	Evaluation of low-dose fractionated radiation therapy as a chemopotentiator of gemcitabine in advanced pancreatic cancer: results from an international multi-institutional phase II trial. Journal of Radiation Oncology, 2015, 4, 401-409.	0.7	0
1484	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer, 2015, 15, 783.	1.1	37
1485	Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer, 2015, 15, 802.	1.1	17
1486	A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World Journal of Surgical Oncology, 2015, 14, 14.	0.8	47
1487	EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. Journal of Experimental and Clinical Cancer Research, 2015, 34, 134.	3.5	57
1488	HER family Receptor Expression and Prognosis in Pancreatic Cancer. International Journal of Biological Markers, 2015, 30, 327-332.	0.7	9
1489	Erlotinib-Associated Interstitial Lung Disease in Advanced Pancreatic Carcinoma: A Case Report and Literature Review. Tumori, 2015, 101, e122-e127.	0.6	4
1490	Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Pancreas, 2015, 44, 1155-1160.	0.5	5
1491	Prognostic Value of Altered N-Glycosylation of Circulating Glycoproteins in Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine. Pancreas, 2015, 44, 551-556.	0.5	7
1492	Primary and Liver Metastasisâ€“Derived Cell Lines From KrasG12D; Trp53R172H; Pdx-1 Cre Animals Undergo Apoptosis in Response to Triptolide. Pancreas, 2015, 44, 583-589.	0.5	20
1493	Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer. Medicine (United States), 2015, 94, e1345.	0.4	9
1495	Cancer Care Burden: Aiming at the Achilles Heel. Current Oncology, 2015, 22, 134-138.	0.9	4
1496	Emerging therapies for pancreatic ductal carcinoma. Journal of Solid Tumors, 2015, 6, .	0.1	1
1497	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	0.8	40
1499	Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo, Brazil), 2015, 13, 347-351.	0.3	8
1500	Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma. Genetics and Molecular Research, 2015, 14, 2707-2715.	0.3	12

#	Article	IF	Citations
1501	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Current Oncology, 2015, 22, 305-315.	0.9	0
1502	Review Hepatotoxicity of molecular targeted therapy. Wspolczesna Onkologia, 2015, 2, 87-92.	0.7	16
1503	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Design, Development and Therapy, 2015, 9, 3529.	2.0	135
1504	GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells. International Journal of Nanomedicine, 2015, 10, 2507.	3.3	36
1505	Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Design, Development and Therapy, 2015, 9, 3767.	2.0	189
1506	Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2015, 10, e0116803.	1.1	15
1507	A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2015, 10, e0121197.	1.1	8
1508	A Multistep High-Content Screening Approach to Identify Novel Functionally Relevant Target Genes in Pancreatic Cancer. PLoS ONE, 2015, 10, e0122946.	1.1	13
1509	Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer. Clinical Journal of Oncology Nursing, 2015, 19, 751-757.	0.3	1
1510	The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer. Gastrointestinal Tumors, 2015, 2, 131-143.	0.3	0
1511	Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. Drug Discoveries and Therapeutics, 2015, 9, 147-155.	0.6	10
1512	Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	4
1513	Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. BioMed Research International, 2015, 2015, 1-12.	0.9	16
1514	Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e222-e227.	1.8	1
1515	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	0.8	90
1516	Current status and progress of pancreatic cancer in China. World Journal of Gastroenterology, 2015, 21, 7988.	1.4	221
1517	Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer: Targets and Therapy, 2015, , 1.	5.5	0
1518	Current Concepts in Pancreatic Cancer. , 2015, , .		0

#	Article	IF	Citations
1519	Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biology and Therapy, 2015, 16, 438-449.	1.5	46
1520	Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut, 2015, 64, 1476-1484.	6.1	444
1521	Pancreatic cancer stromal biology and therapy. Genes and Diseases, 2015, 2, 133-143.	1.5	110
1522	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. Journal of Hematology and Oncology, 2015, 8, 44.	6.9	40
1523	RasGRP1 opposes proliferative EGFRâ€“SOS1â€“Ras signals and restricts intestinal epithelial cell growth. Nature Cell Biology, 2015, 17, 804-815.	4.6	54
1524	The Quest for an Effective Treatment for an Intractable Cancer. Advances in Cancer Research, 2015, 127, 283-306.	1.9	10
1525	Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbeck's Archives of Surgery, 2015, 400, 477-485.	0.8	24
1526	Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. International Journal of Clinical Oncology, 2015, 20, 518-524.	1.0	26
1527	Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy, 2015, 16, 851-861.	0.9	8
1528	Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements. American Journal of Pathology, 2015, 185, 1297-1303.	1.9	93
1529	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. Gastrointestinal Cancer: Targets and Therapy, 0, , 11.	5.5	5
1530	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Medicine, 2015, 4, 1224-1239.	1.3	16
1531	microRNA: Cancer. Advances in Experimental Medicine and Biology, 2015, , .	0.8	2
1532	Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy, 2015, 7, 1249-1258.	1.0	48
1533	Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 1025-1032.	1.1	54
1534	Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (United States), 2015, 94, e1012.	0.4	18
1537	Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Advances in Experimental Medicine and Biology, 2015, 889, 71-87.	0.8	49
1538	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Translational Oncology, 2015, 8, 40-46.	1.7	16

#	Article	IF	Citations
1539	CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 530-538.	0.6	19
1540	N,Nâ€²-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer cells via apoptosis and G2/M cell cycle arrest. Oncology Reports, 2015, 33, 1915-1921.	1.2	6
1542	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncology, The, 2015, 16, e32-e42.	5.1	152
1543	Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition. Clinical Cancer Research, 2015, 21, 157-165.	3.2	24
1544	Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma. Seminars in Oncology, 2015, 42, 134-143.	0.8	17
1545	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1036-1043.	3.2	31
1546	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, dju413-dju413.	3.0	487
1547	Pancreatic cancer: diagnosis and treatments. Tumor Biology, 2015, 36, 1375-1384.	0.8	39
1548	A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci of the Colorectum. Cancer Prevention Research, 2015, 8, 222-230.	0.7	1
1549	Use and Safety of Intratumoral Application of European Mistletoe (Viscum album L) Preparations in Oncology. Integrative Cancer Therapies, 2015, 14, 140-148.	0.8	32
1550	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer and Metastasis Reviews, 2015, 34, 97-114.	2.7	69
1551	Pancreatic cancer genomics: where can the science take us?. Clinical Genetics, 2015, 88, 213-219.	1.0	13
1552	ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. British Journal of Cancer, 2015, 112, 704-713.	2.9	30
1553	First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical Findings. Molecular Therapy, 2015, 23, 779-789.	3.7	93
1554	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. Annals of Surgical Oncology, 2015, 22, 295-301.	0.7	145
1555	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology, 2015, 7, 68-84.	1.4	123
1556	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist, 2015, 20, 143-150.	1.9	123
1557	Molecular Pathogenesis of Pancreatic Adenocarcinoma. , 2015, , 515-522.e2.		0

#	Article	IF	Citations
1558	Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection. Journal of Gastrointestinal Surgery, 2015, 19, 6-14.	0.9	51
1559	Current Adjuvant Therapeutic Approaches for Pancreatic Cancer. Advances in Therapy, 2015, 32, 42-56.	1.3	6
1560	Advances in Chemotherapy for Pancreatic Cancer. Indian Journal of Surgical Oncology, 2015, 6, 47-56.	0.3	5
1561	Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Journal of Gastroenterology, 2015, 50, 694-702.	2.3	63
1562	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 396-404.	3.2	121
1563	HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clinical Cancer Research, 2015, 21, 2886-2888.	3.2	9
1564	hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2015, 112, 1076-1087.	2.9	47
1565	Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study. American Journal of Clinical Dermatology, 2015, 16, 221-229.	3.3	12
1566	Effect of NF-Î¹B inhibition on chemoresistance in biliaryâ€“pancreatic cancer. Surgery Today, 2015, 45, 1481-1488.	0.7	22
1567	Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clinical Therapeutics, 2015, 37, 1301-1316.	1.1	26
1568	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Annals of Oncology, 2015, 26, 1923-1929.	0.6	89
1569	Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 579-589.	0.7	10
1570	Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology, 2015, 15, 525-530.	0.5	0
1571	Pancreatic cancer: current management and treatment strategies. Postgraduate Medical Journal, 2015, 91, 601-607.	0.9	22
1572	Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clinical Cancer Research, 2015, 21, 5612-5618.	3.2	6
1573	Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. Advances in Biological Regulation, 2015, 59, 19-35.	1.4	65
1574	Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Translational Oncology, 2015, 8, 196-203.	1.7	21
1575	Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Therapy, 2015, 22, 375-379.	2.2	17

#	Article	IF	Citations
1576	Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Therapeutic Advances in Medical Oncology, 2015, 7, 198-205.	1.4	28
1577	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology, 2015, 26, 1194-1200.	0.6	78
1578	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	1.1	59
1579	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 741-759.	0.9	9
1580	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	0.9	11
1582	Pancreatic cancer, treatment options, and GI-4000. Human Vaccines and Immunotherapeutics, 2015, 11, 931-937.	1.4	14
1583	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 839-847.	5.1	321
1584	Clinical Translation of Nanomedicine. Chemical Reviews, 2015, 115, 11147-11190.	23.0	619
1585	Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 1570-1581.	1.9	53
1586	Immunotherapy of Pancreatic Cancer. , 2015, , 237-248.		1
1587	A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Pancreatology, 2015, 15, 397-404.	0.5	9
1588	Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology, 2015, 15, S39-S43.	0.5	44
1589	Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma. American Journal of Pathology, 2015, 185, 1022-1032.	1.9	46
1590	Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities. Journal of Clinical Oncology, 2015, 33, 1779-1786.	0.8	66
1591	Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta OncolÃ³gica, 2015, 54, 403-410.	0.8	30
1592	Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opinion on Investigational Drugs, 2015, 24, 781-794.	1.9	4
1593	Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 623-634.	1.4	21
1594	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunology, Immunotherapy, 2015, 64, 727-736.	2.0	47

#	Article	IF	Citations
1595	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Journal of Cancer Research and Clinical Oncology, 2015, 141, 933-939.	1.2	21
1596	A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1653-1660.	1.2	22
1597	Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1827-1833.	1.2	23
1598	Pancreatic Cancer in the USA: Persistence of Undertreatment and Poor Outcome. Journal of Gastrointestinal Cancer, 2015, 46, 9-20.	0.6	38
1599	Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Medical Oncology, 2015, 32, 121.	1.2	10
1600	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology and Oncology, 2015, 8, 16.	6.9	80
1601	Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 30.	3.5	98
1602	Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 13-27.	3.3	60
1603	Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice. ACS Nano, 2015, 9, 3540-3557.	7.3	367
1604	Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemotherapy and Pharmacology, 2015, 75, 457-464.	1.1	16
1606	Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyteâ€“macrophage function in vitro. Transplant Immunology, 2015, 32, 175-178.	0.6	15
1607	Assessing the benefitâ€“risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. British Journal of Cancer, 2015, 112, 971-976.	2.9	26
1608	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Critical Reviews in Oncology/Hematology, 2015, 95, 318-336.	2.0	18
1610	The Potential Role of the Glycoprotein Osteoactivin/Glycoprotein Nonmetastatic Melanoma Protein B in Pancreatic Cancer. Pancreas, 2015, 44, 302-310.	0.5	7
1611	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature Reviews Clinical Oncology, 2015, 12, 319-334.	12.5	489
1612	Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anti-Cancer Drugs, 2015, 26, 90-100.	0.7	29
1613	Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals. Anti-Cancer Drugs, 2015, 26, 565-572.	0.7	55
1614	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1475-1481.	0.8	152

#	Article	IF	Citations
1615	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015, 75, 1091-1101.	0.4	68
1617	Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells. Human Cell, 2015, 28, 167-174.	1.2	36
1618	Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy, 2015, 15, 1183-1198.	1.1	11
1619	Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Human Pathology, 2015, 46, 1315-1322.	1.1	7
1620	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 4284-4292.	0.8	431
1621	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	3.2	12
1622	Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis. ANZ Journal of Surgery, 2015, 85, 174-178.	0.3	11
1623	Impact of early tumor shrinkage on clinical outcome in wildâ€typeâ€‹scp›KRAS‹/scp› colorectal liver metastases treated with cetuximab. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 674-679.	1.4	13
1624	Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 563-570.	1.4	27
1625	Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v56-v68.	0.6	1,015
1627	The Globalization of Cooperative Groups. Seminars in Oncology, 2015, 42, 693-712.	0.8	6
1628	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
1629	Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1695-1707.	1.5	15
1630	Quercetin 3-O-glucoside suppresses epidermal growth factorâ€“induced migration by inhibiting EGFR signaling in pancreatic cancer cells. Tumor Biology, 2015, 36, 9385-9393.	0.8	49
1631	The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. DNA and Cell Biology, 2015, 34, 610-617.	0.9	15
1632	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	0.5	6
1633	RNAi-based therapeutic nanostrategy: IL-8 gene silencing in pancreatic cancer cells using gold nanorods delivery vehicles. Nanotechnology, 2015, 26, 365101.	1.3	23
1634	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82

#	Article	IF	Citations
1635	Hereditary Pancreatic Cancer Syndromes. Surgical Oncology Clinics of North America, 2015, 24, 733-764.	0.6	28
1636	Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of Nephrology, 2015, 28, 647-657.	0.9	33
1637	Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacologica Sinica, 2015, 36, 614-626.	2.8	22
1638	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3Î²-Snail pathway. Cell Death and Disease, 2015, 6, e1795-e1795.	2.7	66
1639	Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. International Journal of Radiation Oncology Biology Physics, 2015, , .	0.4	0
1640	Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenonâ€™s triamcinolone without erlotinib cessation. Canadian Journal of Ophthalmology, 2015, 50, e66-e67.	0.4	4
1641	Secondary localized corneal amyloidosis caused by lower eyelid epiblepharon. Canadian Journal of Ophthalmology, 2015, 50, e67-e69.	0.4	3
1642	Abordaje terapÃ©utico del carcinoma escamoso cutÃ¡neo no operable. Piel, 2015, 30, 594-608.	0.0	0
1643	Personalized medicine in pancreatic cancer: the revolution has begun. Personalized Medicine, 2015, 12, 515-523.	0.8	1
1644	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	1.3	26
1646	Targeted Oncolytic Herpes Simplex Virus Type 1 Eradicates Experimental Pancreatic Tumors. Human Gene Therapy, 2015, 26, 104-113.	1.4	25
1647	Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. Journal of Chemotherapy, 2015, 27, 40-51.	0.7	56
1648	Multiple Layerâ€byâ€Layer Lipidâ€Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Advanced Functional Materials, 2015, 25, 788-798.	7.8	96
1649	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 2015, 15, 8-18.	0.5	404
1650	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827.	3.2	75
1651	Assessment of benefits and risks in development of targeted therapies for cancer â€" The view of regulatory authorities. Molecular Oncology, 2015, 9, 1034-1041.	2.1	21
1652	MUC1 Promoterâ€"Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	1.5	18
1653	Focal adhesion signaling and therapy resistance in cancer. Seminars in Cancer Biology, 2015, 31, 65-75.	4.3	266

#	Article	IF	Citations
1654	Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: utility and experience from the clinic. Gastrointestinal Cancer: Targets and Therapy, 2016, , 13.	5.5	2
1656	Gli2 protein expression level is a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms. Polish Journal of Pathology, 2016, 2, 136-144.	0.1	4
1657	Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Central-European Journal of Immunology, 2016, 4, 404-418.	0.4	3
1658	Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. International Journal of Biological Sciences, 2016, 12, 292-301.	2.6	37
1659	Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology, 2016, 7, 27.	0.9	71
1660	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. International Journal of Nanomedicine, 2016, 11, 1225.	3.3	32
1661	Polymeric Nanobiomaterials forÂTumor Targeting. , 2016, , 541-564.		1
1662	Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2016, 10, 1961.	2.0	39
1663	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. Journal of Cancer, 2016, 7, 1497-1514.	1.2	71
1664	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Current Oncology, 2016, 23, 605-614.	0.9	6
1665	Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 2441.	1.4	71
1666	Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Yonsei Medical Journal, 2016, 57, 1124.	0.9	23
1667	The Past, Present, and Future of Pancreatic Cancer Clinical Trials. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e205-e215.	1.8	22
1668	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget, 2016, 7, 4760-4769.	0.8	56
1669	Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?. Journal of Gastrointestinal Oncology, 2016, 7, 727-737.	0.6	2
1670	How grim is pancreatic cancer?. Oncology Reviews, 2016, 10, 294.	0.8	38
1671	Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Przeglad Gastroenterologiczny, 2016, 3, 155-162.	0.3	9
1672	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Journal of Gastrointestinal Oncology, 2016, 7, 469-478.	0.6	48

#	Article	IF	Citations
1673	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 2016, 7, 12672-12681.	0.8	34
1674	Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut and Liver, 2016, 10, 340-7.	1.4	57
1675	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. Journal of Cancer, 2016, 7, 1328-1339.	1.2	30
1676	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal of Molecular Sciences, 2016, 17, 1090.	1.8	15
1677	Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. Toxins, 2016, 8, 137.	1.5	41
1678	Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines, 2016, 4, 20.	1.4	24
1679	Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. Diagnostic Pathology, 2016, 11, 60.	0.9	24
1680	Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. International Journal of Medical Sciences, 2016, 13, 902-913.	1.1	16
1681	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. International Journal of Biological Sciences, 2016, 12, 283-291.	2.6	53
1682	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	1.4	25
1683	Onivyde for the therapy of multiple solid tumors. OncoTargets and Therapy, 2016, 9, 3001.	1.0	132
1684	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
1685	Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 18-26.	0.6	16
1686	Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Medicine (United States), 2016, 95, e3098.	0.4	24
1687	How Much Should We Pay to Minimize Pancreatic Leak? The Cost-effectiveness of Pasireotide in Pancreatic Resection. Annals of Surgery, 2016, Publish Ahead of Print, .	2.1	1
1688	The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochemical and Biophysical Research Communications, 2016, 476, 260-266.	1.0	27
1689	Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas, 2016, 45, 32-39.	0.5	18
1690	S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	0.8	14

#	Article	IF	Citations
1691	Buccal adhesive nanofibers containing human growth hormone for oral mucositis. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2016, 104, 1396-1406.	1.6	31
1692	Interstitial lung disease associated with gemcitabine: A <scp>J</scp>apanese retrospective cohort study. Respirology, 2016, 21, 338-343.	1.3	25
1693	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 2004-2012.	1.4	5
1694	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer, 2016, 24, 4057-4074.	1.0	21
1695	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3â€“MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 6153-6163.	3.2	56
1696	Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer. Pancreas, 2016, 45, 211-217.	0.5	69
1697	Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells. Pancreas, 2016, 45, 269-280.	0.5	7
1698	Early decrement of serum carbohydrate antigen 19â€9 predicts favorable outcome in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 506-512.	1.4	15
1699	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 2016, 22, 4870-4879.	3.2	26
1700	Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Digestion, 2016, 94, 222-229.	1.2	16
1701	Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro. Oncology Reports, 2016, 35, 2473-2479.	1.2	35
1702	Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?. Journal of Oncology Practice, 2016, 12, 797-805.	2.5	10
1703	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74
1704	Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer, 2016, 16, 443.	1.1	23
1705	Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 17-23.	2.5	15
1706	Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification. Progress in Molecular Biology and Translational Science, 2016, 144, 383-436.	0.9	13
1707	Wilmsâ€™ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy, 2016, 8, 1309-1320.	1.0	14
1708	Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ, The, 2016, 355, i6286.	3.0	7

#	Article	IF	Citations
1709	Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer. Scientific Reports, 2016, 6, 30346.	1.6	52
1710	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist, 2016, 21, 1483-1491.	1.9	64
1711	Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC. Oncology Reports, 2016, 35, 2198-2206.	1.2	3
1712	Antitumor effects of herbal mixture extract in the pancreatic adenocarcinoma cell line PANC1. Oncology Reports, 2016, 36, 2875-2883.	1.2	12
1713	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
1714	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncology Letters, 2016, 12, 4505-4509.	0.8	0
1715	Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety, 2016, 15, 1219-1238.	1.0	52
1716	Precision Medicine in Gastrointestinal Pathology. Archives of Pathology and Laboratory Medicine, 2016, 140, 449-460.	1.2	3
1717	Approving molecularly targeted drugs: different approval processes for cytotoxic agents. International Journal of Clinical Oncology, 2016, 21, 1004-1013.	1.0	1
1718	Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile. Molecular Medicine Reports, 2016, 13, 3779-3786.	1.1	4
1719	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	1.2	20
1720	Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology, 2016, 16, 658-664.	0.5	28
1721	Epigenetic Advancements in Cancer. , 2016, , .		1
1722	Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies. Pancreas, 2016, 45, 1167-1174.	0.5	4
1723	Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters, 2016, 11, 1645-1650.	0.8	20
1724	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics, 2016, 38, 1622-1635.	1.1	18
1725	Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therapeutic Advances in Gastroenterology, 2016, 9, 141-151.	1.4	11
1726	Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1353-1360.	1.2	42

#	Article	IF	Citations
1727	Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. International Journal of Oncology, 2016, 48, 45-54.	1.4	38
1728	Hedgehog Signaling in Pancreatic Fibrosis and Cancer. Medicine (United States), 2016, 95, e2996.	0.4	35
1729	Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology, 2016, 33, 37.	1.2	1
1730	Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opinion on Drug Safety, 2016, 15, 947-954.	1.0	8
1731	Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery, 2016, 160, 136-144.	1.0	121
1732	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clinical Cancer Research, 2016, 22, 2127-2132.	3.2	21
1733	Optimizing Treatment for Locally Advanced Pancreas Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 1837.	3.8	12
1734	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
1735	Dosing to rash? â€“ The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. European Journal of Cancer, 2016, 55, 131-139.	1.3	19
1736	Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Oncology, 2016, 90, 261-266.	0.9	21
1737	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. American Journal of Pathology, 2016, 186, 1537-1546.	1.9	31
1738	The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1165-1170.	1.1	13
1740	Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2016, 18, 425-435.	2.3	30
1741	KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42.		151
1742	Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Cancer Genetics, 2016, 209, 567-581.	0.2	32
1743	Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo. Biochemistry, 2016, 55, 5520-5530.	1.2	7
1744	Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumorâ€“stromal cross-talk. Carcinogenesis, 2016, 37, 1052-1061.	1.3	28
1745	Early surgical bypass versus endoscopic stent placement in pancreatic cancer. Hpb, 2016, 18, 671-677.	0.1	24

#	Article	IF	Citations
1746	Survival advantage with para aortic lymphadenectomy in peri-ampullary cancer: A retrospective cohort study. International Journal of Surgery, 2016, 31, 58-62.	1.1	8
1747	Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells. Oncology Letters, 2016, 12, 177-182.	0.8	2
1748	Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Molecular Biology of the Cell, 2016, 27, 3659-3672.	0.9	26
1749	Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies â€“ experience of a community based hospital. Zeitschrift Fur Gastroenterologie, 2016, 54, 1138-1142.	0.2	6
1750	Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Toxicology and Applied Pharmacology, 2016, 311, 113-116.	1.3	15
1751	Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis. OMICS A Journal of Integrative Biology, 2016, 20, 442-447.	1.0	5
1752	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Current Medical Research and Opinion, 2016, 32, 1839-1848.	0.9	16
1753	Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer. Cancer Genetics, 2016, 209, 582-591.	0.2	4
1754	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Seminars in Radiation Oncology, 2016, 26, 320-337.	1.0	21
1755	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
1756	Pancreatic Cancer. Gastroenterology Clinics of North America, 2016, 45, 429-445.	1.0	73
1757	New treatment strategy with nuclear factor-ÎºB inhibitor for pancreatic cancer. Journal of Surgical Research, 2016, 206, 1-8.	0.8	13
1758	Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer, 2016, 65, 11-20.	1.3	19
1759	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Future Oncology, 2016, 12, 2741-2753.	1.1	8
1760	InÂvitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie, 2016, 130, 4-13.	1.3	6
1761	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nature Reviews Clinical Oncology, 2016, 13, 750-765.	12.5	181
1762	Molecular profiles in foregut oncology. Cancer Genetics, 2016, 209, 537-553.	0.2	0
1763	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology, 2016, 16, 1106-1112.	0.5	13

#	Article	IF	Citations
1764	Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer, 2016, 122, 3765-3775.	2.0	18
1765	Genetic ablation of Smoothened in pancreatic fibroblasts increases acinarâ€“ductal metaplasia. Genes and Development, 2016, 30, 1943-1955.	2.7	46
1766	Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion, 2016, 94, 44-49.	1.2	28
1767	Ablation Strategies for Locally Advanced Pancreatic Cancer. Digestive Surgery, 2016, 33, 351-359.	0.6	36
1768	Drugs That May Cause or Exacerbate Heart Failure. Circulation, 2016, 134, e32-69.	1.6	320
1769	The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. Journal of Surgical Oncology, 2016, 114, 323-328.	0.8	4
1770	The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1549-1555.	1.4	5
1771	Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer. Surgical Clinics of North America, 2016, 96, 1287-1300.	0.5	14
1772	Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America, 2016, 96, 1391-1414.	0.5	10
1773	Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221.	0.5	12
1774	Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016, 16, 579.	1.1	29
1775	Pancreatic cancer and liver metastases: state of the art. Updates in Surgery, 2016, 68, 247-251.	0.9	29
1776	Cancer Drug Discovery. , 2016, , .		6
1777	Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer, 2016, 16, 817.	1.1	28
1778	Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. , 2016, 4, 33.		11
1779	Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Progress in Molecular Biology and Translational Science, 2016, 144, 277-320.	0.9	9
1781	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	18.1	1,301
1782	Systemic Therapy in Pancreatic Cancer. , 2016, , 247-273.		1

#	Article	IF	Citations
1783	Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Scientific Reports, 2016, 6, 32809.	1.6	22
1784	Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodige and MPACT Trials. Tumori, 2016, 102, 294-300.	0.6	14
1785	Comparison of patency and cost-effectiveness of self-expandable metal and plastic stents used for malignant biliary strictures. European Journal of Gastroenterology and Hepatology, 2016, 28, 1223-1228.	0.8	7
1786	Precision Medicine and Pancreatic Cancer. Pancreas, 2016, 45, 1485-1493.	0.5	9
1787	Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. Expert Review of Precision Medicine and Drug Development, 2016, 1, 479-485.	0.4	0
1788	A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma. Therapeutic Drug Monitoring, 2016, 38, 657-662.	1.0	10
1789	Chemotherapy for advanced biliary tract carcinoma. Medicine (United States), 2016, 95, e4584.	0.4	8
1790	Evolution of novel therapeutic options for pancreatic cancer. Current Opinion in Gastroenterology, 2016, 32, 401-407.	1.0	14
1791	Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer. Clinical Therapeutics, 2016, 38, 1174-1183.	1.1	10
1792	Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. European Radiology, 2016, 26, 1835-1842.	2.3	37
1793	Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials. JAMA Oncology, 2016, 2, 1209.	3.4	55
1794	Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology, 2016, 16, 859-864.	0.5	30
1795	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2784-2796.	0.8	267
1796	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular and Cellular Proteomics, 2016, 15, 2671-2685.	2.5	29
1797	Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliative Care, 2016, 15, 25.	0.8	7
1798	Development of Pancreatic Cancer: Targets for Early Detection and Treatment. Digestive Diseases, 2016, 34, 525-531.	0.8	4
1799	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.4	28
1800	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clinical and Translational Oncology, 2016, 18, 653-659.	1.2	8

#	Article	IF	Citations
1801	Induction Chemotherapy. , 2016, , .		3
1802	Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anti-Cancer Drugs, 2016, 27, 723-725.	0.7	17
1803	A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series. Therapeutic Advances in Gastroenterology, 2016, 9, 162-168.	1.4	2
1804	Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Biomacromolecules, 2016, 17, 2507-2513.	2.6	110
1805	Epigenetic Changes and Potential Targets in Pancreatic Cancer. , 2016, , 27-63.		0
1806	CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2016, 22, 6069-6077.	3.2	8
1807	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Pancreas, 2016, 45, 286-292.	0.5	12
1808	Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes. Journal of Surgical Oncology, 2016, 113, 784-788.	0.8	22
1809	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
1810	Pancreatic cancer: yesterday, today and tomorrow. Future Oncology, 2016, 12, 1929-1946.	1.1	286
1811	Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncology Letters, 2016, 12, 727-730.	0.8	8
1812	Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?. Surgery Today, 2016, 46, 139-148.	0.7	13
1813	Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report. Journal of Oncology Pharmacy Practice, 2016, 22, 528-532.	0.5	17
1814	The acinar regulator Gata6 suppressesKrasG12V-driven pancreatic tumorigenesis in mice. Gut, 2016, 65, 476-486.	6.1	83
1815	Neurological Complications of Systemic Cancer and Antineoplastic Therapy. , 0, , .		3
1816	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology, 2016, 16, 249-258.	0.5	17
1817	Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clinical Colorectal Cancer, 2016, 15, 264-276.	1.0	8
1818	Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opinion on Investigational Drugs, 2016, 25, 359-365.	1.9	4

#	Article	IF	Citations
1819	Pancreatic cancer. Lancet, The, 2016, 388, 73-85.	6.3	1,826
1820	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2848-2854.	3.2	272
1821	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 35-41.	1.1	14
1822	An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Applied Materials & Interfaces, 2016, 8, 3438-3445.	4.0	119
1823	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. British Journal of Cancer, 2016, 114, 269-280.	2.9	81
1824	Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal of Oncology, 2016, 48, 908-918.	1.4	25
1825	Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology, 2016, 4, 315-325.	0.4	31
1826	The value of surrogate endpoints for predicting real-world survival across five cancer types. Current Medical Research and Opinion, 2016, 32, 731-739.	0.9	6
1827	Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine. Tumor Biology, 2016, 37, 7555-7564.	0.8	6
1828	Pancreatic cancer: Current research and future directions. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 123-132.	3.3	65
1830	Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 340-345.	0.6	20
1831	Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Review of Proteomics, 2016, 13, 383-394.	1.3	7
1832	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Investigational New Drugs, 2016, 34, 319-328.	1.2	17
1833	Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs. , 2016, 162, 35-57.		16
1834	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2016, 30, 355-385.	2.7	416
1835	Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 595-603.	1.1	131
1836	Life and treatment goals of patients with advanced, incurable cancer. Supportive Care in Cancer, 2016, 24, 2953-62.	1.0	29
1837	Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.. European Journal of Cancer, 2016, 54, 96-103.	1.3	26

#	Article	IF	Citations
1838	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	15.2	184
1839	Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. Molecular Cancer Therapeutics, 2016, 15, 1145-1152.	1.9	27
1840	Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Letters, 2016, 381, 201-210.	3.2	46
1841	Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinomaâ€"An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clinical Colorectal Cancer, 2016, 15, 24-31.	1.0	13
1842	Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treatment Reviews, 2016, 42, 10-17.	3.4	16
1843	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	1.9	25
1844	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35
1845	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
1846	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical and Translational Oncology, 2016, 18, 988-995.	1.2	16
1847	Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Critical Reviews in Oncology/Hematology, 2016, 99, 286-298.	2.0	44
1848	Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2016, 25, 311-326.	0.6	19
1849	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	1.9	49
1850	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. Oncology Letters, 2016, 11, 1101-1104.	0.8	8
1851	The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Methods in Molecular Biology, 2016, 1395, 163-187.	0.4	10
1852	A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemotherapy and Pharmacology, 2016, 77, 693-701.	1.1	10
1853	Optimizing initial chemotherapy for metastatic pancreatic cancer. Future Oncology, 2016, 12, 1125-1133.	1.1	5
1854	Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Human Gene Therapy, 2016, 27, 184-192.	1.4	7
1855	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	2.0	10

#	Article	IF	Citations
1856	Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Targeted Oncology, 2016, 11, 371-381.	1.7	23
1857	Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors. , 2016, , 227-272.		1
1858	MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncology, 2016, 12, 453-464.	1.1	33
1859	Emerging Systemic and Targeted Therapies. , 2016, , 159-168.		1
1860	Overview of Multimodality Therapy. , 2016, , 73-89.		0
1861	Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational New Drugs, 2016, 34, 176-183.	1.2	15
1862	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer, 2016, 24, 301-309.	1.0	11
1864	A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. Journal of Gastroenterology, 2016, 51, 711-721.	2.3	15
1865	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
1866	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2016, 16, 14-27.	0.5	81
1867	Pancreatic Masses. , 2016, , .		0
1868	Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis. Journal of Nephrology, 2016, 29, 359-365.	0.9	10
1870	SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Tumor Biology, 2016, 37, 4323-4330.	0.8	15
1871	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	0.6	90
1872	The influence of subclonal resistance mutations on targeted cancer therapy. Nature Reviews Clinical Oncology, 2016, 13, 335-347.	12.5	185
1873	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 341-359.	1.5	34
1874	Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. International Journal of Clinical Oncology, 2016, 21, 118-125.	1.0	28
1875	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2016, 22, 61-68.	3.2	105

#	Article	IF	Citations
1876	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 197-205.	0.7	39
1877	Intravenous Ï‰-3 Fatty Acids Plus Gemcitabine. Journal of Parenteral and Enteral Nutrition, 2017, 41, 398-403.	1.3	18
1878	Downregulation of STAT3/NFâ€ÎºB potentiates gemcitabine activity in pancreatic cancer cells. Molecular Carcinogenesis, 2017, 56, 402-411.	1.3	32
1879	Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Technology in Cancer Research and Treatment, 2017, 16, 285-294.	0.8	41
1880	Epidermal growth factor receptor (EGFR)â€"MAPKâ€"nuclear factor(NF)â€ÎºBâ€"IL8: A possible mechanism of particulate matter(PM) 2.5â€induced lung toxicity. Environmental Toxicology, 2017, 32, 1628-1636.	2.1	37
1881	The paradoxical functions of EGFR during breast cancer progression. Signal Transduction and Targeted Therapy, 2017, 2, .	7.1	95
1882	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in Health, 2017, 20, 586-592.	0.1	16
1883	Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Annals of Surgical Oncology, 2017, 24, 1722-1730.	0.7	33
1884	Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell, 2017, 31, 5-19.	7.7	309
1885	Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: <scp>VENUS</scp>â€<scp>PC</scp> study. Cancer Science, 2017, 108, 73-80.	1.7	54
1886	A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Scientific Reports, 2017, 7, 41615.	1.6	58
1887	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. British Journal of Cancer, 2017, 116, 609-619.	2.9	205
1888	Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. British Journal of Cancer, 2017, 116, 464-471.	2.9	21
1889	Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Letters, 2017, 390, 91-102.	3.2	50
1890	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
1891	Combination of ruthenium(II)-arene complex [Ru(Î·6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Scientific Reports, 2017, 7, 43005.	1.6	97
1892	Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity inKRASwild-type tumors. International Journal of Cancer, 2017, 140, 2331-2343.	2.3	30
1893	Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. International Journal of Cancer, 2017, 140, 2344-2350.	2.3	133

#	Article	IF	Citations
1894	Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1053-1059.	1.2	24
1895	Emerging protein kinase inhibitors for treating pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 77-86.	1.0	11
1896	Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 159-170.	1.4	26
1897	Gemcitabineâ€“erlotinib versus gemcitabineâ€“erlotinibâ€“capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. European Journal of Cancer, 2017, 75, 73-82.	1.3	15
1898	EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nature Communications, 2017, 8, 14688.	5.8	18
1899	Tackling pancreatic cancer with metronomic chemotherapy. Cancer Letters, 2017, 394, 88-95.	3.2	8
1900	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2017, 79, 595-602.	1.1	12
1901	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 337-346.	3.7	28
1902	Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. Acta OncolÃ³gica, 2017, 56, 377-383.	0.8	46
1903	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	5.1	60
1904	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. International Journal of Radiation Oncology Biology Physics, 2017, 97, 643-650.	0.4	0
1905	Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncology, The, 2017, 18, 421-422.	5.1	11
1906	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Letters, 2017, 397, 94-102.	3.2	50
1907	Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 39-51.	1.0	9
1908	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 82.	6.9	105
1909	Evaluation of Suppressive Effects of Tranilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. Pancreas, 2017, 46, 567-574.	0.5	2
1910	Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials. Annals of Surgical Oncology, 2017, 24, 2371-2378.	0.7	10
1911	Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Scientific Reports, 2017, 7, 470.	1.6	55

#	Article	IF	Citations
1912	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas, 2017, 46, 335-340.	0.5	75
1913	An optofluidic approach for gold nanoprobes based-cancer theranostics. , 2017, , .		0
1914	Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical Reviews in Oncology/Hematology, 2017, 114, 102-113.	2.0	32
1915	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Annals of Oncology, 2017, 28, 711-717.	0.6	125
1916	Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience. Clinical Breast Cancer, 2017, 17, 618-628.	1.1	8
1918	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	2.0	26
1919	Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochemical and Biophysical Research Communications, 2017, 488, 136-140.	1.0	52
1920	The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas, 2017, 46, 341-346.	0.5	33
1921	Paclitaxel: What has been done and the challenges remain ahead. International Journal of Pharmaceutics, 2017, 526, 474-495.	2.6	286
1922	Molecular Events in the Natural History of Pancreatic Cancer. Trends in Cancer, 2017, 3, 336-346.	3.8	60
1923	What treatment in 2017 for inoperable pancreatic cancers?. Annals of Oncology, 2017, 28, 1473-1483.	0.6	30
1925	Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. British Journal of Cancer, 2017, 116, 1544-1550.	2.9	18
1926	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 683-694.	1.4	6
1927	A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 576-588.	1.2	10
1928	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. British Journal of Cancer, 2017, 116, 1462-1469.	2.9	25
1929	Biomarkers in pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1430-1437.	1.2	10
1930	Pancreatic ductal adenocarcinoma: metastatic disease. Clinical and Translational Oncology, 2017, 19, 1423-1429.	1.2	7
1931	A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (United States), 2017, 96, e5702.	0.4	17

#	Article	IF	Citations
1932	Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Scientific Reports, 2017, 7, 2993.	1.6	40
1933	Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. Value in Health, 2017, 20, 866-875.	0.1	69
1934	Longâ€term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 426-433.	1.4	37
1935	EGFR, Immunology. , 2017, , 199-208.		0
1936	Economics of Cancer Medicines: For Whose Benefit?. New Bioethics, 2017, 23, 95-104.	0.5	39
1937	Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer. Pancreas, 2017, 46, 143-150.	0.5	10
1938	miR-144-3p Induces Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells by Targeting Proline-Rich Protein 11 Expression via the Mitogen-Activated Protein Kinase Signaling Pathway. DNA and Cell Biology, 2017, 36, 619-626.	0.9	42
1939	Current and future therapies for advanced pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 25-34.	0.8	123
1940	An overall review of targeted therapy in solid cancers. Current Medicine Research and Practice, 2017, 7, 99-105.	0.1	9
1941	Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. Oncology Letters, 2017, 13, 3437-3444.	0.8	10
1942	K-Ras. , 2017, , 763-772.		0
1943	Anti-tumor effects of a â€˜human & mouse cross-reactiveâ€™ anti-ADAM17 antibody in a pancreatic cancer model in vivo. European Journal of Pharmaceutical Sciences, 2017, 110, 62-69.	1.9	24
1944	Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma. Pathology Research and Practice, 2017, 213, 964-968.	1.0	16
1945	MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells. Pancreas, 2017, 46, 557-566.	0.5	8
1946	Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology, 2017, 47, 832-839.	0.6	9
1947	Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. Pancreas, 2017, 46, 813-819.	0.5	33
1949	Drug-biomarker co-development in oncology â€“ 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	6.5	48
1950	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38

#	Article	IF	Citations
1951	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
1952	Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines. Pancreas, 2017, 46, 575-581.	0.5	22
1953	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clinical Cancer Research, 2017, 23, 4429-4440.	3.2	142
1954	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
1955	Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Molecular and Clinical Oncology, 2017, 6, 583-588.	0.4	5
1956	Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Cancer Chemotherapy and Pharmacology, 2017, 79, 915-922.	1.1	9
1957	EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointestinal Endoscopy, 2017, 86, 161-169.	0.5	58
1958	Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. Future Oncology, 2017, 13, 777-786.	1.1	9
1959	Design, synthesis and biological evaluation of quinazolineâ€“phosphoramidate mustard conjugates as anticancer drugs. European Journal of Medicinal Chemistry, 2017, 127, 442-458.	2.6	15
1960	Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy. JAMA Oncology, 2017, 3, 516.	3.4	142
1961	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 2017, 12, 97-109.	1.7	56
1962	Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. International Journal of Pharmaceutics, 2017, 517, 157-167.	2.6	60
1963	Effect of arenobufagin on human pancreatic carcinoma cells. Oncology Letters, 2017, 14, 4971-4976.	0.8	8
1964	Recombinant human adenovirusâ€‘p53 improves the outcome of midâ€‘late stage pancreatic cancer via arterial infusion. Oncology Letters, 2017, 14, 6829-6832.	0.8	3
1965	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 136-140.	0.3	5
1966	Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. Cancer Letters, 2017, 410, 63-67.	3.2	31
1967	Current Standards of Chemotherapy for Pancreatic Cancer. Clinical Therapeutics, 2017, 39, 2125-2134.	1.1	80
1968	Pancreatic Cancer: Current Status and Challenges. Current Pharmacology Reports, 2017, 3, 396-408.	1.5	15

#	Article	IF	Citations
1969	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews, 2017, 60, 32-43.	3.4	116
1970	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therapeutic Advances in Gastroenterology, 2017, 10, 631-645.	1.4	39
1971	Second line treatment options for pancreatic cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1607-1617.	0.9	11
1972	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
1973	An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nature Communications, 2017, 8, 347.	5.8	151
1974	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?. Journal of Geriatric Oncology, 2017, 8, 407-412.	0.5	10
1975	Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments. Cell Reports, 2017, 20, 2784-2791.	2.9	20
1976	Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology, 2017, 17, 967-973.	0.5	40
1977	A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemotherapy and Pharmacology, 2017, 80, 497-505.	1.1	13
1978	PETâ€“Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. PET Clinics, 2017, 12, 407-421.	1.5	8
1979	Pancreatic cancer screening: Still a delusion?. Pancreatology, 2017, 17, 754-765.	0.5	20
1980	Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene <scp>SO</scp>1861. Molecular Oncology, 2017, 11, 1527-1543.	2.1	11
1981	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	2.0	4
1982	Real five year survival after radical surgery for pancreatic carcinoma: can it be predicted with the usual prognostic factors?. Hpb, 2017, 19, S173.	0.1	0
1983	Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open, 2017, 2, e000151.	2.0	9
1984	New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Expert Opinion on Emerging Drugs, 2017, 22, 223-233.	1.0	25
1985	Thromboembolisms in Advanced Pancreatic Cancer. Pancreas, 2017, 46, 1069-1075.	0.5	18
1986	Randomized Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2017, 26, 767-790.	0.6	7

#	Article	IF	Citations
1987	Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Therapeutic Advances in Gastroenterology, 2017, 10, 563-572.	1.4	24
1988	Safety and efficacy evaluation of pertuzumab in patients with solid tumors. Medicine (United States), 2017, 96, e6870.	0.4	7
1989	Loss of <scp>AMPK</scp> activation promotes the invasion and metastasis of pancreatic cancer through an <scp>HSF</scp>1â€dependent pathway. Molecular Oncology, 2017, 11, 1475-1492.	2.1	67
1990	Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell, 2017, 171, 1678-1691.e13.	13.5	467
1991	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 343-349.	1.0	14
1992	High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Scientific Reports, 2017, 7, 17188.	1.6	94
1993	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 355-361.	1.0	0
1994	DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53â€deficient pancreatic cancer cells. Molecular Medicine Reports, 2018, 17, 117-124.	1.1	4
1995	Cardiovascular Complications of CancerÂTherapy. Journal of the American College of Cardiology, 2017, 70, 2536-2551.	1.2	298
1996	Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nature Communications, 2017, 8, 1420.	5.8	18
1997	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. Medical Oncology, 2017, 34, 136.	1.2	7
1998	Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology, 2017, 28, 2429-2435.	0.6	89
1999	Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Letters, 2017, 403, 296-304.	3.2	20
2000	Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrology Dialysis Transplantation, 2017, 32, 1089-1097.	0.4	38
2001	The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 14.	3.5	8
2002	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 36.	3.5	24
2003	Does â€œOPTINABâ€•strategy (â€œstop-and-goâ€) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxelâ€“gemcitabine?. Cancer Chemotherapy and Pharmacology, 2017, 80, 371-375.	1.1	11
2004	Whatâ€™s new in treatment of pancreatic cancer: a patent review (2010â€“2017). Expert Opinion on Therapeutic Patents, 2017, 27, 1251-1266.	2.4	13

#	Article	IF	Citations
2005	Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. Acta OncolÃ³gica, 2017, 56, 1754-1762.	0.8	22
2006	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	3.4	221
2007	Chemoradiation for Locally Advanced Unresectable Pancreatic Cancerâ€"What Now?. JAMA Oncology, 2017, 3, 850.	3.4	2
2008	COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. Molecular Carcinogenesis, 2017, 56, 607-624.	1.3	14
2009	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2017, 9, 75-82.	1.4	46
2010	HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 369-380.	2.2	37
2011	Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Pharmacoeconomics, 2017, 35, 83-95.	1.7	11
2012	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth and Metastasis, 2017, 10, 117906441770928.	3.5	24
2013	Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer â€œin a Koreanâ€•population: A single-center cohort study. Seminars in Oncology, 2017, 44, 420-427.	0.8	16
2014	EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1085-1089.	2.3	2
2015	Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterology, 2017, 17, 143.	0.8	17
2017	Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Gut and Liver, 2017, 11, 298-305.	1.4	10
2018	The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Frontiers in Physiology, 2017, 8, 381.	1.3	30
2019	A Rapid and Simple UHPLC-UV Method for Quantitative Determination of Erlotinib and Its Active Metabolite OSI-420 in Human Serum, and Its Application in a Non-Small Cell Lung Cancer Patient. Chromatography, 2017, 38, 95-100.	0.8	4
2020	The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2017, 18, 600.	1.8	29
2021	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
2022	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules, 2017, 22, 1515.	1.7	4
2025	Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors. Frontiers in Chemistry, 2017, 5, 101.	1.8	3

#	Article	IF	Citations
2026	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	1.8	21
2027	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences, 2017, 18, 1338.	1.8	431
2028	The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. Current Pharmaceutical Design, 2017, 23, 2314-2320.	0.9	10
2029	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget, 2017, 8, 72127-72132.	0.8	14
2030	Erlotinib: A Targeted Anticancer Drug. Current Cancer Therapy Reviews, 2017, 13, .	0.2	5
2031	A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. Journal of Cancer, 2017, 8, 1872-1883.	1.2	42
2032	Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2017, 12, e0169736.	1.1	16
2033	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS ONE, 2017, 12, e0183639.	1.1	2
2034	Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). Journal of Experimental and Clinical Cancer Research, 2017, 36, 107.	3.5	63
2035	Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS^{G12D}. Biomedical Research, 2017, 38, 29-40.	0.3	7
2036	The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 206-213.	0.5	3
2037	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058.	1.4	15
2038	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets and Therapy, 2017, Volume 10, 591-596.	1.0	22
2039	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. International Journal of Molecular Sciences, 2017, 18, 180.	1.8	16
2040	A review on the effects of current chemotherapy drugs and natural agents in treating nonâ€“small cell		

#	Article	IF	Citations
2044	Promise of Wearable Physical Activity Monitors in Oncology Practice. Journal of Oncology Practice, 2017, 13, 82-89.	2.5	77
2045	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2017, 8, 566-571.	0.6	67
2046	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2017, 8, 387-404.	0.6	21
2047	MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. Neoplasma, 2017, 64, 358-366.	0.7	20
2048	Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancerâ€"retrospective analysis of response. Journal of Gastrointestinal Oncology, 2017, 8, 556-565.	0.6	32
2049	The Dutch Pancreas Biobank Within the Parelsnoer Institute. Pancreas, 2018, 47, 495-501.	0.5	8
2050	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	5.1	51
2051	Expression of ICAM-1, E-cadherin, periostin and midkine in metastases of pancreatic ductal adenocarcinomas. Experimental and Molecular Pathology, 2018, 104, 109-113.	0.9	8
2052	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 435-446.	0.7	9
2053	Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas, 2018, 47, 631-636.	0.5	15
2054	A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 497-506.	1.5	6
2055	4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncology Letters, 2018, 15, 6297-6301.	0.8	12
2056	Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Annals of Surgical Oncology, 2018, 25, 1880-1888.	0.7	127
2057	Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer, 2018, 94, 26-36.	1.3	7
2058	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investigational New Drugs, 2018, 36, 732-741.	1.2	87
2059	Monoclonal Antibody L₁Mab-13 Detected Human PD-L1 in Lung Cancers. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2018, 37, 110-115.	0.8	45
2060	Masitinib in treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 759-764.	0.9	12
2061	Evaluation of comparative effectiveness research: a practical tool. Journal of Comparative Effectiveness Research, 2018, 7, 503-515.	0.6	13

#	Article	IF	Citations
2062	Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Clinical Colorectal Cancer, 2018, 17, e451-e456.	1.0	12
2063	Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 261-268.	1.4	31
2065	A look at the progress of treating pancreatic cancer over the past 20 years. Expert Review of Anticancer Therapy, 2018, 18, 295-304.	1.1	23
2066	Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. International Journal of Clinical Oncology, 2018, 23, 443-451.	1.0	10
2070	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas, 2018, 47, 142-157.	0.5	19
2071	The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Review of Anticancer Therapy, 2018, 18, 131-148.	1.1	36
2072	Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma. Cancer Letters, 2018, 419, 40-52.	3.2	7
2073	Induced <scp>PTF</scp>1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment. Molecular Oncology, 2018, 12, 1104-1124.	2.1	17
2074	Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology, 2018, 45, 18-26.	0.8	40
2075	Chemotherapy and radiotherapy for advanced pancreatic cancer. The Cochrane Library, 2018, 2018, CD011044.	1.5	80
2076	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	8.2	762
2077	EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2018, , 383-408.		1
2078	Palliative Management of Pancreatic Cancer. , 2018, , 771-798.		0
2079	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0
2080	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
2081	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. , 2018, , 1577-1611.		1
2082	Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. , 2018, , 1203-1217.		0
2083	Targeted agents for patients with advanced/metastatic pancreatic cancer. Medicine (United States), 2018, 97, e0115.	0.4	1

#	Article	IF	Citations
2084	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	7.7	58
2085	Management of Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1155-1174.	0.4	48
2086	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™. European Journal of Cancer, 2018, 94, 95-103.	1.3	32
2087	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
2088	Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic PancreaticÂCancer. Clinical Colorectal Cancer, 2018, 17, 187-197.	1.0	20
2089	PAK4 pathway as a potential therapeutic target in pancreatic cancer. Future Oncology, 2018, 14, 579-582.	1.1	19
2090	A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naÃ¯ve Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 230-235.	0.6	8
2091	Predictive approaches for drug combination discovery in cancer. Briefings in Bioinformatics, 2018, 19, 263-276.	3.2	75
2092	Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesisâ€”A connection to licensing nodes. Small GTPases, 2018, 9, 457-464.	0.7	10
2093	Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer. Pathology and Oncology Research, 2018, 24, 237-244.	0.9	6
2094	Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Annals of Surgery, 2018, 267, 544-551.	2.1	14
2095	Neurological complications of new chemotherapy agents. Neuro-Oncology, 2018, 20, 24-36.	0.6	28
2096	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 2018, 27, 1230-1239.	0.7	43
2097	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. Journal of the National Cancer Institute, 2018, 110, 232-240.	3.0	40
2098	Drug-Induced Lung Injury. Respiratory Disease Series, 2018, , .	0.1	2
2099	Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results. Investigational New Drugs, 2018, 36, 442-450.	1.2	16
2100	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	2.4	37
2101	Neurological Complications of Targeted Therapies. , 2018, , 311-333.		2

#	Article	IF	Citations
2102	Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle, 2018, 17, 191-199.	1.3	10
2103	Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells. Journal of Drug Targeting, 2018, 26, 676-683.	2.1	16
2104	Molecular Analysis for Therapeutic Targets of Pancreatic Cancer. Current Human Cell Research and Applications, 2018, , 127-144.	0.1	0
2106	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031435.	2.9	563
2107	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Journal of Gastrointestinal Cancer, 2018, 49, 1-8.	0.6	11
2108	Efficacy and safety of antiâ€EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and metaâ€analysis of randomized controlled trials. International Journal of Cancer, 2018, 142, 2198-2206.	2.3	24
2109	Locally advanced pancreatic cancer: An emerging entity. Current Problems in Cancer, 2018, 42, 12-25.	1.0	13
2110	A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Supportive Care in Cancer, 2018, 26, 1169-1179.	1.0	17
2111	Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy, 2018, 18, 51-62.	1.1	17
2112	A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 772-776.	0.6	13
2113	Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 867-873.	0.6	2
2114	Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 2018, 1, 20-20.	1.2	5
2115	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 135-139.	0.6	11
2116	Immunotherapy in pancreatic adenocarcinomaâ€"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
2117	Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. Journal of Gastrointestinal Oncology, 2018, 9, 377-389.	0.6	2
2118	Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?â€"review of the open label phase III trial CONKO 005. Hepatobiliary Surgery and Nutrition, 2018, 7, 399-402.	0.7	0
2119	Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surgery and Nutrition, 2018, 7, 406-408.	0.7	1
2120	LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget, 2018, 9, 3131-3142.	0.8	8

#	Article	IF	Citations
2121	Gemcitabine plus S-1 for metastatic pancreatic cancer. Medicine (United States), 2018, 97, e12836.	0.4	1
2122	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 494-502.	0.5	2
2123	Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Annals of Pancreatic Cancer, 2018, 1, 26-26.	1.2	3
2124	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 421-430.	0.8	25
2125	Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology, 2018, 2, 1-11.	1.5	13
2126	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases (Basel, Switzerland), 2018, 6, 103.	1.0	7
2127	New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. Targeted Oncology, 2018, 13, 691-704.	1.7	6
2128	A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. Journal of Biomedical Science, 2018, 25, 83.	2.6	9
2129	Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression. OncoTargets and Therapy, 2018, Volume 11, 8227-8237.	1.0	9
2130	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbeck's Archives of Surgery, 2018, 403, 917-932.	0.8	67
2131	Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget, 2018, 9, 19396-19405.	0.8	37
2132	Metaâ€'analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatmentâ€'associated toxicities. Molecular Medicine Reports, 2019, 19, 477-489.	1.1	5
2133	Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Scientific Reports, 2018, 8, 17914.	1.6	65
2134	Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS ONE, 2018, 13, e0200664.	1.1	13
2135	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 2018, 9, 21613-21627.	0.8	39
2137	Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. Journal of Experimental and Clinical Cancer Research, 2018, 37, 319.	3.5	81
2138	A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model. OncoTargets and Therapy, 2018, Volume 11, 8655-8672.	1.0	12
2139	Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. Anticancer Research, 2018, 38, 6591-6606.	0.5	65

#	Article	IF	Citations
2140	Glutamine Deprivation Enhances Acetyl-CoA Carboxylase Inhibitor-induced Death of Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 6683-6689.	0.5	22
2141	The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Switzerland), 2018, 3, 85.	0.6	4
2142	A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 1249-1270.	1.1	164
2143	Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Japanese Journal of Clinical Oncology, 2018, 48, 966-973.	0.6	16
2144	The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nationâ€wide cancer registryâ€based study from Taiwan. Cancer Medicine, 2018, 7, 5775-5788.	1.3	27
2145	Advanced pancreatic cancer: The standard of care and new opportunities. Oncology Reviews, 2018, 12, 370.	0.8	10
2146	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
2147	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 619-625.	0.8	11
2148	Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. Oncology Research and Treatment, 2018, 41, 596-602.	0.8	17
2149	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 590-594.	0.8	9
2151	Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer, 2018, 18, 1034.	1.1	7
2152	Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. BJR|case Reports, 2018, 4, 20170086.	0.1	2
2153	Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 6633-6646.	1.0	1
2154	Drug Discovery from Natural Products for Pancreatic Cancer. , 0, , .		1
2155	Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Molecules, 2018, 23, 2608.	1.7	21
2156	Currently available first-line drug therapies for treating pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1927-1940.	0.9	5
2157	Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC Cancer, 2018, 18, 988.	1.1	21
2159	A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer, 2018, 18, 596.	1.1	110

#	Article	IF	Citations
2160	Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro. Journal of Cancer, 2018, 9, 890-900.	1.2	29
2161	Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Translational Oncology, 2018, 11, 1307-1322.	1.7	19
2162	Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2377-2390.	1.2	22
2163	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE,) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	104
2164	A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 829-838.	1.1	10
2165	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy, 2018, Volume 11, 4591-4608.	1.0	6
2166	Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 2018, Volume 12, 475-480.	2.0	19
2167	BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo. Digestive Diseases and Sciences, 2018, 63, 3367-3375.	1.1	10
2168	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metabolism, 2018, 28, 848-865.e6.	7.2	184
2169	Gastrointestinal Cancersâ€"Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. International Journal of Radiation Oncology Biology Physics, 2018, 102, 233-242.	0.4	0
2170	Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Nonâ€"Small Cell Lung Cancer. Therapeutic Drug Monitoring, 2018, 40, 699-704.	1.0	22
2171	Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Experimental and Therapeutic Medicine, 2018, 16, 370-376.	0.8	9
2173	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Medical Oncology, 2018, 35, 100.	1.2	13
2174	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer, 2018, 143, 2053-2064.	2.3	76
2175	NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	7.7	189
2176	Towards an Optimal Treatment Algorithm for Metastatic Pancreatic Ductal Adenocarcinoma (PDA). Current Oncology, 2018, 25, 90-94.	0.9	11
2177	Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. Medical Molecular Morphology, 2018, 51, 237-243.	0.4	9
2178	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	0.8	11

#	Article	IF	Citations
2179	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
2180	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Targeted Oncology, 2018, 13, 447-459.	1.7	13
2181	Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 2144-2155.	1.9	32
2183	Erlotinib. Recent Results in Cancer Research, 2018, 211, 1-17.	1.8	17
2184	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers, 2018, 10, 35.	1.7	19
2185	TGF-Î²RII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Cancers, 2018, 10, 254.	1.7	16
2186	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2018, 11, 71.	6.9	30
2187	Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Cancer Management and Research, 2018, Volume 10, 1907-1918.	0.9	6
2188	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers, 2018, 10, 14.	1.7	26
2189	Targeted Therapies for Pancreatic Cancer. Cancers, 2018, 10, 36.	1.7	69
2190	Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1333-1343.	1.7	12
2192	Inhibition of interleukin 8/Câ€˜X-C chemokine receptorÃ¯Â¿Â½1,/2 signaling reduces malignant features in human pancreatic cancer cells. International Journal of Oncology, 2018, 53, 349-357.	1.4	16
2193	Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers, 2018, 10, 174.	1.7	12
2194	Tumor angiogenesis and antiâ€˜angiogenic gene therapy for cancer (Review). Oncology Letters, 2018, 16, 687-702.	0.8	160
2195	Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Molecular Cancer, 2018, 17, 25.	7.9	89
2196	Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Molecular Cancer, 2018, 17, 2.	7.9	61
2197	Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation. Comparative Clinical Pathology, 2018, 27, 1113-1117.	0.3	0
2198	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas, 2018, 47, 637-642.	0.5	3

#	Article	IF	Citations
2200	Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 343-355.	2.2	38
2201	miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. International Urology and Nephrology, 2018, 50, 1811-1819.	0.6	29
2202	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. Current Cancer Drug Targets, 2018, 18, 430-441.	0.8	1
2204	Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. Scientific Reports, 2018, 8, 12000.	1.6	49
2205	Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. ACS Chemical Biology, 2018, 13, 2623-2632.	1.6	19
2206	Differentiation Therapy Targeting the Î²-Catenin/CBP Interaction in Pancreatic Cancer. Cancers, 2018, 10, 95.	1.7	39
2207	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Journal of Cancer, 2018, 9, 1978-1988.	1.2	27
2208	iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Molecular Cancer Therapeutics, 2018, 17, 2377-2388.	1.9	52
2209	A singleâ€index threshold Cox proportional hazard model for identifying a treatmentâ€sensitive subset based on multiple biomarkers. Statistics in Medicine, 2018, 37, 3267-3279.	0.8	11
2210	Eucalyptus microcorys leaf extract derived HPLC-fraction reduces the viability of MIA PaCa-2 cells by inducing apoptosis and arresting cell cycle. Biomedicine and Pharmacotherapy, 2018, 105, 449-460.	2.5	16
2211	Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Seminars in Oncology, 2018, 45, 107-115.	0.8	6
2212	Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells inÃ‚Â¿Â½vitro. Oncology Letters, 2018, 15, 8761-8769.	0.8	6
2213	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 2018, 48, 637-644.	0.5	3
2214	Comparison of endoscopic ultrasound-guided fine-needle aspiration and biopsy with 22-gauge and 25-gauge needles for the â€œprecision medicineâ€•of pancreatic cancer. Medicine (United States), 2018, 97, e11096.	0.4	6
2215	An Array of Bioactive Compounds From Australian Eucalypts and Their Relevance in Pancreatic Cancer Therapeutics. Pancreas, 2018, 47, 690-707.	0.5	4
2216	Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 3527-3533.	0.5	20
2217	Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Targeted Oncology, 2018, 13, 461-468.	1.7	24
2218	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 8666.	1.6	55

#	Article	IF	Citations
2219	Sequence therapy in metastatic pancreatic cancer. Zeitschrift Fur Gastroenterologie, 2018, 56, 578-582.	0.2	1
2220	Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. Investigational New Drugs, 2019, 37, 364-374.	1.2	24
2221	Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2019, 144, 981-990.	2.3	40
2222	Newly characterized motile sperm domainâ€containing protein 2 promotes human breast cancer metastasis. International Journal of Cancer, 2019, 144, 125-135.	2.3	6
2223	Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Investigational New Drugs, 2019, 37, 127-138.	1.2	0
2224	Oral Mucosal Injury Caused by Targeted Cancer Therapies. Journal of the National Cancer Institute Monographs, 2019, 2019, .	0.9	14
2226	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1173.	1.0	27
2227	PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene, 2019, 38, 6662-6677.	2.6	55
2230	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	1.2	285
2231	Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential. International Journal of Biological Macromolecules, 2019, 139, 1304-1316.	3.6	46
2232	Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Frontiers in Oncology, 2019, 9, 800.	1.3	123
2233	Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. , 2019, , 103-117.		0
2234	Perioperative Gemcitabineâ€‰+â€‰Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497.	0.7	19
2237	Position emission tomography imaging in pancreatic cancer: recent progress and future directions. Annals of Pancreatic Cancer, 0, 2, 6-6.	1.2	0
2238	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS Journal, 2019, 286, 3510-3539.	2.2	33
2240	Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Molecular Cancer Therapeutics, 2019, 18, 2074-2084.	1.9	24
2241	Targeting PIN 1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. Cancer Science, 2019, 110, 2442-2455.	1.7	9
2242	Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor <scp>DNA</scp>. Molecular Oncology, 2019, 13, 1623-1650.	2.1	64

#	Article	IF	Citations
2243	miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 900.	1.7	23
2244	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	1.5	14
2245	State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?. Anticancer Research, 2019, 39, 3405-3412.	0.5	21
2246	Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology and Hepatology, 2019, 4, 559-570.	3.7	15
2247	Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment . OncoTargets and Therapy, 2019, Volume 12, 4585-4593.	1.0	31
2248	Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers, 2019, 11, 1550.	1.7	13
2249	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. Cancers, 2019, 11, 1547.	1.7	10
2250	An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987556.	1.4	144
2251	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterology Research and Practice, 2019, 2019, 1-17.	0.7	8
2252	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Frontiers in Oncology, 2019, 9, 1085.	1.3	48
2253	Evolving Treatment Paradigms for Pancreatic Cancer. Visceral Medicine, 2019, 35, 362-372.	0.5	6
2254	Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer. Cancers, 2019, 11, 1746.	1.7	6
2255	PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers, 2019, 11, 1749.	1.7	13
2256	An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23264-23273.	3.3	27
2258	Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. In Vivo, 2019, 33, 271-276.	0.6	26
2259	Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. Journal of Gastrointestinal Oncology, 2019, 10, 703-711.	0.6	22
2260	Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19609-19618.	3.3	244
2261	Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers, 2019, 11, 1326.	1.7	21

#	Article	IF	Citations
2262	Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2855-2862.	1.2	12
2263	Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Anticancer Research, 2019, 39, 4817-4828.	0.5	14
2264	A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas. Scientific Reports, 2019, 9, 13396.	1.6	27
2265	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	1.6	10
2266	Prognostic Impact of the Neutrophilâ€toâ€Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. World Journal of Surgery, 2019, 43, 3153-3160.	0.8	11
2267	MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes, 2019, 10, 752.	1.0	81
2268	Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network. Annals of Surgical Oncology, 2019, 26, 4173-4174.	0.7	0
2269	Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. Bioconjugate Chemistry, 2019, 30, 2703-2713.	1.8	12
2270	Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987763.	1.4	5
2271	Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology and Hepatology, 2019, 4, 805-810.	3.7	29
2272	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. International Journal of Molecular Sciences, 2019, 20, 4543.	1.8	68
2273	Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 399-409.	0.9	26
2274	A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy - Oncolytics, 2019, 12, 56-67.	2.0	36
2275	A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist, 2019, 24, 589-e160.	1.9	27
2276	FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology, 2019, 19, 325-330.	0.5	3
2277	EGFR, but not COXâ€‘2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. Oncology Letters, 2019, 17, 5361-5368.	0.8	9
2278	Pancreatic cancer in young adults: changes, challenges, and solutions . OncoTargets and Therapy, 2019, Volume 12, 3387-3400.	1.0	15
2279	Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience . OncoTargets and Therapy, 2019, Volume 12, 3077-3085.	1.0	14

#	Article	IF	Citations
2280	Hiding in plain sight. Science, 2019, 364, 1132-1133.	6.0	2
2281	Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 583-592.	1.9	17
2282	Medical Science and Research. Advances in Experimental Medicine and Biology, 2019, , .	0.8	2
2283	New Perspective in Pancreatic Cancer. , 2019, , 151-161.		0
2284	Pharmacogenetics of treatments for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 437-447.	1.5	20
2285	Pancreatic cancer microenvironment: a current dilemma. Clinical and Translational Medicine, 2019, 8, 2.	1.7	72
2286	Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT. Cancer Letters, 2019, 459, 15-29.	3.2	13
2287	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	1.7	4
2288	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
2289	Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine, 2019, 8, 3471-3478.	1.3	11
2290	Effect of Sâ€1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7â€year multicenter observational cohort study in Taiwan. Cancer Medicine, 2019, 8, 2085-2094.	1.3	9
2291	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 588.	1.7	42
2292	The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 491-504.	2.1	18
2293	HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients . OncoTargets and Therapy, 2019, Volume 12, 1021-1029.	1.0	38
2294	Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. Cell Communication and Signaling, 2019, 17, 19.	2.7	19
2295	Pancreatic Cancer and Possible Therapeutic Options. , 2019, , 57-85.		0
2296	Pancreatic Cancer Resistance to Gemcitabine. , 2019, , 45-56.		1
2297	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treatment Reviews, 2019, 75, 27-38.	3.4	32

#	Article	IF	Citations
2298	Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. Molecular Aspects of Medicine, 2019, 70, 106-116.	2.7	20
2299	Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. Journal of Cancer, 2019, 10, 968-978.	1.2	9
2300	2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K. European Journal of Medicinal Chemistry, 2019, 172, 36-47.	2.6	18
2301	Chemotherapy for pancreatic cancer. Presse Medicale, 2019, 48, e159-e174.	0.8	171
2302	Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. Journal of Clinical Oncology, 2019, 37, 570-579.	0.8	115
2303	Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials, 2019, 208, 83-97.	5.7	100
2304	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell, 2019, 35, 573-587.e6.	7.7	75
2305	Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016 . Cancer Management and Research, 2019, Volume 11, 2119-2127.	0.9	9
2306	Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. Journal of Experimental and Clinical Cancer Research, 2019, 38, 150.	3.5	25
2307	Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. International Journal of Hyperthermia, 2019, 36, 393-401.	1.1	7
2308	Mesothelin and TGF-Î± predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. PLoS ONE, 2019, 14, e0213294.	1.1	5
2309	Causes, Consequences, and Control of High Cancer Drug Prices. , 2019, , 39-57.		1
2310	Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology, 2019, 156, 2041-2055.	0.6	52
2311	Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International, 2019, 2019, 1-12.	0.9	5
2312	Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 682-694.	1.3	27
2313	Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Biochemical and Biophysical Research Communications, 2019, 511, 482-489.	1.0	15
2314	An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. Journal of Geriatric Oncology, 2019, 10, 584-590.	0.5	3
2315	Reflections on depletion of tumor stroma in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 267-272.	3.3	13

#	Article	IF	Citations
2316	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas, 2019, 48, 275-280.	0.5	13
2317	Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells. Advances in Experimental Medicine and Biology, 2019, 1153, 55-61.	0.8	3
2318	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Scientific Reports, 2019, 9, 1788.	1.6	57
2319	Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study . OncoTargets and Therapy, 2019, Volume 12, 1341-1350.	1.0	14
2320	Cyclooxygenaseâ€2 in gastrointestinal malignancies. Cancer, 2019, 125, 1221-1227.	2.0	31
2321	Evolving trends in pancreatic cancer therapeutic development. Annals of Pancreatic Cancer, 2019, 2, 17-17.	1.2	1
2322	Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?. ESMO Open, 2019, 4, e000537.	2.0	3
2323	Latest developments in chemotherapy for metastatic pancreatic cancer. , 2019, , 111-139.		0
2324	Genetic manipulations with chemotherapy in pancreatic cancer. , 2019, , 141-152.		0
2325	Epidermal growth factor receptor role in pancreatic cancer. , 2019, , 295-324.		3
2326	EGFR^{vIII}: An Oncogene with Ambiguous Role. Journal of Oncology, 2019, 2019, 1-20.	0.6	45
2327	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
2328	As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-7.	0.8	2
2329	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Expert Review of Clinical Pharmacology, 2019, 12, 1081-1090.	1.3	22
2330	Brain metastasis in pancreatic cancer. Medicine (United States), 2019, 98, e14227.	0.4	12
2331	Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden. Pancreas, 2019, 48, 1232-1236.	0.5	15
2332	Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling . Cancer Management and Research, 2019, Volume 11, 10609-10621.	0.9	8
2333	A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 184-189.	0.6	20

#	Article	IF	Citations
2334	Palliative chemotherapy in pancreatic cancerâ€"treatment sequences. Translational Gastroenterology and Hepatology, 2019, 4, 56-56.	1.5	21
2335	Cytogenetic, Molecular, and Translational Applications in Pancreatic Ductal Adenocarcinoma: Current Evidence and Future Concepts. Critical Reviews in Oncogenesis, 2019, 24, 119-132.	0.2	0
2336	Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles . International Journal of Nanomedicine, 2019, Volume 14, 9693-9706.	3.3	41
2337	A CARE-compliant case report: total pancreatectomy and total gastrectomy to treat pancreatic ductal adenocarcinoma. Medicine (United States), 2019, 98, e18151.	0.4	0
2338	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Journal of Hematology and Oncology, 2019, 12, 130.	6.9	64
2339	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 307-314.	1.2	5
2340	Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis. Internal Medicine, 2019, , .	0.3	0
2341	A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiology, 2019, 58, 104-110.	0.8	92
2342	Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 161-177.	1.9	62
2343	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy, 2019, 20, 535-546.	0.9	22
2344	Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. Journal of Pharmacy and Pharmacology, 2019, 71, 196-205.	1.2	23
2345	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68
2346	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research, 2019, 139, 395-411.	3.1	315
2347	Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology, 2019, 8, e1523096.	2.1	52
2348	Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer. , 2019, , 313-327.		1
2349	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. Journal of Cancer Research and Clinical Oncology, 2019, 145, 445-455.	1.2	6
2350	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. European Journal of Cancer, 2019, 106, 99-105.	1.3	30
2351	Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers, 2019, 11, 57.	1.7	14

#	Article	IF	Citations
2352	NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. European Journal of Cancer, 2019, 108, 78-87.	1.3	185
2353	Cytoplasmic PARPâ€1 promotes pancreatic cancer tumorigenesis and resistance. International Journal of Cancer, 2019, 145, 474-483.	2.3	25
2354	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	0.8	3
2355	Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Targeted Oncology, 2019, 14, 93-105.	1.7	28
2356	Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. European Journal of Medicinal Chemistry, 2019, 165, 80-92.	2.6	34
2357	Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. BMC Cancer, 2019, 19, 28.	1.1	44
2358	Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer, 2019, 19, 40.	1.1	53
2359	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	0.5	34
2360	Therapeutic potential of targeting the Wnt/Î²â€catenin pathway in the treatment of pancreatic cancer. Journal of Cellular Biochemistry, 2019, 120, 6833-6840.	1.2	36
2361	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treatment Reviews, 2019, 72, 1-6.	3.4	46
2362	Small molecule tyrosine kinase inhibitors and pancreatic cancerâ€"Trials and troubles. Seminars in Cancer Biology, 2019, 56, 149-167.	4.3	23
2363	Value-added anticancer reactivity of sub-5 nm Ag-drug nanoparticles derived from organosilver(I) MOF. Science China Chemistry, 2019, 62, 347-354.	4.2	8
2364	Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology, 2019, 10, 420-426.	0.5	4
2365	Targeted therapies in pancreatic cancer: Promises and failures. Journal of Cellular Biochemistry, 2019, 120, 2726-2741.	1.2	17
2366	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
2367	Erlotinib Protects LPS-Induced Acute Lung Injury in Mice by Inhibiting EGFR/TLR4 Signaling Pathway. Shock, 2019, 51, 131-138.	1.0	25
2368	Clinical Effectiveness and Potential Survival Benefit of US-Guided High-Intensity Focused Ultrasound Therapy in Patients with Advanced-Stage Pancreatic Cancer. Ultraschall in Der Medizin, 2019, 40, 625-637.	0.8	39
2369	Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology, 2020, 98, 53-60.	0.9	24

#	Article	IF	Citations
2370	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. Journal of the Formosan Medical Association, 2020, 119, 238-246.	0.8	7
2371	Pancreatic Ductal Adenocarinoma. , 2020, , 55-70.		0
2372	Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian Journal of Pharmaceutical Sciences, 2020, 15, 26-41.	4.3	35
2373	Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 603-611.	0.5	4
2374	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs, 2020, 38, 821-830.	1.2	59
2375	Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. Journal of Drug Delivery Science and Technology, 2020, 55, 101374.	1.4	31
2376	Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 2020, 77, 1745-1770.	2.4	927
2377	Update on Management Periampullary/Pancreatic Head Cancer. Indian Journal of Surgery, 2020, , 1.	0.2	1
2378	A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR. International Journal of Radiation Biology, 2020, 96, 461-468.	1.0	11
2379	FOXO3a Activation by HDAC Class IIa Inhibition Induces Cell Cycle Arrest in Pancreatic Cancer Cells. Pancreas, 2020, 49, 135-142.	0.5	17
2380	Efficacy of Sâ€1 in secondâ€line chemotherapy after nabâ€paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1215.	0.6	11
2381	Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene, 2020, 39, 1831-1845.	2.6	25
2382	Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer. American Journal of Physiology - Renal Physiology, 2020, 318, G109-G119.	1.6	12
2383	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1
2384	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	0.5	17
2385	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Targeted Oncology, 2020, 15, 67-73.	1.7	1
2386	Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Cancer Letters, 2020, 470, 149-160.	3.2	14
2387	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology, 2020, 13, 130.	6.9	166

#	Article	IF	Citations
2388	Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer & Metabolism, 2020, 8, 19.	2.4	17
2389	Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188444.	3.3	16
2390	Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers. Pharmacological Research, 2020, 161, 105133.	3.1	49
2391	Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Visceral Medicine, 2020, 36, 373-380.	0.5	3
2392	Metachronous hepatic resection for liver only pancreatic metastases. Surgical Oncology, 2020, 35, 169-173.	0.8	20
2393	Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. Journal of Controlled Release, 2020, 326, 310-323.	4.8	26
2394	Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Frontiers in Oncology, 2020, 10, 1018.	1.3	6
2395	WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation. Cell Death and Disease, 2020, 11, 537.	2.7	27
2396	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	157.7	237
2397	Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3402.	1.7	23
2398	Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib . Drug Design, Development and Therapy, 2020, Volume 14, 4465-4475.	2.0	10
2399	Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	1.4	9
2400	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	3.3	11
2402	Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. Biomedicines, 2020, 8, 273.	1.4	13
2403	Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. Cancers, 2020, 12, 2005.	1.7	18
2404	Protein arginine methylation promotes therapeutic resistance in human pancreatic cancer. Cytokine and Growth Factor Reviews, 2020, 55, 58-69.	3.2	4
2405	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology, 2020, 152, 63-69.	0.3	19
2406	Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 394-408.	0.5	10

#	Article	IF	Citations
2408	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 586-590.	0.6	5
2409	Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. Cells, 2020, 9, 1855.	1.8	20
2410	Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 520330.	1.3	29
2411	Erlotinib is effective against FLT3â€ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB Journal, 2020, 34, 10182-10190.	0.2	3
2412	Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Cancers, 2020, 12, 2487.	1.7	7
2413	Predictive implications of decreased <scp>CA19</scp>â€9 at 8â€‰weeks during nabâ€paclitaxel plus gemcitabine for the induction of secondâ€line chemotherapy for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1289.	0.6	9
2414	Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes, 2020, 11, 1098.	1.0	9
2415	Potential diagnostic and therapeutic roles of exosomes in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188414.	3.3	12
2416	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibodyâ€“Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	1.9	30
2417	Carrierâ€Free Nanoassembly of Curcuminâ€“Erlotinib Conjugate for Cancer Targeted Therapy. Advanced Healthcare Materials, 2020, 9, e2001128.	3.9	21
2418	Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma . Cancer Management and Research, 2020, Volume 12, 12657-12666.	0.9	4
2419	Advances and challenges of neoadjuvant therapy in pancreatic cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 425-434.	0.7	9
2420	Tackling DNA damage repair mechanismsâ€”aÂpromising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 380-384.	0.3	1
2421	Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Molecular Cancer Therapeutics, 2020, 19, 1623-1635.	1.9	9
2422	A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 1423-1435.	1.9	14
2423	Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer. Cellular Oncology (Dordrecht), 2020, 43, 821-834.	2.1	17
2424	Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 620.	1.3	6
2425	Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers, 2020, 12, 1189.	1.7	6

#	Article	IF	Citations
2427	Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers, 2020, 12, 1366.	1.7	23
2428	Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Investigational New Drugs, 2020, 38, 1707-1716.	1.2	13
2429	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552.	21.5	569
2430	Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 356-363.	1.1	18
2431	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Targeted Oncology, 2020, 15, 407-410.	1.7	17
2432	PAWI-2: A novel inhibitor for eradication of cancer. Medicinal Chemistry Research, 2020, 29, 1147-1159.	1.1	1
2433	Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Journal of Controlled Release, 2020, 324, 545-559.	4.8	19
2434	Icotinib: efficacy in different solid tumors and gene mutations. Anti-Cancer Drugs, 2020, 31, 205-210.	0.7	3
2435	Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Questionâ€"Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 173-179.	0.6	40
2436	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Investigational New Drugs, 2020, 38, 1483-1494.	1.2	15
2437	Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Research, 2020, 80, 3179-3192.	0.4	15
2438	Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Journal of Clinical Medicine, 2020, 9, 648.	1.0	24
2439	Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens. JAMA Network Open, 2020, 3, e200452.	2.8	49
2440	Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research, 2020, 155, 104740.	3.1	46
2441	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 2020, 10, 973.	1.8	16
2442	The impact of molecular classification based on the transcriptome of pancreatic cancer: from bench to bedside. Chinese Journal of Academic Radiology, 2020, 3, 67-75.	0.4	0
2443	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Letters, 2020, 490, 12-19.	3.2	10
2444	Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas. Scientific Reports, 2020, 10, 10373.	1.6	4

#	Article	IF	Citations
2445	Poly(ester-thioether) microspheres co-loaded with erlotinib and Î±-tocopheryl succinate for combinational therapy of non-small cell lung cancer. Journal of Materials Chemistry B, 2020, 8, 1728-1738.	2.9	22
2446	Impact of ethanolic extract of Equisetum arvense (EA1) on pancreatic carcinoma AsPC-1 cells. Saudi Journal of Biological Sciences, 2020, 27, 1260-1264.	1.8	8
2447	Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib â€“ results from a non-interventional multi-center study. BMC Cancer, 2020, 20, 155.	1.1	3
2448	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Japanese Journal of Clinical Oncology, 2020, 50, 483-489.	0.6	44
2449	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncology, The, 2020, 21, e135-e145.	5.1	155
2450	Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. Journal of Geriatric Oncology, 2020, 11, 640-646.	0.5	5
2451	Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. Scientific Reports, 2020, 10, 260.	1.6	20
2452	HB-EGFâ€“EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 2020, 12, 173.	1.7	28
2453	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers, 2020, 12, 195.	1.7	25
2454	The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surgery Today, 2020, 50, 335-343.	0.7	11
2455	In silico analysis of the prognostic value of FAS mRNA in malignancies. Journal of Cancer, 2020, 11, 542-550.	1.2	3
2456	Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 2410-2417.	2.9	6
2457	Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors. European Journal of Cell Biology, 2020, 99, 151083.	1.6	25
2458	Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 1268.	1.0	42
2459	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2020, 149, 102940.	2.0	5
2460	Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Molecular Cancer Therapeutics, 2020, 19, 187-198.	1.9	6
2461	Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. Molecular Oncology, 2020, 14, 1653-1669.	2.1	7
2462	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1625-1645.	1.2	14

#	Article	IF	Citations
2463	NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129625.	1.1	13
2464	Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Molecular Therapy - Oncolytics, 2020, 17, 107-117.	2.0	25
2465	Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology, 2020, 20, 686-690.	0.5	9
2466	A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 3641-3648.	3.2	41
2467	Antireflux metal stent for biliary obstruction: Any benefits?. Digestive Endoscopy, 2021, 33, 310-320.	1.3	16
2468	Molecular Targets in Cholangiocarcinoma. Hepatology, 2021, 73, 62-74.	3.6	26
2469	Autophagy in the physiological endometrium and cancer. Autophagy, 2021, 17, 1077-1095.	4.3	100
2470	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188461.	3.3	68
2471	Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Cancer Discovery, 2021, 11, 736-753.	7.7	73
2472	Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein and Cell, 2021, 12, 128-144.	4.8	41
2473	Phase <scp>II</scp> study evaluating the association of gemcitabine, trastuzumab and erlotinib as firstâ€line treatment in patients with metastatic pancreatic adenocarcinoma (<scp>GATE</scp> 1). International Journal of Cancer, 2021, 148, 682-691.	2.3	23
2474	Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Research Methods in Medicine & Health Sciences, 2021, 2, 39-49.	0.7	12
2475	Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. International Journal of Clinical Oncology, 2021, 26, 543-551.	1.0	11
2476	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1529-1536.	1.2	4
2477	Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Translational Oncology, 2021, 14, 100965.	1.7	11
2478	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. Statistics in Medicine, 2021, 40, 553-565.	0.8	5
2479	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. Journal of Biological Chemistry, 2021, 296, 100034.	1.6	35
2480	Discordant reporting of VTE in pancreatic cancer: A systematic review and metaâ€analysis of thromboprophylaxis versus chemotherapeutic trials. Journal of Thrombosis and Haemostasis, 2021, 19, 489-501.	1.9	14

#	Article	IF	Citations
2481	Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. Bioorganic and Medicinal Chemistry Letters, 2021, 33, 127725.	1.0	7
2482	DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1â€mediated antioxidant effects. Journal of Cellular and Molecular Medicine, 2021, 25, 2163-2175.	1.6	33
2483	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Investigational New Drugs, 2021, 39, 605-613.	1.2	6
2484	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. Cytotherapy, 2021, 23, 137-145.	0.3	10
2485	An evaluation of olaparib for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 521-526.	0.9	4
2486	Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Annals of Gastroenterological Surgery, 2021, 5, 7-23.	1.2	23
2487	Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Investigational New Drugs, 2021, 39, 131-141.	1.2	2
2488	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut, 2021, 70, 606-617.	6.1	108
2489	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	1.4	9
2490	Dysfunctional EGFR and oxidative stress-induced PKD1 signaling drive formation of DCLK1+ pancreatic stem cells. IScience, 2021, 24, 102019.	1.9	9
2491	Arterial infusion and arterial chemoembolization for pancreatic cancer. , 2021, , 319-328.		0
2492	Molecular-targeted therapy of pancreatic carcinoma and its progress. , 2021, , 487-503.		0
2493	Can Patients with Pancreatic Cancer and Liver Metastases Obtain Survival Benefit from Surgery? A Population-Based Study. Journal of Cancer, 2021, 12, 539-552.	1.2	8
2494	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs, 2021, 13, 1914883.	2.6	4
2495	Suppressing LncRNA HOXA-AS3 by CRISPR-dCas9 inhibits pancreatic cancer development. Journal of Cancer, 2021, 12, 6439-6444.	1.2	7
2496	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Investigational New Drugs, 2021, 39, 821-828.	1.2	24
2497	Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Central-European Journal of Immunology, 2021, 46, 258-263.	0.4	2
2498	Incidence of bone metastases in patients with organâ€specific cancers: A nationwide populationâ€based cohort study. International Journal of Clinical Practice, 2021, 75, e13997.	0.8	1

#	Article	IF	Citations
2499	Internal medicine treatment of pancreatic lesions. , 2021, , 141-180.		0
2500	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. Advances in Experimental Medicine and Biology, 2021, 1301, 7-24.	0.8	1
2501	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano, 2021, 15, 1186-1198.	7.3	32
2502	Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. , 2021, , 195-205.		0
2503	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 2021, 5, 1900236.	1.4	13
2504	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	0.8	7
2505	Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. Suizo, 2021, 36, 12-19.	0.1	0
2506	Pancreatic ductal adenocarcinoma in the era of precision medicine. Seminars in Oncology, 2021, 48, 19-33.	0.8	8
2507	KRAS mutation in pancreatic cancer. Seminars in Oncology, 2021, 48, 10-18.	0.8	95
2508	LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 546-556.	1.3	39
2509	Aptamerâ€SH2 superbinderâ€based targeted therapy for pancreatic ductal adenocarcinoma. Clinical and Translational Medicine, 2021, 11, e337.	1.7	11
2511	The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines. Asian Pacific Journal of Cancer Prevention, 2021, 22, 381-390.	0.5	2
2512	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacologica Sinica, 2021, 42, 1725-1741.	2.8	53
2513	Future directions in drug development in pancreatic cancer. Seminars in Oncology, 2021, 48, 47-56.	0.8	10
2514	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische OnkologieÂwith an integrated analysis of the â€˜burden of therapyâ€™ method. European Journal of Cancer, 2021, 146, 95-106.	1.3	21
2515	Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group. Statistics in Biopharmaceutical Research, 2023, 15, 280-294.	0.6	30
2516	Metastatic Acinar Cell Carcinoma of the Pancreas. Pancreas, 2021, 50, 300-305.	0.5	8
2517	Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas, 2021, 50, 313-316.	0.5	3

#	Article	IF	Citations
2518	Invadopodia: A potential target for pancreatic cancer therapy. Critical Reviews in Oncology/Hematology, 2021, 159, 103236.	2.0	14
2519	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. European Journal of Medicinal Chemistry, 2021, 214, 113218.	2.6	65
2520	Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Journal of Gastrointestinal Surgery, 2021, 25, 2871-2880.	0.9	5
2521	Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition. Molecular Therapy - Oncolytics, 2021, 20, 364-372.	2.0	6
2522	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics, 2021, 4, 2000262.	1.6	9
2524	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. Journal of Gastrointestinal Oncology, 2021, 12, 464-473.	0.6	16
2525	MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. Frontiers in Oncology, 2021, 11, 616481.	1.3	7
2526	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines, 2021, 9, 389.	1.4	21
2527	Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Journal of Gastrointestinal Oncology, 2021, 12, 455-463.	0.6	2
2528	A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Aging, 2021, 13, 12493-12513.	1.4	5
2529	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 2021, 13, 1781.	1.7	17
2530	3d tissue models as tools for radiotherapy screening for pancreatic cancer. British Journal of Radiology, 2021, 94, 20201397.	1.0	17
2531	Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 644156.	1.3	2
2533	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 662205.	1.3	7
2535	A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine, 2021, 66, 103327.	2.7	16
2536	Role of stromal activin A in human pancreatic cancer and metastasis in mice. Scientific Reports, 2021, 11, 7986.	1.6	16
2537	A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. Reviews on Recent Clinical Trials, 2021, 16, 180-192.	0.4	5
2538	Pancreatic adenocarcinoma: Beyond first line, where are we?. World Journal of Gastroenterology, 2021, 27, 1847-1863.	1.4	6

#	Article	IF	Citations
2539	Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews, 2021, 96, 102180.	3.4	82
2540	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. Oncotarget, 2021, 12, 982-995.	0.8	0
2541	KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. International Journal of Molecular Sciences, 2021, 22, 5070.	1.8	7
2542	Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. Frontiers in Immunology, 2021, 12, 678028.	2.2	5
2543	Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 659987.	1.3	9
2544	Microbial cancer therapeutics: A promising approach. Seminars in Cancer Biology, 2022, 86, 931-950.	4.3	10
2546	The case for a stratified application of targeted agents against pancreatic cancer. EBioMedicine, 2021, 67, 103344.	2.7	1
2547	Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. Molecular Pharmaceutics, 2021, 18, 2495-2506.	2.3	35
2548	Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. International Journal of Molecular Sciences, 2021, 22, 6413.	1.8	12
2549	Targeted therapy for pancreatic cancer: lessons learned and future opportunities. Digestive Medicine Research, 0, 4, 32-32.	0.2	5
2550	Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. International Immunopharmacology, 2021, 95, 107508.	1.7	19
2551	Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. Frontiers in Oncology, 2021, 11, 683788.	1.3	8
2552	Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 550-559.	0.8	2
2553	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Current Treatment Options in Oncology, 2021, 22, 71.	1.3	3
2554	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 672.	1.1	0
2555	Performance status as prognostic factor in phase III trials of firstâ€line chemotherapy of unresectable or metastatic pancreatic cancer: A trialâ€level metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 232-239.	0.7	4
2556	Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A real life experience and outcome from a tertiary referral centre.. Journal of Cancer & Allied Specialties, 2021, 7, .	0.1	1
2557	Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer. Clinical Therapeutics, 2021, 43, 1107-1115.	1.1	5

#	Article	IF	Citations
2558	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 825-e1674.	1.9	11
2560	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1416-1422.	0.6	11
2561	Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future. Nihon Ika Daigaku Igakkai Zasshi, 2021, 17, 98-107.	0.0	0
2562	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology, 2021, 188, 114516.	2.0	21
2563	Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer. Cancers, 2021, 13, 2940.	1.7	8
2564	Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 699610.	2.0	4
2565	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics, 2021, 11, 1195.	1.3	9
2566	Targeted agents in older patients with gastrointestinal cancers â€“ An overview. Journal of Geriatric Oncology, 2021, 12, 1240-1252.	0.5	0
2567	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals, 2021, 14, 677.	1.7	23
2568	Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 2021, 50, 773-787.	0.5	3
2569	S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. Biochemical Pharmacology, 2021, 189, 114396.	2.0	20
2570	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Frontiers in Oncology, 2021, 11, 688377.	1.3	82
2571	Emerging strategies to target RAS signaling in human cancer therapy. Journal of Hematology and Oncology, 2021, 14, 116.	6.9	98
2572	Application of natural killer cells in pancreatic cancer (Review). Oncology Letters, 2021, 22, 647.	0.8	6
2573	3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Communications Biology, 2021, 4, 893.	2.0	38
2574	Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. International Journal of Molecular Sciences, 2021, 22, 8125.	1.8	11
2575	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracilÂand leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. European Journal of Cancer, 2021, 151, 14-24.	1.3	18
2577	Branebrutinib (BMS-986195), a Brutonâ€™s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology, 2021, 9, 699571.	1.8	3

#	Article	IF	Citations
2578	Roles of voltageâ€'gated potassium channels in the maintenance of pancreatic cancer stem cells. International Journal of Oncology, 2021, 59, .	1.4	7
2579	Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. Otolaryngologic Clinics of North America, 2021, 54, 789-801.	0.5	2
2580	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology, 2021, 21, 903-911.	0.5	15
2581	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences, 2021, 22, 9440.	1.8	3
2582	Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Frontiers in Oncology, 2021, 11, 695627.	1.3	10
2583	Tissue factor and its procoagulant activity on cancerâ€associated thromboembolism in pancreatic cancer. Cancer Science, 2021, 112, 4679-4691.	1.7	20
2584	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	1.1	12
2585	An urgent call to raise the bar in oncology. British Journal of Cancer, 2021, 125, 1477-1485.	2.9	34
2586	Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy â€" a retrospective observational study. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 27.	0.4	4
2587	Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. Cancers, 2021, 13, 4187.	1.7	4
2588	Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial. Scandinavian Journal of Gastroenterology, 2021, 56, 1229-1235.	0.6	9
2589	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188557.	3.3	6
2590	Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?. Surgery, 2021, 170, 1807-1814.	1.0	7
2591	Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin. Anticancer Research, 2021, 41, 4321-4331.	0.5	5
2592	Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 4834.	1.7	4
2593	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Current Oncology, 2021, 28, 3525-3536.	0.9	2
2594	Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 736113.	1.3	6
2595	Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer. International Heart Journal, 2021, 62, 1171-1175.	0.5	6

#	Article	IF	Citations
2596	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight, 2021, 6, .	2.3	29
2597	Prediction and identification of synergistic compound combinations against pancreatic cancer cells. IScience, 2021, 24, 103080.	1.9	2
2598	Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World Journal of Clinical Oncology, 2021, 12, 787-799.	0.9	12
2599	Tumor-Specific Delivery of 5-Fluorouracilâ€“Incorporated Epidermal Growth Factor Receptorâ€“Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. Gastroenterology, 2021, 161, 996-1010.e1.	0.6	20
2600	Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. Frontiers in Oncology, 2021, 11, 754146.	1.3	10
2601	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
2603	LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1Î± Pathway. Cancer Research, 2021, 81, 5678-5691.	0.4	63
2604	Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. Journal of Hematology and Oncology, 2021, 14, 141.	6.9	36
2605	Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surgical Oncology Clinics of North America, 2021, 30, 673-691.	0.6	1
2606	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer, 2021, 157, 21-30.	1.3	18
2607	Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas. Phytomedicine Plus, 2021, 1, 100133.	0.9	0
2608	Pankreas. , 2021, , 621-674.		0
2609	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Medical Journal, 2021, 62, 671.	0.9	4
2610	Biomarkers in Pancreatic Cancer. , 2021, , 467-487.		1
2612	Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treatment and Research Communications, 2021, 27, 100342.	0.7	5
2614	Interventional therapy combined with molecular-targeted therapy for pancreatic cancer. , 2021, , 541-552.		0
2615	Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. Cancer and Metastasis Reviews, 2021, 40, 355-371.	2.7	6
2616	Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 1400-1406.	0.7	10

#	Article	IF	Citations
2617	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemotherapy and Pharmacology, 2021, 87, 397-404.	1.1	5
2618	Strategies and methods for selecting suitable combined interventional therapy for pancreatic carcinoma. , 2021, , 553-568.		0
2619	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Journal of Cancer, 2021, 12, 912-917.	1.2	5
2620	A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International Journal of Clinical Oncology, 2021, 26, 941-950.	1.0	15
2621	Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer. , 2008, , 511-533.		3
2622	Chemotherapy for Advanced Pancreatic Cancer. , 2010, , 913-949.		1
2623	Adjuvant Chemotherapy in Pancreatic Cancer. , 2010, , 1051-1077.		2
2624	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
2625	The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis. , 2013, , 309-333.		1
2626	Crosstalk Between COX-2 and EGFR: A Potential Therapeutic Opportunity. , 2008, , 325-339.		2
2628	The Role of Inflammation in Pancreatic Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 129-151.	0.8	80
2629	Pancreatic Cancer: Step by Step Forward. , 2008, 177, 1-2.		2
2630	Erlotinib. Recent Results in Cancer Research, 2010, 184, 21-31.	1.8	3
2631	Targeted Drug Therapies and Cancer. Recent Results in Cancer Research, 2011, 185, 159-171.	1.8	13
2632	Radiotherapy of the Pancreas: State of the Art in 2012. Recent Results in Cancer Research, 2012, 196, 89-103.	1.8	1
2633	Toxicology, Safety and Herbâ€“drug Interactions in Cancer Therapy. , 2010, , 293-340.		1
2635	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Journal of Gastroenterology, 2020, 55, 369-382.	2.3	48
2636	Carcinoma of the Pancreas. , 2008, , 1595-1611.		5

#	Article	IF	Citations
2637	Chemotherapy and radiotherapy for pancreatic and periampullary cancer. , 2012, , 972-978.e2.		1
2638	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
2639	Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Biochemical and Biophysical Research Communications, 2020, 524, 378-384.	1.0	4
2640	The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. Biochemical Pharmacology, 2017, 142, 21-38.	2.0	7
2641	Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Bioscience Reports, 2020, 40, .	1.1	24
2642	Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clinical Science, 2020, 134, 2091-2115.	1.8	59
2644	Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opinion on Drug Safety, 2021, 20, 335-348.	1.0	7
2645	A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 111-116.	0.6	17
2648	Progress in the chemotherapy of pancreatic carcinoma. World Chinese Journal of Digestology, 2009, 17, 1422.	0.0	4
2650	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. JCI Insight, 2019, 4, .	2.3	17
2651	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight, 2020, 5, .	2.3	36
2652	Radioembolization with Yttrium-90 Microspheres for Pancreatic Cancer Liver Metastases: Results from a Pilot Study. Tumori, 2010, 96, 955-958.	0.6	21
2653	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology, 2006, 24, 4115-4115.	0.8	3
2654	An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib.. Journal of Clinical Oncology, 2011, 29, 7523-7523.	0.8	1
2655	Sequencing Strategies to Guide Decision Making in Cancer Treatment. PLoS Medicine, 2016, 13, e1002189.	3.9	4
2656	Hedgehog Promotes Neovascularization in Pancreatic Cancers by Regulating Ang-1 and IGF-1 Expression in Bone-Marrow Derived Pro-Angiogenic Cells. PLoS ONE, 2010, 5, e8824.	1.1	71
2657	Comprehensive Analysis of Cellular Galectin-3 Reveals No Consistent Oncogenic Function in Pancreatic Cancer Cells. PLoS ONE, 2011, 6, e20859.	1.1	22
2658	Cord Blood Stem Cells Inhibit Epidermal Growth Factor Receptor Translocation to Mitochondria in Glioblastoma. PLoS ONE, 2012, 7, e31884.	1.1	15

#	Article	IF	Citations
2659	FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer. PLoS ONE, 2012, 7, e36252.	1.1	48
2660	Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer. PLoS ONE, 2012, 7, e38477.	1.1	32
2661	Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2012, 7, e40847.	1.1	39
2662	Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer. PLoS ONE, 2013, 8, e58089.	1.1	24
2663	Targeting Cancer-Related Inflammation: Chinese Herbal Medicine Inhibits Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. PLoS ONE, 2013, 8, e70334.	1.1	33
2664	Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models. PLoS ONE, 2013, 8, e77243.	1.1	36
2665	Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis. PLoS ONE, 2014, 9, e87103.	1.1	16
2666	Gemcitabine Induces Poly (ADP-Ribose) Polymerase-1 (PARP-1) Degradation through Autophagy in Pancreatic Cancer. PLoS ONE, 2014, 9, e109076.	1.1	17
2667	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS ONE, 2016, 11, e0147995.	1.1	13
2668	Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS ONE, 2016, 11, e0149028.	1.1	22
2669	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS ONE, 2016, 11, e0149833.	1.1	21
2670	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS ONE, 2016, 11, e0153533.	1.1	32
2671	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0156910.	1.1	8
2672	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS ONE, 2016, 11, e0164811.	1.1	17
2673	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e157-e164.	1.8	5
2674	1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. World Journal of Oncology, 2015, 6, 410-415.	0.6	3
2675	Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2015, 20, 5-13.	0.0	2
2676	High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2020, 9, 50.	0.0	2

#	Article	IF	Citations
2678	Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax, Va), 2019, 3, e1-e4.	1.4	69
2679	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. IssledovaniÃ¢ I Praktika V Medicine, 2020, 7, 118-134.	0.1	3
2680	FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging, 2020, 12, 53-69.	1.4	20
2681	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2015, 2, 285-293.	0.9	4
2682	Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget, 2017, 8, 50460-50475.	0.8	12
2683	MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget, 2016, 7, 82338-82353.	0.8	21
2684	Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. Oncotarget, 2016, 7, 62177-62193.	0.8	23
2685	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget, 2017, 8, 4399-4409.	0.8	12
2686	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	0.8	22
2687	Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. Oncotarget, 2017, 8, 14173-14191.	0.8	31
2688	Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget, 2017, 8, 15004-15013.	0.8	26
2689	Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiencyin vitro. Oncotarget, 2017, 8, 38568-38580.	0.8	36
2690	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-529.	0.8	12
2691	CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR. Oncotarget, 2014, 5, 1969-1986.	0.8	65
2692	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget, 2017, 8, 87221-87233.	0.8	38
2693	B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. Oncotarget, 2017, 8, 74856-74868.	0.8	16
2694	Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget, 2017, 8, 92401-92410.	0.8	20
2695	Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget, 2017, 8, 113662-113672.	0.8	5

#	Article	IF	Citations
2696	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget, 2017, 8, 102721-102738.	0.8	41
2697	Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients. Oncotarget, 2017, 8, 111333-111345.	0.8	13
2698	Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer. Oncotarget, 2014, 5, 9150-9168.	0.8	21
2699	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget, 2018, 9, 18540-18547.	0.8	15
2700	Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget, 2018, 9, 19994-20007.	0.8	10
2701	The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. Oncotarget, 2018, 9, 28069-28082.	0.8	6
2702	Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget, 2018, 9, 31861-31876.	0.8	4
2703	Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget, 2019, 10, 5349-5358.	0.8	15
2704	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. Oncotarget, 2020, 11, 3489-3501.	0.8	30
2705	Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget, 2015, 6, 4553-4561.	0.8	85
2706	Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. Oncotarget, 2015, 6, 8255-8260.	0.8	14
2707	Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 2015, 6, 5164-5181.	0.8	42
2708	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the â€œTHERAPYâ€phase 1-2 trial. Oncotarget, 2015, 6, 12796-12808.	0.8	56
2709	Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking Î²1 integrin activation. Oncotarget, 2015, 6, 15940-15952.	0.8	10
2710	Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget, 2015, 6, 39140-39150.	0.8	21
2711	Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget, 2015, 6, 15788-15801.	0.8	51
2712	Novel agents for advanced pancreatic cancer. Oncotarget, 2015, 6, 39521-39537.	0.8	29
2713	Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 33290-33305.	0.8	29

#	Article	IF	Citations
2714	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	0.8	27
2715	Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget, 2016, 7, 15492-15506.	0.8	8
2716	KRAS above and beyond - EGFR in pancreatic cancer. Oncotarget, 2012, 3, 1262-1263.	0.8	21
2717	The role of histone lysine demethylases in cancer cellsâ€™ resistance to tyrosine kinase inhibitors. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 326-334.	0.9	2
2718	Drug metabolism and pancreatic cancer. Annals of Gastroenterology, 2016, 30, 54-61.	0.4	5
2719	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Annals of Translational Medicine, 2016, 4, 165-165.	0.7	19
2720	Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: a retrospective cohort study from the SEER database. Annals of Translational Medicine, 2019, 7, 522-522.	0.7	12
2721	EGFR first- and second-generation TKIsâ€”there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 2018, 8, S23-S47.	0.4	48
2722	Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clinica Belgica, 2011, 66, 10-7.	0.5	22
2723	Role of erlotinib in the management of pancreatic cancer. Therapeutics and Clinical Risk Management, 2006, 2, 435-445.	0.9	23
2724	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. Molecular Diagnosis and Therapy, 2012, 16, 209-22.	1.6	14
2725	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Current Medicinal Chemistry, 2020, 26, 7196-7211.	1.2	9
2726	A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. Current Drug Metabolism, 2020, 20, 958-966.	0.7	9
2727	Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment. Current Cancer Drug Targets, 2016, 16, 175-185.	0.8	8
2728	Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Current Cancer Drug Targets, 2019, 19, 417-427.	0.8	22
2729	Mathematical Modeling to Address Challenges in Pancreatic Cancer. Current Topics in Medicinal Chemistry, 2020, 20, 367-376.	1.0	16
2730	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 815-834.	1.0	229
2731	Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples. Anticancer Research, 2017, 37, 1975-1978.	0.5	7

#	Article	IF	Citations
2732	Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice via Inhibition of Gastrin-induced Anti-Apoptotic Effects. Anticancer Research, 2017, 37, 4127-4137.	0.5	3
2734	High-level Skp2 expression in pancreatic ductal adenocarcinoma: Correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Suizo, 2006, 21, 542-544.	0.1	1
2735	A phase I study of gemcitabine and S-1 concurrent radiotherapy in patients with locally advanced pancreatic cancer. Suizo, 2010, 25, 109-116.	0.1	2
2736	Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma. Disease Markers, 2012, 32, 203-10.	0.6	19
2737	Ductal Pancreatic Adenocarcinoma. Deutsches Ärzteblatt International, 2014, 111, 396-402.	0.6	23
2738	Molecular Targeted Intervention for Pancreatic Cancer. Cancers, 2015, 7, 1499-1542.	1.7	30
2739	Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World Journal of Gastroenterology, 2008, 14, 2461.	1.4	30
2740	c-Met targeted therapy of cholangiocarcinoma. World Journal of Gastroenterology, 2008, 14, 2990.	1.4	35
2741	Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World Journal of Gastroenterology, 2008, 14, 3681.	1.4	29
2742	Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World Journal of Gastroenterology, 2008, 14, 5403.	1.4	14
2743	A patient with unresectable advanced pancreatic cancer achieving long-term survival with Gemcitabine chemotherapy. World Journal of Gastroenterology, 2008, 14, 6876.	1.4	5
2744	Exploiting novel molecular targets in gastrointestinal cancers. World Journal of Gastroenterology, 2007, 13, 5845.	1.4	16
2745	Intraoperative radiofrequency ablation combined with125iodine seed implantation for unresectable pancreatic cancer. World Journal of Gastroenterology, 2010, 16, 5104.	1.4	33
2746	Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1357.	1.4	17
2747	Pancreatic cancer: Translational research aspects and clinical implications. World Journal of Gastroenterology, 2012, 18, 1417.	1.4	23
2748	Adjuvant and neoadjuvant treatment in pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1565.	1.4	46
2749	Role of taxanes in pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 4457.	1.4	7
2750	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World Journal of Gastroenterology, 2012, 18, 4533.	1.4	41

#	Article	IF	Citations
2751	Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. World Journal of Gastroenterology, 2012, 18, 4944.	1.4	66
2752	Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World Journal of Gastroenterology, 2012, 18, 6226.	1.4	13
2753	Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?. World Journal of Gastroenterology, 2012, 18, 736.	1.4	61
2754	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World Journal of Gastroenterology, 2013, 19, 4511.	1.4	13
2755	Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cellsin vitroby inhibition of nuclear factor-ÎºB activity. World Journal of Gastroenterology, 2013, 19, 5485.	1.4	39
2756	Current evidence for histone deacetylase inhibitors in pancreatic cancer. World Journal of Gastroenterology, 2013, 19, 813.	1.4	39
2757	Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?. World Journal of Gastroenterology, 2013, 19, 1173.	1.4	48
2758	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World Journal of Gastroenterology, 2014, 20, 4151.	1.4	27
2759	Pancreatic biomarkers: Could they be the answer?. World Journal of Gastroenterology, 2014, 20, 7819.	1.4	8
2760	Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World Journal of Gastroenterology, 2014, 20, 7830.	1.4	83
2761	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	1.4	22
2762	Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells. World Journal of Gastroenterology, 2014, 20, 7914.	1.4	13
2763	Pancreatic cancer: advances in treatment. World Journal of Gastroenterology, 2014, 20, 9354-60.	1.4	144
2764	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World Journal of Gastroenterology, 2014, 20, 10769.	1.4	20
2765	MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11199.	1.4	40
2766	Adjuvant therapy in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14733.	1.4	36
2767	S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 15110.	1.4	41
2768	Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World Journal of Gastroenterology, 2015, 21, 3441-3446.	1.4	3

#	Article	IF	Citations
2769	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology, 2015, 21, 4788.	1.4	56
2770	New targeted therapies in pancreatic cancer. World Journal of Gastroenterology, 2015, 21, 6127.	1.4	43
2771	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World Journal of Gastroenterology, 2015, 21, 8271.	1.4	36
2772	Perspectives in the treatment of pancreatic adenocarcinoma. World Journal of Gastroenterology, 2015, 21, 9297.	1.4	124
2773	Advanced pancreatic cancer - how to choose an adequate treatment option. World Journal of Gastroenterology, 2015, 21, 10709.	1.4	3
2774	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World Journal of Gastroenterology, 2015, 21, 11793.	1.4	29
2775	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
2776	Management of pancreatic cancer in the elderly. World Journal of Gastroenterology, 2016, 22, 764.	1.4	113
2777	Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World Journal of Gastroenterology, 2016, 22, 776.	1.4	48
2778	Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World Journal of Gastroenterology, 2016, 22, 906.	1.4	19
2779	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 6987.	1.4	68
2780	Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 7080.	1.4	10
2781	Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World Journal of Gastroenterology, 2016, 22, 10502.	1.4	3
2782	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World Journal of Gastroenterology, 2017, 23, 7478-7488.	1.4	23
2783	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. World Journal of Gastroenterology, 2018, 24, 3222-3238.	1.4	77
2784	Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. International Journal of Oncology, 2019, 54, 527-536.	3.9	7
2785	High mobility group ATâ€'hook 2 and câ€'MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncology Letters, 2020, 19, 1584-1592.	0.8	2
2786	Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. Oncology Reports, 2020, 44, 2581-2594.	1.2	7

#	Article	IF	Citations
2787	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean Journal of Internal Medicine, 2020, 35, 171-184.	0.7	10
2788	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 376-91.	0.7	16
2789	Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. Journal of Gastrointestinal Oncology, 2013, 4, 20-9.	0.6	22
2790	Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. Journal of Gastrointestinal Oncology, 2012, 3, 326-34.	0.6	44
2791	Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2013, 4, 370-3.	0.6	11
2792	Current and future systemic treatment options in metastatic pancreatic cancer. Journal of Gastrointestinal Oncology, 2014, 5, 280-95.	0.6	33
2793	Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. Journal of Gastrointestinal Oncology, 2015, 6, 436-44.	0.6	20
2794	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
2795	Targeted agents: how can we improve the outcome in biliary tract cancer?. Hepatobiliary Surgery and Nutrition, 2013, 2, 31-3.	0.7	4
2796	Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surgery and Nutrition, 2013, 2, 216-26.	0.7	8
2797	Molecular Characteristics of Pancreatic Ductal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-16.	1.4	43
2798	Î±, Î³-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines. Biomolecules and Therapeutics, 2017, 25, 609-617.	1.1	18
2799	Common pitfalls in statistical analysis: Clinical versus statistical significance. Perspectives in Clinical Research, 2015, 6, 169.	0.5	172
2800	The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endoscopic Ultrasound, 2017, 6, 66.	0.6	3
2801	Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endoscopic Ultrasound, 2017, 6, 300.	0.6	5
2802	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. Indian Journal of Cancer, 2018, 55, 138.	0.2	5
2803	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian Journal of Medical Research, 2018, 148, 284.	0.4	5
2804	Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis. Cancer Research and Treatment, 2008, 40, 22.	1.3	11

#	Article	IF	Citations
2805	A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2012, 44, 127-132.	1.3	9
2806	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2015, 47, 266-273.	1.3	9
2807	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. Cancer Research and Treatment, 2015, 47, 501-508.	1.3	29
2808	Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Research and Treatment, 2016, 48, 1264-1273.	1.3	40
2809	The Choice of the Endpoint to Assess the Efficacy or Effectiveness in Advanced or Metastatic Cancer Tumors. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	1
2810	Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants. World Journal of Gastrointestinal Oncology, 2009, 1, 38.	0.8	4
2811	FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 182-194.	0.8	40
2812	Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?. World Journal of Gastrointestinal Oncology, 2015, 7, 172.	0.8	6
2813	Genomic alterations in pancreatic cancer and their relevance to therapy. World Journal of Gastrointestinal Oncology, 2015, 7, 250.	0.8	24
2814	State of the art biological therapies in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 55.	0.8	30
2815	Is metastatic pancreatic cancer an untargetable malignancy?. World Journal of Gastrointestinal Oncology, 2016, 8, 297.	0.8	8
2816	Molecular therapeutics in pancreas cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 366.	0.8	18
2817	Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World Journal of Gastrointestinal Oncology, 2016, 8, 555.	0.8	32
2818	Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World Journal of Gastrointestinal Oncology, 2017, 9, 235.	0.8	19
2819	Evolving treatment landscape for early and advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 281.	0.8	26
2820	The Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Gut and Liver, 2010, 4, 433-449.	1.4	22
2821	Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response. Gut and Liver, 2013, 7, 611-615.	1.4	14
2822	Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer. Gut and Liver, 2013, 7, 739-746.	1.4	17

#	Article	IF	Citations
2823	Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut and Liver, 2020, 14, 387-394.	1.4	31
2824	Targeting metastatic upper gastrointestinal adenocarcinomas. World Journal of Clinical Oncology, 2011, 2, 135.	0.9	4
2825	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World Journal of Clinical Oncology, 2011, 2, 158.	0.9	22
2826	Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World Journal of Clinical Oncology, 2016, 7, 1.	0.9	11
2827	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
2828	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese Journal of Cancer, 2014, 33, 267-276.	4.9	17
2829	Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer. , 0, , .		1
2830	Pathological Complete Response after S-1 Therapy for an Unresectable Pancreatic Head Cancer with Liver Metastasis. Japanese Journal of Gastroenterological Surgery, 2017, 50, 461-468.	0.0	1
2831	The Pathology and Genetics of Metastatic Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 413-422.	1.2	186
2832	Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 598.	2.3	63
2833	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 439-457.	2.3	564
2834	First-line treatment for advanced pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 129-32.	1.5	7
2835	Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2013, 14, 395-400.	1.5	4
2836	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOP: Journal of the Pancreas, 2013, 14, 515-20.	1.5	3
2838	Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2012, 13, 497-501.	1.5	69
2839	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biology and Medicine, 2015, 12, 284-91.	1.4	5
2840	Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus, 2015, 7, e423.	0.2	5
2841	Cancer of Exocrine Pancreas. UNIPA Springer Series, 2021, , 645-674.	0.1	0

#	Article	IF	Citations
2842	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Molecular Cancer, 2021, 20, 128.	7.9	41
2843	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Science, 2021, 112, 5020-5033.	1.7	19
2844	Ð¡onsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology, 2021, 26, 4703.	0.4	36
2845	Pre-clinical Models of Metastasis in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 748631.	1.8	14
2846	The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study. Yeungnam University Journal of Medicine, 2022, 39, 124-132.	0.7	2
2847	Systemic Therapy for Metastatic Pancreatic Cancer. Current Treatment Options in Oncology, 2021, 22, 106.	1.3	33
2848	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapyâ€”A Review of the Literature. Biomolecules, 2021, 11, 1469.	1.8	9
2850	Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma. Frontiers in Oncology, 2021, 11, 736694.	1.3	7
2851	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World Journal of Gastroenterology, 2021, 27, 6527-6550.	1.4	23
2852	The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers, 2021, 13, 4979.	1.7	9
2853	Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World Journal of Gastroenterology, 2021, 27, 6844-6860.	1.4	11
2854	ThÃ©rapies ciblÃ©es: inhibiteurs de Ä¾activitÃ© tyrosine kinase du rÃ©cepteur Ã Ä¾EGF. , 2008, , 45-53.		0
2855	Improved Patients Outcomes by Chemotherapy mainly with Gemcitabine for Resected and Unresected Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2008, 41, 717-722.	0.0	1
2856	HER Family of Receptors as Treatment Targets in Pancreatic Cancer. , 2008, , 609-634.		0
2857	An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer. , 2008, , 565-575.		0
2858	Novel Targets for the Treatment of Pancreatic Cancer I: Insulin-like Growth Factor Receptor. , 2008, , 665-676.		0
2859	EGF-R Protein Expression and Gene Amplification do not Correlate in Pancreas Cancer. Gastroenterology Research, 2008, 1, 55-56.	0.4	0
2860	Pitfalls in Clinical Trials and Future Directions. , 2008, , 723-731.		0

#	Article	IF	Citations
2861	Gemcitabine/5-FU/leucovorin for the treatment of pancreatic cancer. Journal of Clinical Oncology, 2008, 26, 15651-15651.	0.8	0
2863	Targeting Signaling Pathways in Cancer Therapy. , 2009, , 309-326.		0
2864	JPN (Japan Pancreas Society) guidelines for the management of pancreatic cancer. Okayama Igakkai Zasshi, 2009, 121, 195-198.	0.0	0
2865	Chemotherapy and Radiotherapy in Pancreatic Cancer. , 2009, , 481-500.		0
2866	CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS. , 2009, , 83-90.		0
2867	The Medical Oncologistâ€™s Point of View. , 2009, , 37-47.		0
2869	Cancer of the Pancreas. , 2010, , 801-819.		0
2870	EGFR Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2010, , 387-402.		0
2871	Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-241.		0
2872	Application of molecular medicine to pancreatic cancer. Suizo, 2010, 25, 35-45.	0.1	0
2873	Biologisch zielgerichtete medikamentÃ¶se Therapie. , 2010, , 265-275.		0
2875	Antiangiogenic cancer therapy using peptide vaccine for patients with advanced pancreatic cancer. Suizo, 2010, 25, 53-58.	0.1	0
2876	A New Preclinical Paradigm for Pancreas Cancer. , 2010, , 73-93.		2
2877	Proteomic Analysis of Blood and Pancreatic Juice. , 2010, , 223-241.		0
2878	Drug Evaluations in Pancreatic Cancer Culture Systems. , 2010, , 1-27.		0
2879	The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer. , 2010, , 271-289.		0
2880	Molecular Targeted Therapy. , 2010, , 1523-1531.		0
2881	Gastrointestinal Stromal Tumor: Cause of Gastrointestinal Bleeding. Gastroenterology Research, 2010, 3, 93-95.	0.4	2

#	Article	IF	Citations
2882	MicroRNA Profiling and Its Application in Drug Discovery in Pancreatic Cancer. , 2010, , 171-180.		0
2883	Emerging Therapeutic Targets for Pancreatic Cancer. , 2010, , 1319-1335.		0
2885	Unresectable Pancreatic Cancer. , 2011, , 205-224.		0
2886	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
2887	Phase III Clinical Trials with Anticancer Agents. , 2011, , 163-188.		0
2888	Gastrointestinal Malignancies. , 2011, , 421-434.		0
2889	Cancer Stem Cells in Pancreatic Cancer. , 2011, , 79-97.		0
2890	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2011, , 347-355.		0
2891	Translational Research in Head and Neck Oncology. , 2011, , 179-189.		0
2892	Priorisierung in der Onkologie. , 2011, , 39-58.		0
2893	Series Introduction. Cleveland Clinic Journal of Medicine, 2011, 78, 24-24.	0.6	2
2894	Adjuvant trials for pancreatic cancer: where are we going and what is needed?. Clinical Investigation, 2011, 1, 651-667.	0.0	0
2898	Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	4
2899	The quandary of autoimmune pancreatitis and pancreatic ductal adenocarcinoma: A case report and review of IgG4 immunostaining in a cohort of patients receiving neoadjuvant chemotherapy. International Journal of Hepatobiliary and Pancreatic Diseases, 2012, 2, 38.	0.2	0
2900	Controversies in medicine: a learning opportunity. Medwave, 2012, 12, e5308-e5308.	0.2	0
2901	Characterization of the Molecular Genetic Mechanisms that Contribute to Pancreatic Cancer Carcinogenesis. , 0, , .		0
2902	Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma. , 0, , .		0
2903	Immunotherapy for Pancreatic Cancer. , 0, , .		0

#	Article	IF	Citations
2904	Multi-Disciplinary Management of Metastatic Pancreatic Cancer. , 0, , .		0
2905	Le cancer du pancrÃ©as. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1819-1828.	0.0	2
2906	Molecular Mechanisms of Tumor Metastasis. Molecular Pathology Library, 2013, , 213-228.	0.1	0
2908	Neue Therapieprinzipien beim Pankreaskarzinom: Zweitlinientherapie/Second Line, Targeted Therapies. , 2013, , 394-400.		0
2909	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
2910	EGFR, Immunology. , 2013, , 1-10.		0
2911	K-Ras. , 2013, , 1-10.		0
2912	Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. , 2013, , 249-269.		0
2913	Cisplatin plus Gemcitabine in patients with inoperable or metastatic pancreatic cancer. IOSR Journal of Dental and Medical Sciences, 2013, 11, 65-71.	0.0	0
2915	Recent Developments and Current Issues in the Treatment of Pancreatic Cancer. Journal of Cancer Therapy, 2013, 04, 13-27.	0.1	1
2916	Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom. , 2013, , 217-224.		0
2917	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
2918	The Efficacy and Cost of Biological Targeted Agents in Oncology. SSRN Electronic Journal, 0, , .	0.4	0
2919	The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. , 2013, , 83-115.		0
2921	The clinical significance of SWI/SNF complex in pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 149-149.	0.8	2
2922	Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Research, 2013, 2, 105.	0.8	1
2923	Clinical study report. , 2013, , 289-291.		4
2925	The Role of Phase III Trials in Modern Drug Development. Cancer Drug Discovery and Development, 2014, , 763-783.	0.2	0

#	Article	IF	Citations
2926	Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancerâ€"A Potential Strategy for Improved Survival. Journal of Cancer Therapy, 2014, 05, 1072-1091.	0.1	2
2927	Was tun mit all den Daten? Studienauswertung leicht gemacht!. Springer-Lehrbuch, 2014, , 37-51.	0.1	0
2928	Medical Oncology. , 2014, , 71-82.		0
2929	EBM-based Clinical Guidelines for Pancreatic Cancer (2013): perspectives on chemotherapy. Suizo, 2014, 29, 892-897.	0.1	0
2930	Progress and perspectives of post-operative adjuvant chemotherapy for adenocarcinoma of the pancreas. Suizo, 2014, 29, 878-884.	0.1	0
2931	The current status of FOLFIRINOX for unresectable pancreatic cancer. Suizo, 2014, 29, 885-891.	0.1	0
2932	RAS Genes and Cancer. , 2014, , 157-171.		0
2933	Carcinoma of the Pancreas. , 2014, , 1397-1415.e7.		3
2934	Gene Expression Profiling of Pancreatic Cancer Reveals a Significant Deregulation of the TGF-Î² Pathway and the Discovery of Genes for Prognosis. Global Journal of Human Genetics & Gene Therapy, 2014, 1, 67-76.	0.0	0
2935	Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.. Journal of Clinical Oncology, 2014, 32, 4136-4136.	0.8	0
2936	Liver Metastases from Pancreatic Adenocarcinoma. , 2015, , 95-109.		0
2937	Gemcitabine Plus Erlotinib Combination Therapy in Four Patients with Unresectable Advanced Recurrent Pancreatic Cancer:. Journal of the Nihon University Medical Association, 2015, 74, 106-108.	0.0	0
2938	Targeted Therapies for Pancreatic Cancer. Current Clinical Pathology, 2015, , 127-135.	0.0	0
2939	Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. Cancer Drug Discovery and Development, 2015, , 381-412.	0.2	0
2940	Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 235-265.	0.1	0
2941	Pankreastumoren. , 2015, , 557-567.		0
2943	Erlotinib for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
2944	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0

#	Article	IF	Citations
2945	Clinical Observation of High Intensity Focused Ultrasound (HIFU) Ablation Combined with Qingyihuaji Formula for Salvage Treatment for Advanced Pancreatic Cancer Patients Failed to Systemic Chemotherapy. Asian Case Reports in Oncology, 2015, 04, 1-7.	0.0	0
2946	A case of long term survival of pancreatic cancer with paraaortic nodal metastasis. Suizo, 2015, 30, 137-143.	0.1	0
2947	Efficacy and Safety of Fixed-Dose-Rate Infusions of Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer. Journal of Analytical Oncology, 2015, 4, 44-51.	0.1	0
2948	Advanced pancreatic cancer. , 2015, , 99-108.		0
2952	Current Treatment Options for Metastatic Pancreatic Adenocarcinoma.. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2015, 25, 263-274.	0.1	1
2953	Genetic factors affecting patient responses to pancreatic cancer treatment. Annals of Gastroenterology, 2016, 29, 466-476.	0.4	5
2954	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0
2956	Strategies to Target Pancreatic Cancer. , 2016, , 1-20.		0
2957	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
2958	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2016, , 243-251.		0
2959	Cardiovascular Emergencies. , 2016, , 179-190.		0
2960	Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. , 2016, , 121-150.		1
2961	Translational Research in Head and Neck Oncology. , 2016, , 215-227.		0
2962	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-188.	0.1	0
2963	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
2964	Identification and functional analysis of an EMT-accelerating factor induced in pancreatic cancer cells by an anticancer agent. Suizo, 2016, 31, 76-84.	0.1	1
2965	Pankreaskarzinom beim alten und geriatrischen Patienten. , 2016, , 1-9.		0
2966	A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2016, 21, 156-162.	0.0	0

#	Article	IF	Citations
2967	Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. , 2017, , 709-726.		0
2968	Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. Anticancer Research, 2016, 36, 6347-6356.	0.5	2
2969	EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2017, , 1-26.		1
2970	Development of Hypoxia: Activated Cytotoxic Prodrug. , 2017, , 243-252.		0
2971	Palliative Onkologie â€“ MÃ¶glichkeiten und Herausforderungen. , 2017, , 257-280.		0
2972	Anti-Angiogenics in Pancreatic Cancer Therapy. , 2017, , 1-20.		0
2973	Chemotherapy in the Management of Pancreatic Cancer. , 2017, , 387-419.		0
2974	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0
2975	Palliative Management of Pancreatic Cancer. , 2017, , 1-28.		0
2976	Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. , 2017, , 1-15.		0
2978	DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. Respiratory Disease Series, 2018, , 139-164.	0.1	0
2979	Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233.		0
2980	Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed. , 2018, , 205-217.		0
2981	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
2982	Enhanced Selective Cytotoxicity in Pancreatic Cancer Cells Using EGF-Conjugated Liposome-Encapsulated Curcumin. IFMBE Proceedings, 2018, , 217-221.	0.2	1
2983	Precision Medicine Based on Next Generation Sequencing and Master Controllers. , 2018, , 1-35.		0
2984	Cytotoxic Effect of Bitter Melon (Momordica charantia L.) Ethanol Extract and Its Fractions on Pancreatic Cancer Cells in vitro. Exploratory Research and Hypothesis in Medicine, 2017, 2, 1-11.	0.1	3
2985	EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. , 2018, , 97-105.		0

#	Article	IF	Citations
2986	Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives. Indian Journal of Medical Research, 2018, 148, 254.	0.4	2
2987	Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer. , 2018, , 63-70.		0
2988	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
2989	Pankreaskarzinom beim alten und geriatrischen Patienten. , 2018, , 333-341.		0
2990	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
2991	Hepatotoxicity and Hepatic Dysfunction. , 2018, , 445-465.		0
2992	4ï¼Žå^‡é™ä¸èƒ½è†µç™Œã«å¯¾ã™ã‚‹æ²»ç™‚æˆ¦ç•¥ã®ç¾çŠ¶ã¨èª²é¡Œ. Suizo, 2018, 33, 37-47.	0.1	0
2995	Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment. Cureus, 2018, 10, e2798.	0.2	1
2997	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	0.5	0
2998	Treatment of Advanced Pancreatic Carcinoma. , 2019, , 255-268.		0
2999	A Case of Pancreatic Head Cancer with a Hepatic Metastasis that Showed Complete Response to Administration of Gemcitabine + Nab-Paclitaxel Therapy. Nihon Gekakei Rengo Gakkaishi (Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	0
3001	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		0
3002	Research Progress on the Treatment of Pancreatic Cancer. Advances in Clinical Medicine, 2019, 09, 638-644.	0.0	0
3003	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. Oncology & Hematology Review, 2019, 15, 27.	0.2	2
3004	Resectable and Borderline Resectable Pancreatic Cancer. , 2019, , 235-254.		0
3005	Novel Targeted Treatment Approaches in Pancreatic Cancer. , 2019, , 479-491.		0
3006	Anti-angiogenics in Pancreatic Cancer Therapy. , 2019, , 415-434.		0
3007	æ¶ˆåŒ–å™¨ã€Œã‚“. Journal of Otolaryngology of Japan, 2019, 122, 717-723.	0.1	0

#	Article	IF	Citations
3008	Hepatocyte Growth Factor and Macrophage-stimulating Protein â€œHingeâ€•Analogs to Treat Pancreatic Cancer. Current Cancer Drug Targets, 2019, 19, 782-795.	0.8	1
3009	Chemotherapy for patients with unresesctable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. Suizo, 2020, 35, 69-74.	0.1	0
3012	Role of Erlotinib in Influencing the Quality of Life of Cancer Patients. Clinical Cancer Drugs, 2020, 07, .	0.3	0
3013	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
3016	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
3017	Gastrointestinal Toxicities of Targeted Therapy. , 2020, , 119-132.		0
3019	Tumours of the pancreas. , 2020, , 3227-3238.		0
3020	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
3021	How to read a published clinical trial: A practical guide for clinicians. Avicenna Journal of Medicine, 2020, 10, 68.	0.3	0
3022	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
3023	Pancreatic cancer: Ukrainian and world tendencies. Practical Oncology, 2020, 3, 42-45.	0.1	1
3024	Current perspective on the treatment of advanced pancreatic adenocarcinoma. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overlo	0.0	0
3025	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1089-1107.	1.9	1
3026	Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). International Journal of Oncology, 2021, 59, .	1.4	5
3027	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51.	1.1	0
3028	Context Mattersâ€"Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	1.8	3
3029	Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 72-82.	0.0	1
3030	Unresectable Locally Advanced Pancreatic Cancer: Concurrent Chemotherapy. , 2008, , 227-236.		0

#	Article	IF	Citations
3032	Emerging therapies in pancreas cancer. Journal of Gastrointestinal Oncology, 2011, 2, 93-103.	0.6	11
3033	Nanovector-based therapies in advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2011, 2, 185-94.	0.6	15
3034	Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer. JOP: Journal of the Pancreas, 2012, 13, 345-8.	1.5	1
3035	Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?. Journal of Gastrointestinal Oncology, 2014, 5, 166-77.	0.6	21
3036	Molecular biology of pancreatic cancer: how useful is it in clinical practice?. JOP: Journal of the Pancreas, 2012, 13, 332-7.	1.5	4
3037	Thromboembolism in gastrointestinal cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, 267-72.	0.8	6
3038	Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointestinal Cancer Research: GCR, 2007, 1, S8-S12.	0.8	1
3039	Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2007, 1, S13-6.	0.8	0
3040	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale Journal of Biology and Medicine, 2009, 82, 1-6.	0.2	46
3041	First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues. Gastrointestinal Cancer Research: GCR, 2009, 3, 37-9.	0.8	2
3042	Targeted therapies for pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S16-9.	0.8	15
3043	Accomplishments in 2007 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S37-41.	0.8	10
3044	Pancreatic adenocarcinoma: new strategies for success. Gastrointestinal Cancer Research: GCR, 2009, 3, S11-5.	0.8	14
3045	Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics: Targets and Therapy, 2007, 1, 335-46.	3.0	24
3046	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets and Therapy, 2009, 3, 419-28.	3.0	29
3047	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, 3, 429-41.	3.0	3
3048	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S43-7.	0.8	2
3049	Accomplishments in 2008 in the management of localized pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S37-42.	0.8	2

#	Article	IF	Citations
3050	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P and T, 2009, 34, 554-64.	1.0	17
3051	The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal Cancer Research: GCR, 2009, 3, 197-203.	0.8	3
3052	Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Current Opinion in Molecular Therapeutics, 2009, 11, 481-4.	2.8	4
3053	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evidence, 2007, 2, 111-9.	4.7	1
3054	Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. Journal of Medicine and Life, 2010, 3, 96-9.	0.4	2
3055	Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. Sultan Qaboos University Medical Journal, 2008, 8, 137-48.	0.3	8
3057	Diagnosing and managing pancreatic cancer. Practitioner, 2011, 255, 21-5, 2-3.	0.3	5
3058	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-29.	0.8	9
3059	A 71-year-old man with a large cystic pancreatic mass. Gastrointestinal Cancer Research: GCR, 2012, 5, 29-31.	0.8	0
3060	Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP: Journal of the Pancreas, 2011, 12, 377-83.	1.5	3
3061	Personalized therapy for pancreatic cancer: Myth or reality in 2010?. Journal of Gastrointestinal Oncology, 2010, 1, 24-33.	0.6	4
3062	Pancreatic cancer: current standards, research updates and future directions. Journal of Gastrointestinal Oncology, 2011, 2, 123-5.	0.6	9
3063	A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 77-83.	0.8	12
3065	A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 112-8.	0.8	5
3066	A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 155-60.	0.8	3
3067	Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Research, 2012, 32, 799-806.	0.5	14
3070	Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Research, 2011, 31, 1093-103.	0.5	35
3071	Molecular targeted therapy for biliary tract malignancy: defining the target. Hepatobiliary Surgery and Nutrition, 2012, 1, 53-4.	0.7	5

#	Article	IF	Citations
3072	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging, 2011, 10, 153-67.	0.7	18
3073	Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options. Giornale Di Chirurgia, 2014, 35, 5-14.	0.5	4
3074	Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines. Integrative Cancer Science and Therapeutics, 2015, 2, 133-142.	0.1	8
3075	Novel adjuvant therapies for pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2015, 6, 430-5.	0.6	3
3076	Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 509-15.	0.7	3
3077	Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. Journal of Gastrointestinal Oncology, 2016, 7, E6-E12.	0.6	1
3078	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. Cancer Biology and Medicine, 2016, 13, 136-41.	1.4	2
3079	Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. American Journal of Cancer Research, 2018, 8, 1812-1822.	1.4	12
3080	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. American Journal of Cancer Research, 2019, 9, 390-405.	1.4	7
3081	Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. , 2021, 4, 52-59.		0
3082	New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. JOP: Journal of the Pancreas, 2020, 21, 108-111.	1.5	1
3083	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research, 2021, 11, 236-250.	1.4	2
3084	A new 7-gene survival score assay for pancreatic cancer patient prognosis prediction. American Journal of Cancer Research, 2021, 11, 495-512.	1.4	3
3085	Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. American Journal of Cancer Research, 2021, 11, 3515-3536.	1.4	1
3086	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patientsâ€™ experience within a population-based study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110582.	1.4	5
3087	Application of two lines of chemotherapy: gemcitabine with nab-paclitaxel and liposomal irinotecan with 5-fluorouracil and leucovorin in patient with advanced pancreatic adenocarcinoma. OnCOReview, 2021, 11, 68-72.	0.1	1
3088	Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nature Reviews Cancer, 2022, 22, 131-142.	12.8	123
3089	Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review. Frontiers in Oncology, 2021, 11, 748200.	1.3	5

#	Article	IF	Citations
3090	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 751568.	1.6	10
3092	ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer, 2021, 21, 1199.	1.1	4
3093	Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 753456.	1.8	11
3094	Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer. Medicine (United States), 2021, 100, e27870.	0.4	4
3096	Use of supportive anthroposophic medicine in a German integrative paediatric oncology centre. Der Merkurstab, 2021, 74, 472-477.	0.0	0
3097	Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines, 2022, 10, 149.	1.4	5
3098	Targeting RAS in neuroblastoma: Is it possible?. , 2022, 236, 108054.		9
3100	Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective. , 2021, , 221-255.		0
3101	Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan. JAMA Network Open, 2022, 5, e2145515.	2.8	6
3103	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare (Switzerland), 2022, 10, 218.	1.0	1
3104	OUP accepted manuscript. Oncologist, 2022, , .	1.9	2
3105	The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers, 2022, 14, 217.	1.7	24
3106	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Visceral Medicine, 2022, 38, 20-29.	0.5	7
3107	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discovery, 2022, 12, 1233-1247.	7.7	60
3108	Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy. Cell Genomics, 2022, 2, 100095.	3.0	26
3109	Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 2021, 59, 100796.	6.5	122
3110	Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP: Journal of the Pancreas, 2014, 15, 19-24.	1.5	8
3111	Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Internal Medicine, 2022, 61, 2741-2746.	0.3	2

#	Article	IF	Citations
3112	Neurological complications of GI cancers. , 2022, , 365-386.		0
3113	Genome analyses of pancreatic ductal adenocarcinoma: Current status and future perspectives. Suizo, 2022, 37, 40-46.	0.1	0
3114	Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma. Acta Pharmaceutica Sinica B, 2022, 12, 3410-3426.	5.7	15
3115	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Current Oncology Reports, 2022, 24, 475-491.	1.8	4
3116	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers, 2022, 14, 985.	1.7	25
3117	ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells. Cells, 2022, 11, 702.	1.8	5
3118	Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)â€"basis and current status. Ecancermedicalscience, 0, 16, .	0.6	0
3119	Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor. Immunologic Research, 2022, , .	1.3	0
3120	Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Science Translational Medicine, 2022, 14, eabc1600.	5.8	37
3121	Interaction Analysis of Adenovirus L5 Protein With Pancreatic Cancer Cell Surface Receptor to Analyze Its Affinity for Oncolytic Virus Therapy. Frontiers in Oncology, 2022, 12, 832277.	1.3	2
3122	Multiply robust subgroup analysis based on a singleâ€index threshold linear marginal model for longitudinal data with dropouts. Statistics in Medicine, 2022, 41, 2822-2839.	0.8	3
3123	Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort. Annals of Translational Medicine, 2022, 10, 294-294.	0.7	5
3124	Evaluation of Proposed Protocol Changing Statistical Significance From 0.05 to 0.005 in Foot and Ankle Randomized Controlled Trials. Journal of Foot and Ankle Surgery, 2022, 61, 925-926.	0.5	2
3125	The Predictive Individual Effect for Survival Data. Therapeutic Innovation and Regulatory Science, 2022, 56, 492-500.	0.8	1
3126	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5â€fluorouracil and leucovorin. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 670-681.	1.4	4
3128	Late metachronous cerebral metastasis of pancreatic adenocarcinoma of the tail of the pancreas: a caseÂreport. Journal of Medical Case Reports, 2022, 16, 144.	0.4	2
3129	Proteome and secretome analysis of pancreatic cancer cells. Proteomics, 2022, 22, e2100320.	1.3	8
3130	The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine and Pharmacotherapy, 2022, 149, 112922.	2.5	4

#	Article	IF	Citations
3131	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology, 2022, 34, 15-22.	0.9	6
3132	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 6164.	1.7	8
3133	EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Frontiers in Oncology, 2021, 11, 770022.	1.3	4
3135	Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation. Frontiers in Oncology, 2021, 11, 809035.	1.3	1
3136	Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian Journal of Cancer, 0, , .	0.2	0
3137	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	10
3153	Current status and future direction of chemotherapy for pancreatic cancer. Chinese Clinical Oncology, 2013, 2, 6.	0.4	3
3154	EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development. Chinese Clinical Oncology, 2014, 3, 5.	0.4	3
3156	Locally advanced pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 126-8.	1.5	2
3157	Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 316-7.	1.5	0
3158	Preclinical research in treatment of pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 384-7.	1.5	2
3159	Biomarkers for pancreatic cancer: is it ready for primetime?. JOP: Journal of the Pancreas, 2013, 14, 309-11.	1.5	1
3160	Pancreatic cancer in 2014. JOP: Journal of the Pancreas, 2014, 15, 84-6.	1.5	1
3161	Biomarkers in pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2014, 15, 308-9.	1.5	1
3162	High-dose corticosteroid therapy for erlotinib-induced interstitial lung disease in Japanese patient with advanced pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 611-4.	1.5	1
3163	Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2012, 13, 338-41.	1.5	0
3164	Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?. JOP: Journal of the Pancreas, 2012, 13, 358-60.	1.5	2
3165	Research in pancreatic cancer: an update after ASCO 2012. JOP: Journal of the Pancreas, 2012, 13, 330-1.	1.5	1

#	Article	IF	Citations
3166	Highlights on the first line treatment of metastatic pancreatic cancer. JOP: Journal of the Pancreas, 2012, 13, 361-7.	1.5	3
3169	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics, 2022, 12, 1058.	1.3	4
3170	Calcium channel blockers potentiate gemcitabine chemotherapy Âin pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200143119.	3.3	14
3171	FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. Cellular and Molecular Life Sciences, 2022, 79, 268.	2.4	8
3172	Extracellular PKCÎ´ signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells. Cancer Science, 2022, 113, 2378-2385.	1.7	8
3173	Rational Design and Systemic Appraisal of an EGFR-Targeting Antibodyâ€“Drug Conjugate LR-DM1 for Pancreatic Cancer. Journal of Medicinal Chemistry, 2022, 65, 7141-7153.	2.9	3
3174	Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping. Journal of Gastrointestinal Surgery, 2022, 26, 1670-1678.	0.9	5
3175	Palliative laparoscopic Roux-en-Y choledochojejunostomy as a feasible treatment option for malignant distal biliary obstruction. Surgery Today, 2022, 52, 1568-1575.	0.7	1
3177	EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Scientific Reports, 2022, 12, 8007.	1.6	14
3178	FOLFIRINOX in Advanced Pancreatic Cancer, NEMROCK Experience. Cancer and Oncology Research, 2014, 2, 35-41.	0.2	0
3179	Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. PLoS ONE, 2022, 17, e0266620.	1.1	5
3180	Overcoming immunotherapeutic resistance in PDAC: SIRPÎ±-CD47 blockade. Pharmacological Research, 2022, 181, 106264.	3.1	4
3183	<i>In Silico</i> Studies, Biological Activities, and Anti-human Pancreatic Cancer Potential of 6-Hydroxy-4-methylcoumarin and 2,5-Dihydroxyacetophenone as Flavonoid Compounds. Journal of Oleo Science, 2022, 71, 853-861.	0.6	1
3184	Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 124-141.	0.9	1
3185	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers, 2022, 14, 2486.	1.7	29
3186	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 2022, 14, 2588.	1.7	7
3187	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. IScience, 2022, 25, 104483.	1.9	4
3188	Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics, 2022, 14, 1202.	2.0	7

#	Article	IF	Citations
3189	A phase I/<scp>II</scp> study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. International Journal of Cancer, 2022, 151, 1565-1577.	2.3	8
3190	Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Advanced Drug Delivery Reviews, 2022, 187, 114357.	6.6	20
3192	Treatment of biliary tract carcinoma over the last 30 years. BioScience Trends, 2022, 16, 189-197.	1.1	2
3193	Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie (Czech Republic), 2022, 16, 127-129.	0.0	0
3195	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 2022, 12, 815.	1.8	15
3196	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2022, 176, 103749.	2.0	37
3197	E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. , 2022, 39, .		7
3198	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget, 2022, 13, 828-841.	0.8	9
3199	An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation. Drug Research, 2022, 72, 424-434.	0.7	2
3200	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Cancers, 2022, 14, 3239.	1.7	11
3201	Management of elderly patients with unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	1
3202	Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies, 2022, 11, 47.	1.2	7
3203	Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments. Advanced Therapeutics, 2022, 5, .	1.6	8
3204	Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). Frontiers in Oncology, 0, 12, .	1.3	4
3205	Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 1252-1264.	0.8	11
3206	NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. Oncogenesis, 2022, 11, .	2.1	15
3207	Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology, 2022, 16, 3034-3051.	2.1	8
3208	Cystic Pancreatic Lesions. , 2023, , 177-196.		0

#	Article	IF	Citations
3209	Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Hpb, 2022, 24, 1878-1887.	0.1	15
3210	Defining clinically important overall survival thresholds: lessons from quality of life. Nature Reviews Clinical Oncology, 0, , .	12.5	1
3211	The VEGF and HER2 Expressions as Prognostic Factors in Osteosarcoma Patients. SSRN Electronic Journal, 0, , .	0.4	0
3212	Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. Immunologic Research, 2022, 70, 725-741.	1.3	13
3214	Resveratrol Effects on Molecular Pathways and MicroRNAs in Gastrointestinal Cancers. Current Medicinal Chemistry, 2023, 30, 820-840.	1.2	3
3215	Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancerâ€"The CONKO-008 Phase I Investigation. Journal of Clinical Medicine, 2022, 11, 4905.	1.0	0
3216	Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Journal of the National Cancer Center, 2022, 2, 205-215.	3.0	5
3218	PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment. ESMO Open, 2022, 7, 100524.	2.0	3
3219	The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomedicine and Pharmacotherapy, 2022, 154, 113663.	2.5	5
3220	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
3221	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	13
3222	Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study. Frontiers in Surgery, 0, 9, .	0.6	1
3223	A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, 13, 1989-1996.	0.6	1
3224	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resistance Updates, 2022, 64, 100864.	6.5	16
3225	Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. Plants, 2022, 11, 2466.	1.6	4
3226	Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Molecular and Cellular Proteomics, 2022, 21, 100409.	2.5	6
3227	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Lithuania), 2022, 58, 1298.	0.8	0
3229	Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Cancer Letters, 2022, 551, 215922.	3.2	3

#	Article	IF	Citations
3230	Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 1011-1018.	0.9	2
3231	Pancreatic Adenocarcinoma Management. JCO Oncology Practice, 2023, 19, 19-32.	1.4	17
3232	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Frontiers in Oncology, 0, 12, .	1.3	3
3234	Management of Locally Advanced/Metastatic Disease: Medical Oncology. , 2022, , 97-106.		0
3235	Patient Reported Outcomes and Quality of Life. , 2022, , 351-373.		0
3236	A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 3216-3226.	0.6	6
3237	STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules, 2022, 12, 1450.	1.8	7
3238	A generalized singleâ€index linear threshold model for identifying treatmentâ€sensitive subsets based on multiple covariates and longitudinal measurements. Canadian Journal of Statistics, 0, , .	0.6	0
3239	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	3.1	25
3240	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 345-368.	1.0	4
3241	Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. Cellular Oncology (Dordrecht), 0, , .	2.1	2
3242	FDA approved six-membered ring fused pyrimidine-based derivatives. , 2023, , 221-248.		0
3243	Wildâ€‘type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/Î²â€‘catenin pathway. Molecular Medicine Reports, 2022, 27, .	1.1	1
3245	Back to basic: Trials and tribulations of alkalizing agents in cancer. Frontiers in Oncology, 0, 12, .	1.3	9
3246	Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?. ESMO Open, 2022, 7, 100638.	2.0	11
3247	Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. EBioMedicine, 2022, 86, 104352.	2.7	13
3248	Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. British Journal of Cancer, 2023, 128, 321-330.	2.9	0
3251	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1

#	Article	IF	Citations
3252	Screening for Pancreatic Cancer: Current Status and Future Directions. European Medical Journal (Chelmsford, England), 0, , 59-67.	3.0	1
3253	Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.0	4
3254	Targeted Delivery Polymeric Nanosystem Reinforced by Synergism of Embilin and RPI-1 for Therapeutics of Pancreatic Cancer. ACS Applied Nano Materials, 2022, 5, 18622-18636.	2.4	1
3255	Integrated genomic analysis to identify druggable targets for pancreatic cancer. Frontiers in Oncology, 0, 12, .	1.3	5
3257	The antitumor effect of the novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5717-5728.	1.2	2
3258	Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology - Cell Physiology, 2023, 324, C540-C552.	2.1	16
3259	Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncology, 0, , .	1.1	0
3260	LY6D marks pre-existing resistant basosquamous tumor subpopulations. Nature Communications, 2022, 13, .	5.8	7
3261	Pancreatic Cancer: Beyond Brca Mutations. Journal of Personalized Medicine, 2022, 12, 2076.	1.1	2
3262	Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Frontiers in Immunology, 0, 13, .	2.2	13
3264	Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 2023, 25, 1017-1028.	0.6	12
3265	TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Translational Oncology, 2023, 28, 101608.	1.7	2
3266	HROP68: A rare case of medullary pancreatic cancerâ€"characterization and chemosensitivity of the first patient-derived cell line. Frontiers in Oncology, 0, 12, .	1.3	1
3268	A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Frontiers in Endocrinology, 0, 14, .	1.5	0
3269	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. Npj Genomic Medicine, 2023, 8, .	1.7	15
3270	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Computational Biology, 2023, 19, e1010104.	1.5	2
3271	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Current Cardiology Reports, 2023, 25, 269-280.	1.3	6
3273	A Novel 3DNAÂ® Nanocarrier effectively delivers payloads to pancreatic tumors. Translational Oncology, 2023, 32, 101662.	1.7	1

#	Article	IF	Citations
3274	Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPinâ€“Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences, 2023, 24, 2838.	1.8	2
3275	Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharmaceutica Sinica B, 2023, 13, 1554-1567.	5.7	7
3276	Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
3277	Radioterapia: papel actual en el cÃ¡ncer de pÃ¡ncreas. Iatreia, 2012, 25, 149-158.	0.1	0
3278	Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling. Molecular Cancer Research, 2023, 21, 316-331.	1.5	0
3279	Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist, 2023, 28, 425-432.	1.9	1
3280	Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2023, 18, e0282360.	1.1	0
3281	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Current Medical Science, 2023, 43, 1-12.	0.7	1
3282	Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Advances in Cancer Research, 2023, , 145-184.	1.9	5
3283	Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. Advances in Cancer Research, 2023, , 113-143.	1.9	2
3284	Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2023, , .	0.9	1
3285	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 2023, 15, 1766.	1.7	6
3286	Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Function, 2023, 4, .	1.1	6
3289	Structureâ€“Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017â€“Present). Pharmaceuticals, 2023, 16, 534.	1.7	7
3290	Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Frontiers in Oncology, 0, 13, .	1.3	2
3291	Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 571-595.	0.8	10
3292	IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. Frontiers in Immunology, 0, 14, .	2.2	3
3293	Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. Cancers, 2023, 15, 2354.	1.7	2

#	Article	IF	Citations
3294	Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy. Advances in Cancer Research, 2023, , 285-341.	1.9	1
3296	Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review. Frontiers in Genetics, 0, 14, .	1.1	1
3297	Targeted therapy. , 2023, , 205-411.		0
3303	Pathophysiology of Gastrointestinal Tract Cancers and Therapeutic Status. , 2023, , 1-32.		0
3306	Palliative Onkologie â€“ MÃ¶glichkeiten und Herausforderungen. , 2023, , 217-236.		0
3340	Therapeutic developments in pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2024, 21, 7-24.	8.2	7
3341	Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine. , 2023, 40, .		2
3344	Outcome measurements. , 2023, , 107-109.		0
3349	Overpowering. , 2023, , 73-75.		0
3361	Potential application of nanotechnology in the treatment and overcoming of pancreatic cancer resistance. , 2024, , 37-71.		0
3363	Clinical practice guidelines for interventional treatment of pancreatic cancer. , 2024, , 345-373.		0
3365	Therapy for Metastatic Pancreatic Cancer. , 2023, , 57-65.		0
3380	Molecular biomarkers in pancreatic ductal adenocarcinoma. , 2024, , 151-173.		0